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Abstract 
 
In collaboration with David Baulcombe and Attila Molnar we have generated 
microRNA libraries for human embryonic stem cells (hESCs) before and after 
differentiation along the neuronal lineage and also from human mesenchymal stem 
cells (hMSCs). Both cell types are of medical importance and understanding how 
their proliferation and differentiation is regulated by microRNAs is also of scientific 
interest. The hMSC library was sequenced by 454 technology and the two subsequent 
hESC libraries by Solexa sequencing.  
 
Approximately a quarter of all currently known microRNAs were identified between 
the libraries, in addition to 3 novel microRNAs and 25 annotated piRNAs. For the 
hESC libraries, we verified the presence of embryonic specific microRNAs (miR-302 
family) and neuronal specific microRNAs (miR-9/miR-9*), and demonstrated that 
expression of these miRNAs is regulated at the transcriptional level. Additionally, 
promoter assessments of miR-9 transcription revealed that multiple upstream regions 
may be important in neuronal specific expression.    
 
Almost half of all known human microRNAs are located within the introns of host 
genes. We used microarrays to analyse host gene expression and found that there was 
little correlation with microRNA expression, indicating that many microRNAs are not 
regulated at the transcriptional level by their host promoter. Furthermore, the 
expression of microRNAs from the same cluster, and also from the same hairpin 
precursor, did not always correlate when compared between the stem cell libraries. 
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Taken together, this data indicates that microRNAs are regulated at a variety of levels 
both pre- and post-transcriptionally.  
 
Many microRNA isomers were also detected that differed in expression between 
human cell types, and upon differentiation of the hMSCs through the osteoblastic 
lineage. Interestingly, microRNAs and some of their isomers showed different 
affinities for Argonaute proteins in pulldown assays. We also profiled mRNAs that 
were immunoprecipitated with Argonaute in order to identify miRNA targets.   
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CHAPTER 1 – INTRODUCTION 
 
1.1 THE ADVENT OF SMALL REGULATORY RNAS 
Small regulatory RNAs are essentially short non-coding RNA sequences (~20-30 
nucleotides) with a number of roles including that of gene regulation, viral and 
transposon defence, as well as in epigenetics (Baulcombe, 2008, Fire, 2007). The 
majority of small RNAs can be classified into one of the following groups: small 
interfering RNAs (siRNA), microRNAs (miRNA), and piwi-interacting RNA 
(piRNA), distinguished by their origins and mechanisms of function. A theory of the 
role of RNAs as regulatory molecules was initially proposed in 1969, (Britten and 
Davidson, 1969), but it was not until the 1990s that the mechanisms of RNA silencing 
were deduced (Fire et al., 1998), namely from parallel work in the model organism 
Caenorhabditis elegans (Lee et al., 1993, Wightman et al., 1993), and in plants 
(Hamilton and Baulcombe, 1999, Lindbo et al., 1993).  
 
Viral resistance studies in plants have played a large part in the work that eventually 
led to the discovery of RNA silencing. Attempts to develop transgenic plants 
expressing virus-derived genes to confer resistance led to the discovery that certain 
transgenes have nucleotide sequence specific silencing properties, though the 
mechanisms were largely unknown at that time (English et al., 1996, Lindbo et al., 
1993, Smith et al., 1988). Independently in C. elegans it was found that the expression 
of both sense and antisense RNA could generate a targeted interference effect (Fire et 
al., 1991), and this type of interference was reproducible with direct injection of 
RNAs (Guo and Kemphues, 1995). Many of these types of studies conducted in both 
plants and worms culminated in what is now termed RNA interference (RNAi). 
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Subsequent work by Fire el al., 1998, identified double stranded RNAs (dsRNAs) as 
the actual trigger for RNAi. Specifically, short 21-25 nucleotide dsRNAs (termed 
small interfering RNAs; siRNAs) that were processed from longer intermediates were 
found to be able to bind to and cleave homologous transcripts (Hamilton and 
Baulcombe, 1999, Hammond et al., 2000, Zamore et al., 2000). Various groups 
demonstrated that these siRNAs behaved as guides to mediate cleavage of target 
mRNAs near the centre of the region encompassed by the siRNA (Hammond et al., 
2000, Tuschl et al., 1999, Zamore et al., 2000). Furthermore, this type of silencing 
could also be used experimentally to silence mammalian genes, particularly as the 
small size of siRNAs bypassed the interferon response (Elbashir et al., 2001, Caplen 
et al., 2001). In the last decade, the use of RNAi and the elucidation of the 
mechanisms and pathways behind it have progressed at an exponential pace. RNAi is 
the predominant tool for loss of function studies in a variety of organisms but with the 
continued advances being made the focus in mammalian systems is shifting to that of 
their own endogenous small RNA regulators; the microRNAs (miRNAs).   
 
Typically, endogenous siRNAs are a feature of plants and C. elegans biology, though 
a new subtype (endo-siRNAs) has been discovered in mice (Tam et al., 2008, 
Watanabe et al., 2006). In mammals, miRNAs are the predominant endogenous small 
RNA regulators and are ubiquitously expressed. Endo-siRNAs and piRNAs constitute 
a more specialised type of endogenous RNA regulatory species and, along with 
miRNAs, the presence of these small RNAs as gene regulators is now recognised as 
an extensive and essential layer of control in wide range of eukaryotes, including 
single-celled plants (Molnar et al., 2007). 
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1.2. MICRORNAS 
MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs, ranging in 
size from 19 - 26 nucleotides that play important roles in the regulation of genes at the 
post-transcriptional level. Originally isolated in Caenorhabditis elegans, lin-4 and let-
7 were the first genes shown to encode miRNAs, which were essential for the timing 
of larval development at the LI to L2, and late larval to adult stages respectively (Lee 
et al., 1993, Wightman et al., 1993). Homologs of let-7 were then identified in 
humans (Pasquinelli et al., 2000), and even in some simple multicellular organisms, 
such as sponges and sea anemone (Grimson et al., 2008), demonstrating that these 
novel small RNAs are conserved regulators of development (Ibanez-Ventoso et al., 
2008). However, animal miRNAs are somewhat diverged from plants and show 
distinct sequence and biogenesis mechanisms (Chapman and Carrington, 2007, Millar 
and Waterhouse, 2005).  
 
To date, thousands of miRNAs have been isolated and verified, including over 700 in 
humans, with the numbers expected to continue to rise (miRNA Registry, v13.0; 
(Griffiths-Jones, 2004). Overall, miRNAs comprise one of the largest gene families in 
higher eukaryotes, accounting for ~1% of the genome (Bartel, 2004). The diverse 
expression patterns and possible collaborative function of miRNAs highlights an 
extensive layer of gene regulation that may affect over 30% of known genes (Krek et 
al., 2005, Lewis et al., 2005), regulating various developmental and physiological 
processes. 
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1.2.1 Biogenesis of the microRNA primary transcript 
Figure 1.1 illustrates the steps involved in the basic model of miRNA biogenesis 
(Winter et al., 2009). Mild variances exist in the precise elements involved in miRNA 
processing between different organisms, but the basic biogenesis pathway remains the 
same. The miRNAs are first transcribed by RNA polymerase II or III into a long 
primary transcript (pri-miRNA) with a stem-loop structure of up to several kilobases 
in length (Borchert et al., 2006, Lee et al., 2004). This is then processed by the RNase 
III endonuclease, Drosha, in complex with DiGeorge syndrome critical region 8 
(DGCR8), into a 60 – 80 nucleotide precursor miRNA (pre-miRNA). DGCR8 
contains two double-stranded RNA-binding domains and is essential for miRNA 
processing in all mammals (Denli et al., 2004, Gregory et al., 2004, Han et al., 2004, 
Landthaler et al., 2004). DGCR8 interaction with the pri-miRNAs, through the 
ssRNA segments and the stem of 33 bp, assists Drosha to cleave the substrate (Han 
et al., 2006, Zeng et al., 2005). Specifically, Drosha is able to cleave the pri-miRNA 
at approximately two helical turns into the stem from the junction of the loop of a 
recognised miRNA hairpin (Lee et al., 2003). A single nucleotide polymorphism in 
the miRNA hairpin has been shown to inhibit Drosha processing (Duan et al., 2007), 
though a screen of cancer cell lines for negative effects of nucleotide alterations in 
miRNAs show that this may be the exception rather than the rule (Diederichs and 
Haber, 2006). 
 
The pre-miRNA contains a 5’ phosphate and 2 nucleotide overhangs at the 3’ 
hydroxylated end (Basyuk et al., 2003, Lee et al., 2003, Lee et al., 2004), and is  
transported from the nucleus to the cytoplasm by the export receptor, Exportin-5, 
catalysed by Ran-GTP. Sequence and loop variations in the pre-miRNA do not affect 
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recognition, but a defined length is required for binding to Exportin-5; Exportin-5 
recognises a >14 bp dsRNA stem along with a short 3’ overhang (Lund and Dahlberg, 
2006, Lund et al., 2004, Zeng and Cullen, 2004).  
 
 
 
Figure 1.1. The miRNA biogenesis pathway for mammalian miRNAs. The pri-
miRNA is generated by RNA polymerase II or III and subsequently cleaved by the 
microprocessor complex Drosha–DGCR8 in the nucleus. The resulting pre-miRNA, is 
then exported from the nucleus by Exportin-5–Ran-GTP into the cytoplasm [Modified 
from Winter et al., 2009]. 
 
 
1.2.2 The microRNA precursor and RLC assembly 
MicroRNA precursor processing is coupled with RISC (RNA-induced silencing 
complex) assembly in the cytoplasm, in what is collectively termed the RISC loading 
complex (RLC). Other name variations of RISC include the ‘miRNP’ (microRNA 
containing ribonucleoprotein complex) and the ‘miRISC’ (microRNA containing 
RNA-induced silencing complex). The RLC is comprised of the RNase III 
endonuclease Dicer, TRBP (trans-activator RNA (Tar) binding protein), PACT 
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(protein activator of protein kinase R (PKR)), and subsequently an Argonaut protein 
(Ago) (Fig. 1.2). PACT and TRBP are not essential for RLC function but do help 
facilitate Dicer mediated cleavage, and the recruitment of Ago (Lee et al., 2006).  
 
 
 
 
Figure 1.2. Mature microRNA processing in the RISC Loading Complex (RLC). 
The RLC is formed when Dicer and TRBP recruit an Ago protein and bind to the pre-
miRNA. The pathway on the left represents the normal pathway of Dicer mediated 
cleavage. The pathway on the right depicts a RLC containing Ago2 cleaving the 3’ 
arm of the pre-miRNA hairpin to generate an ac-pre-microRNA to facilitate passenger 
strand degradation and RISC activation [Reproduced from Diederichs and Haber, 
2007].   
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In mammals, there are four Ago proteins (Ago1-4) and they form the core component 
of RISC, of which only Ago2 is able to demonstrate endonuclease activity (Liu et al., 
2004, Meister et al., 2004). Formation of the RLC occurs before the association to the 
exported pre-miRNA in the cytoplasm (Fig. 1.2) (Gregory et al., 2005). Typically, the 
stem of the miRNA hairpin will not be perfectly complementary and will often 
contain several mismatches and internal bulges. Once in complex with the RLC, the 
pre-miRNA is cleaved by Dicer, which interacts with the 5’ phosphate and the 3’ 
overhang of the pre-miRNA, to release a miRNA duplex with 2 nucleotide overhangs 
at both 3’ ends (Luciano et al., 2004). There is only one Dicer encoding gene in the 
mammalian genome, and aberrant Dicer activity has been demonstrated to have 
detrimental effects in development (Bernstein et al., 2003, Kanellopoulou et al., 2005, 
Murchison et al., 2005). Following cleavage, Dicer and its partners, TRBP and PACT, 
disengage from the miRNA to effectively disband the RLC. The remaining RISC 
containing the Ago protein is activated upon isolation of the functional miRNA strand 
from the duplex. The strands of the duplex are unwound by a helicase, which may not 
be universal (Meister et al., 2005, Robb and Rana, 2007, Salzman et al., 2007), or 
even necessary in the case of ac-pre-miRNAs (Matranga et al., 2005, Rand et al., 
2005), to release the functional miRNA from its passenger strand.  
 
The mechanisms governing miRNA strand selection in mammals remain unclear. 
Thermodynamic stability is thought to be an important factor and used to determine 
strand selection in the majority of cases, but not all (Schwarz et al., 2003, Khvorova et 
al., 2003). Typically the miRNA strand with the lesser 5’ pairing is preferentially 
selected (Khvorova et al., 2003), though there are now increasing numbers of 
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miRNAs derived from both strands, hinting at the possibility of an additional, as of 
yet undefined, strand sorting mechanism. 
 
In cases where the pre-miRNA has a high degree of complementarity along the stem, 
and is associated with a RLC containing Ago2 specifically, the 3’ arm of the pre-
miRNA is nicked by Ago2 to generate an intermediate Ago2 cleaved pre-miRNA 
called ac-pre-miRNA (Diederichs and Haber, 2007). The generation of an ac-pre-
miRNA is expected to facilitate passenger strand dissociation and aid mature miRNA 
activation, though both the ac-pre-miRNA and the normal pre-miRNA are processed 
subsequently by Dicer in the same manner (Figure 1.2). The nature of the ac-pre-
miRNA ensures that only the 5’ arm of the hairpin can give rise to a functional 
miRNA, and therefore only un-nicked original pre-miRNAs can produce miRNAs 
from the 3’ arm. 
 
1.2.3 The effect of splicing and ADAR editing on microRNAs 
The RNA splicing machinery may in certain cases displace the need for Drosha 
processing of the pri-miRNA transcript. Splicing occurs prior to Drosha processing, 
and releases intronic miRNAs from their host transcripts. If the debranched intron can 
fold in a manner similar to a pre-miRNA (known as a mirtron), the mirtron can be 
exported directly into the cytoplasm by Exportin-5 to be processed by Dicer, 
effectively bypassing the need for Drosha (Berezikov et al., 2007, Okamura et al., 
2007, Ruby et al., 2007). Only a handful of mammalian mirtrons have been 
discovered, the majority of which are species specific, constituting a very small subset 
of the miRNAs processed (Berezikov et al., 2007).  
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RNAs are subject to editing by adenosine deaminases acting on RNA (ADAR), which 
can convert adenosines (A) to inosine (I) in double-stranded RNAs (Valente and 
Nishikura, 2005). The converted base reads as a guanine (G) due to the similar base 
pairing properties. ADAR editing has been reported for a number of miRNAs and has 
been shown in certain miRNAs to alter Drosha (Yang et al., 2006, Kawahara et al., 
2008) and Dicer processing (Kawahara et al., 2007a), but not necessarily in a 
detrimental manner. When the edited base is situated in the ‘seed’ targeting region 
(refer to Section 1.2.4) of the miRNA, the alteration can be sufficient to redirect the 
miRNA to new target genes (Kawahara et al., 2007b).  
 
1.2.4 Mechanisms of microRNA-messenger RNA target interaction 
A defining characteristic of miRNA function is the ability to inhibit its target mRNA 
through base pairing with incomplete complementarity (Brennecke et al., 2005, 
Doench and Sharp, 2004, Lewis et al., 2005, Grimson et al., 2007). The most 
important region of the miRNA is the nucleotide region between positions 2 to 8 from 
the 5’ end, known as the seed region, which is often flanked by adenosines (Fig. 1.3) 
(Brennecke et al., 2005, Doench and Sharp, 2004, Lewis et al., 2005). The presence of 
mismatches predominantly in the centre which generates a central bulge is common, 
often followed by a less stringent degree of complementarity at the 3’ region, though 
positions 13 to 16 may be important when the seed complementarity is lacking 
(Brennecke et al., 2005, Grimson et al., 2007).  
 
The vast majority of known miRNA target sites lie within the 3’UTR and their 
position as well as the number of binding sites can influence repression efficiency. 
Target site accessibility is influenced by mRNA secondary structures and by 
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association with RNA-binding proteins in, or near, target sites (Ameres et al., 2007, 
Kertesz et al., 2007). Factors such as an AU-rich region, length of 3’ UTR and 
distance from poly(A) tail and terminal codon may also have an impact on the 
accessibility of the miRNA binding site (Gaidatzis et al., 2007, Grimson et al., 2007, 
Kertesz et al., 2007). Single target sites may be sufficient but multiple sites are often 
present, though they may need to be within a certain distance from one another (~ 10 
to 40 nucleotides) in order to act cooperatively, and may even require a specific 
configuration inbetween sites such as a defined sequence of nucleotides (Doench and 
Sharp, 2004, Grimson et al., 2007, Vella et al., 2004).  
 
 
 
 
 
 
 
 
 
 
Figure 1.3. MicroRNA-mRNA target interaction mechanisms. Base pairing of the 
miRNA to its target requires sufficient complementarity at positions 2 – 8 from the 5’ 
end of the miRNA (seed region shown in the red box). The presence of an A or A/U 
at positions 1 and 9 respectively improves target efficiency (yellow boxes).  
Reasonable complementarity at the 3’ end of the miRNA is also required to stabilise 
the interaction, particularly at positions 13 – 16 (pink boxes) and when there is 
suboptimal seed region complementarity. [Reproduced from Filipowicz et al., 2008]. 
 
 
Deviations from these rules have been found in C. elegans where an internal 
mismatch within the seed region has been shown to be required for let-7 binding to its 
target lin-41 3’ UTR (Vella et al., 2004). In humans, miR-10a also targets ribosomal 
protein transcripts via non-seed sites (Orom et al., 2008). A number of groups have 
also shown that miRNAs can repress via binding at the 5’ UTR and exonic regions, 
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with possible emphasis on the miRNA 3’ region for binding (Lee et al., 2009, Lytle et 
al., 2007, Orom et al., 2008, Tay et al., 2008).  
 
1.2.5 Mechanisms of messenger RNA repression 
Generally, the degree of complementarity of a miRNA and its target determines the 
mechanism of repression; mRNA degradation or translational inhibition. Highly 
matched mammalian targets have been shown to undergo degradation or slicing 
(Yekta et al., 2004), and the addition of central mismatches can reduce slicing activity 
(Martinez and Tuschl, 2004). Additionally, structural models indicate that the mRNA 
faces the Ago RNaseH active site ~ 10 nucleotides from the beginning of the miRNA-
mRNA duplex (Song et al., 2004), highlighting the importance of the central region 
for cleavage activity. However, in mammals, only Ago2 has endonucleolytic activity, 
which undoubtedly confers a level of specificity in the mode of target repression. 
Furthermore, a recent study demonstrated that the promoter of an mRNA target can 
influence the mechanism to be used for its translational inhibition by miRNAs in the 
cytoplasm (Kong et al., 2008), highlighting that additional factors may also be 
involved for certain miRNA-mRNA interactions.  
 
Figure 1.4 summarises the current main models of miRNA mediated repression. 
Regardless of the mechanisms involved, the argonaute proteins are likely to be key 
mediators given that, in the absence of miRNAs, the tethering of functional Ago 
proteins to target mRNAs can induce repression (Pillai et al., 2004). 
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Figure 1.4. Mechanisms of miRNA mediated repression. The association of the 
miRNP with a target mRNA can induce mRNA degradation by the process of 
deadenlyation (upper left). Alternatively, the target mRNA may be prevented from the 
process of translation by blocking initiation at the cap (lower left), blocking at the 
elongation steps (lower right) or subsequent degradation of the nascent peptide (upper 
right). Repression by deadenylation or at the translation initiation stage is followed by 
relocation of the mRNA to P-bodies for either degradation or storage. [Reproduced 
from Filipowicz et al., 2008]. 
 
 
Possibly the best characterised model is based on repression at the initiation stage of 
translation, with emphasis on the m7G cap of mRNAs (Humphreys et al., 2005, Pillai 
et al., 2005, Kiriakidou et al., 2007). Ago2 has been demonstrated to be able to 
compete with the eukaryotic translation initiation factor subunit 4E (eIF4E) for the 
m7G cap and thus inhibit translation of specifically capped mRNAs (Kiriakidou et al., 
2007). Binding affinity for the m7G cap is lower for Ago2 than eIF4E which may 
provide an explanation as to the benefits of multiple target sites in order to be able to 
effectively out compete eIF4E (Kiriakidou et al., 2007). Alternatively, translation 
initiation could be prevented by blocking the association of the 60S ribosomal subunit 
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protein (Chendrimada et al., 2007), which is consistent with the theory that poly(A) 
tails may have a role in translational repression (Wakiyama et al., 2007, Wang et al., 
2006, Humphreys et al., 2005, Chendrimada et al., 2007).   
 
Inhibition at the translation initiation stage may not be the only mechanism for mRNA 
repression. Known miRNA targets have been shown to remain associated with 
polysomes despite evidence of reduction in their protein levels, hinting at a post-
initiation mode of repression (Petersen et al., 2006, Nottrott et al., 2006). Co-
sedimentation of miRNAs and Ago proteins with polysomes have further argued for a 
post-initiation mechanism (Kim et al., 2004, Nelson et al., 2004). Suggested 
mechanisms include a ribosome drop-off model; where miRNAs may affect ribosome 
association and function and induce premature termination of translation (Petersen et 
al., 2006), or alternatively miRNAs may hinder translation elongation (Maroney et al., 
2006), though the precise mechanisms of either model remains unclear. Regardless of 
whether the initiation or post-initiation models are most prevalent, it is likely that the 
two are not mutually exclusive. 
 
Another possible post-transcriptional mechanism has been suggested, involving the 
continuous generation but rapid subsequent degradation of the nascent peptide (Olsen 
and Ambros, 1999). This proteolysis model is based on negative rather than positive 
data and is perhaps the least accepted model as proteasome inhibitors have been 
shown to have no effect on miRNA mediated repression (Nottrott et al., 2006, 
Petersen et al., 2006, Pillai et al., 2005) and no alternative mechanism has been 
suggested.  
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Irrespective of miRNA mediated cleavage, target mRNAs may also be destabilised 
and degraded as a result of miRNP association, possibly due to deadenylation (Wu et 
al., 2006). Studies have shown that validated target mRNA levels can vary 
dramatically when the miRNA pathway is inhibited, or when the expression levels of 
specific miRNAs were experimentally altered (Lim et al., 2005, Schmitter et al., 2006, 
Krutzfeldt et al., 2005). Synthetic targets of let-7 have also been shown to be 
destabilised to varying degrees in mammalian cell lines, and this was not attributed to 
Ago2 mediated cleavage (Schmitter et al., 2006). In zebrafish, maternal miR-430 
mRNA targets are deadenylated and subsequently degraded at the onset of zygotic 
transition (Giraldez et al., 2006). It is not known what determines mRNA degradation 
over translational repression, but the dynamics of the miRNA-mRNA interaction and 
accessory proteins may be involved (Schmitter et al., 2006). Further, mRNA 
degradation may follow translational repression, particularly in the eIF4E and m7G 
cap model, where association of Ago2 would not only prevent initiation onset but 
disrupt circularisation and render the poly(A) tail more vulnerable to subsequent 
exonucleolytic degradation (Kiriakidou et al., 2007, Filipowicz et al., 2008).    
 
Following miRNA mediated translational repression, various experiments have shown 
that miRNAs, target mRNAs and Ago proteins are compartmentalised and enriched in 
cytoplasmic foci known as processing bodies (P-bodies or GW-bodies) (Jakymiw et 
al., 2005, Liu et al., 2005). However, P-bodies have no effect on, and are not essential 
for, miRNA function and are therefore a consequence rather than a cause of mRNA 
silencing (Eulalio et al., 2007). Nevertheless, P-body formation requires functional 
miRNA based repression as demonstrated when global miRNA depletion leads to the 
dispersal of visible P-body aggregates (Eulalio et al., 2007, Pauley et al., 2006).  
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In certain cases, miRNA mediated repression has been shown to be reversible or 
preventable (Bhattacharyya et al., 2006, Schratt et al., 2006). Repression of Limk1 
mRNA by miR-134 is partially relieved in rat neurons in response to extracellular 
stimuli (Schratt et al., 2006), while the CAT1 mRNA can be relieved from miR-122 
induced inhibition and is released from P-bodies and recruited to polysomes in human 
hepatocarcinoma cells subject to different stress conditions (Bhattacharyya et al., 
2006). Interestingly, miRNAs have also been shown to be able to act as translational 
activators (Vasudevan et al., 2007), demonstrating the versatility and wide-ranging 
effects of miRNA mediated regulation.  
 
1.2.6 MicroRNA gene transcription  
The genes encoding miRNAs can be found in a variety of locations; from within the 
transcription units of host genes (intragenic), to regions outside of annotated genes 
(intergenic); individually or within polycistronic clusters (Lagos-Quintana et al., 
2001, Lau et al., 2001). Transcriptional regulation is likely to be essential for 
governing miRNA expression, and the specific localisation of a miRNA is expected to 
be a major factor in determining the mechanisms of transcription.  
 
Approximately half of all miRNAs are located within host transcriptional units and 
the host gene transcripts can be either protein-coding or non protein-coding. The 
majority of these miRNAs, whether it is one or multiple, are localized within an 
intronic region. However, there are a few documented miRNAs that have been found 
in the exons of non-protein coding genes, such as miR-155 transcribed from the B-cell 
Integration Cluster (BIC) (Lagos-Quintana et al., 2002). Approximately half of all 
human miRNAs are located within host genes (Saini et al., 2007), and miRNAs and 
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their host genes often portray similar expression profiles, which indicates that these 
miRNAs are transcribed as part of the long host transcription unit (Lagos-Quintana et 
al., 2001, Rodriguez et al., 2004, Baskerville and Bartel, 2005). Co-expression of 
miRNAs with their host genes confers a degree of temporal and/or spatial control that 
may constitute one of the ways in which miRNA expression can be regulated. 
Nonetheless, recent evidence has also emerged that more than 26% of intragenic 
miRNAs may be transcribed from their own promoters (Corcoran et al., 2009), 
suggesting that in some cases there may be an additional, if not entirely separate, 
approach to regulating intragenic miRNA transcription, which in turn may hint at a 
mechanism more akin to intergenic miRNAs.  
 
The nature of intergenic miRNAs strongly implies the existence of an independent 
miRNA containing transcription unit, often referred to as the miRNA gene, which can 
be up to several kilobases long (Saini et al., 2007). As with intragenic miRNAs, 
intergenic miRNAs can also be expressed individually or as polycistronic clusters. 
Approximately 50% of miRNAs are located in polycistronic clusters, and studies of 
various intergenic polycistronic miRNAs have provided evidence of transcription 
from their own promoters, and that the resulting transcripts have 5′ 7-
methylguanosine cap and a 3′ polyadenylated tail consistent with RNA polymerase II 
transcription and processing (Cai et al., 2004, Lee et al., 2002, Lee et al., 2004). 
However, fully verified intergenic miRNA transcriptional units are very few. A 
number of studies have utilized genome wide comparative approaches to elucidate 
miRNA promoters and define the precise start and end of miRNA transcription units 
(Saini et al., 2008, Zhou et al., 2007). A common strategy is to compare common 
features of known RNA polymerase II (or III) transcribed promoters of alternative 
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genes, with that of miRNA genes. Unfortunately, only a handful of these predictions 
have been fully characterised by experimental means, and it has become increasingly 
clear that though miRNAs may share similar properties to known gene promoters, 
there are also many exceptions (Zhou et al., 2007, Corcoran et al., 2009). For 
example, the experimentally verified promoter of the miR-23a~27a~24-2 cluster 
appears to lack common promoter elements required for transcription initiation, such 
as the TATA box, initiator element, downstream promoter element (DPE), TFIIB 
recognition element (BRE) (Lee et al., 2004). While a TATA box was found in mouse 
miR-290~291~292~293~294~295 cluster, deletion of this box showed little effect on 
expression levels (Houbaviy et al., 2005).  
 
1.2.7 Regulation of microRNAs 
Although many miRNAs are expected to be regulated at the transcriptional level, 
there is emerging evidence of post-transcriptional regulation for certain miRNAs. 
Many of these cases were discovered when a spatial discrepancy was observed in the 
expression of the mature processed miRNA against its primary and precursor forms 
(Obernosterer et al., 2006, Wulczyn et al., 2007). Drosha is likely to confer a point of 
post-transcriptional regulation, and has been shown for miR-18 to be dependent on 
the heterogeneous ribonucleoprotein particle, A1, to generate its pre-miRNA (Guil 
and Caceres, 2007, Michlewski et al., 2008). Human miR-31, miR-128 and miR-105, 
however, might be controlled at the nuclear export step because in certain cell types 
the precursors are retained in the nucleus without producing mature miRNA (Lee et 
al., 2008).  
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The let-7 miRNA in particular has been reported to be post-transcriptionally regulated  
in embryonic stem cells by a precise mechanism of LIN28 binding to the terminal 
loop of the pri-let-7 thereby blocking Drosha processing (Newman et al., 2008, 
Viswanathan et al., 2008). However, this association and regulation is stronger with 
pre-let-7, and given the cytoplasmic localisation of LIN28, it is now most widely 
believed to be a Dicer inhibition mechanism (Heo et al., 2008, Rybak et al., 2008), 
that may ultimately induce degradation of the precursor as a result of 3’ uridylation 
(Heo et al., 2008). In C. elegans, this process may be due to the recruitment of a 
poly(U) polymerase enzyme, PUP-2, by LIN28 to the terminal loop (Miska lab, 
Cambridge, unpublished). Though no other example of this type of regulation has 
been reported so far, it is feasible that other miRNAs may be similarly regulated at 
their pri-miRNA and pre-miRNA stages by RNA binding proteins.  
 
In many cases, miRNAs have been shown to be under the control of developmental or 
cell specific signalling pathways, giving rise to the use of miRNAs as genetic 
markers. One of the best characterised is the miR-302 family of miRNAs, which is 
expressed only in pluripotent cells, and is known to contain binding sites for the Oct4 
and Sox2 transcription factors in its core promoter (Barroso-delJesus et al., 2008, 
Card et al., 2008). Other well characterised cell specific miRNA markers are miR-1 
and miR-133 in skeletal muscle; also likely to be regulated by the myogenic specific 
factors Myogenin and MyoD (Chen et al., 2006, Rao et al., 2006). The tumor 
suppressor p53 has also been shown to activate the miR-34 family of miRNAs (He et 
al., 2007), while the oncogenic protein MYC may be involved in regulating a host of 
miRNAs involved in the cell cycle and apoptosis (Chang et al., 2008, Chang et al., 
2009).  
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Multiple feedback loops are also involved in the regulation of miRNAs. Drosha and 
its partner DGCR8 form a regulatory circuit; Drosha can cleave DGCR8 mRNA while 
DGCR8 stablises Drosha protein expression (Han et al., 2009). In humans, Dicer is  
negatively controlled by let-7 which binds to its 3’UTR and coding region (Forman et 
al., 2008, Tokumaru et al., 2008). Double negative feedback control is also seen with 
let-7 and LIN28 during differentiation, where let-7 inhibits lin-28 translation while 
LIN28 protein blocks let-7 maturation (Heo et al., 2008, Newman et al., 2008, 
Viswanathan et al., 2008).  
 
Degradation of miRNAs and their individual half-lives has not been fully elucidated 
in mammals. Depletion of miRNA processing enzymes indicate that some mature 
miRNAs can remain stable for long periods of time (Gregory et al., 2004), while its 
detrimental effect on the development of mouse embryonic stem cells suggest that 
other miRNAs may be turned-over more rapidly (Kanellopoulou et al., 2005, 
Murchison et al., 2005). The half-life of most miRNAs is likely to be greater than 14 
hours, and miRNAs bound to Ago proteins are likely to be more stable than unbound 
miRNAs (Hwang et al., 2007). However it is possible that specific miRNAs in certain 
situations would require a more rapid turnover, such as miR-29b (Hwang et al., 2007), 
and this is likely to be mediated by specific recognition of miRNAs by exonucleases. 
ERI1 (also known as THEX1) has been reported to be involved in the degradation of 
siRNAs in C. elegans (Kennedy et al., 2004), while RNA degrading nuclease (SDN) 
proteins may affect the stability of miRNAs in plants (Ramachandran and Chen, 
2008). Furthermore, recent studies by the Groβhans lab (unpublished) have suggested 
that in C. elegans an exoribonuclease, XRN-2, may be responsible for the degradation 
of certain miRNAs released by the miRNP when their target mRNAs are not present. 
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This suggests that target availability may also have a precise impact on the turnover of 
their targeting miRNA.  
 
In summary, there is no specific universal pathway for miRNA biogenesis, regulation 
and function. There are multiple stages that can be affected by as of yet undefined 
factors, and many of the currently known mechanisms are likely to be subject to 
review with the ongoing identification and characterisation of miRNA-specific 
processes. The discovery of additional miRNA associated partners as well as further 
insights into known associations will help to broaden our understanding of miRNA 
mechanisms, and ultimately, enable the use of miRNAs as a valuable tool for basic 
research and therapeutics.  
 
1.3 OTHER ENDOGENOUS RNA REGULATORS 
Aside from miRNAs, two other classes of small endogenous RNAs with regulatory 
roles have more recently been focused upon in mammalian systems; PIWI-interacting 
RNAs (piRNAs) and endogenous small interfering RNAs (endo-siRNAs).  
 
1.3.1 PIWI-interacting RNAs 
Piwi-interacting RNAs (piRNAs) were first identified in small RNA profiling studies 
of Drosophila, which revealed a subset of RNAs of approximately 24-30 nucleotides 
in length (Aravin et al., 2003, Aravin et al., 2001). These RNAs were endogenous and 
and specific to germ-line cells and many corresponded to intergenic repetitive 
elements including retrotransposons, and hence were termed rasiRNAs (repeat 
associated small interfering RNAs) (Aravin et al., 2003). In other experiments, PIWI 
proteins were shown to be required for self-renewal in germ-line cells (Cox et al., 
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1998, Cox et al., 2000, Szakmary et al., 2005) and for controlling transposons 
(Kalmykova et al., 2005, Sarot et al., 2004). Subsequently, mutations in piwi were 
reported to affect rasiRNA levels in the ovary (Vagin et al., 2006), which provided the 
connection between PIWI proteins and rasiRNAs. PIWI homologues in mice were 
also shown to be associated with rasiRNAs (Aravin et al., 2006, Girard et al., 2006, 
Grivna et al., 2006, Watanabe et al., 2006), which were subsequently renamed as 
piRNAs.   
 
In mammals, piRNAs can be derived from repeat and transposon-rich clusters 
expressed before meiotic pachytene (Aravin et al., 2006), or at the pachytene stage 
(Aravin et al., 2008, Girard et al., 2006). In mouse, the pre-pachytene stage piRNAs 
have been shown to associate with mouse PIWI proteins, MILI and MIWI2, while the 
pachytene stage piRNAs associate with MILI and MIWI (Aravin et al., 2008, Girard 
et al., 2006). Pachytene piRNAs are extremely abundant in spermatocytes but their 
sequences are not conserved among mammals, and Girard et al. (2006) have pointed 
out that this may be an indication that the sequence of a piRNA does not necessarily 
specify its function, and that its true function may be determined by the abundance of 
piRNAs produced from any individual locus. The majority of mammalian piRNAs 
have been studied in mouse and each map as a single copy in the mouse genome 
(Aravin et al., 2007, Girard et al., 2006, Lau et al., 2006). Genomic analysis has 
indicated that the encoding genes for piRNAs can range in size from 1 to 100 
kilobases in length (Girard et al., 2006). Approximately 17% of mammalian piRNAs 
map to repeat sequences, including LINEs, SINEs, and several classes of DNA 
transposons (O'Donnell and Boeke, 2007). Generally, piRNAs exhibit pronounced 
strand bias, suggesting that biogenesis may be from a long single stranded precursor 
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though there is little evidence currently available to validate or refute this theory (Seto 
et al., 2007). Figure 1.5 illustrates the features that are currently known about the 
piRNA biogenesis cycle in mouse, which is based almost entirely on what has been 
discovered in D.melanogaster (Kim et al., 2009).  
 
Drosha and Dicer have not been implicated in piRNA processing, though the slicer 
nuclease activity of the PIWI proteins may be required (Vagin et al., 2006, Saito et al., 
2006). Given the localisation of PIWI proteins in the cytoplasm, primary processing 
of piRNA containing transcript and subsequent loading is likely to occur in the 
cytoplasm though the factors involved are unknown (Kim et al., 2009). The secondary 
processing step (also known as the ping-pong cycle theoretically involves MILI 
introducing a cleavage in the precursor to define the 5' end of piRNA, which is 
subsequently accepted by MIWI2 (also known as PIWIL4) (Kim et al., 2009, 
Brennecke et al., 2007, Gunawardane et al., 2007). MIWI2 can then cleave the 
opposite strand precursor through its slicer activity, generating the 5' end of the 
piRNA that subsequently binds to MILI (Kim et al., 2009, Brennecke et al., 2007, 
Gunawardane et al., 2007). How the 3' end of the piRNA is generated is currently 
unknown.  
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Figure 1.5. Biogenesis of piwi-interacting RNAs. The piRNAs are processed from 
single stranded precursors and subsequently are most likely to be processed by the 
nuclease activity of the Piwi proteins. Biogenesis is split into primary and secondary 
mechanisms. Primary processing is likely to occur in the cytoplasm as the PIWI 
proteins (MILI and MIWI in mouse) are localised to the cytoplasm, but the exact 
factors involved are unknown (shown on the right). Secondary processing (also 
known as the ping pong cycle) involves MILI cleavage of one strand of the precursor 
to define the 5’ end piRNA followed by MIWI2 loading and cleavage of the opposite 
strand precursor to generate the 5’ end of the piRNA that is loaded into MILI (shown 
on the left). Many of the factors involved remains unknown, including how the 3’ end 
of the piRNA is generated and whether MIWI2 is subsequently relocated to the 
nucleus. [Reproduced from Kim et al., 2009]. 
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There have been implications of mouse piRNAs functioning in a similar manner to 
those in flies; in silencing selfish DNA elements, as their sequences correspond to 
known transposon sequences, though whether the mechanisms involved are similar or 
not remains debateable (Kim et al., 2009). It has also been shown in the mouse that 
mutations in Mili and Miwi2 lead to male infertility as a result of the elimination of 
DNA methylation of long interspersed nuclear element 1 (LINE1) and intracisternal A 
particle (IAP) (Aravin et al., 2007, Carmell et al., 2007). It is therefore possible that 
piRNAs are involved in transcriptional silencing of target genes through DNA 
methylation. 
 
As mammalian piRNAs differ significantly from those found in flies, the majority of 
which are not recognizably transposon related, this suggests that the mammalian 
piRNA machinery may possibly have acquired additional germline specific functions. 
O’Donnell and Boeke (2007) have suggested that perhaps this opportunity arose 
because most mammalian genomes, unlike those of invertebrates and lower 
vertebrates, appear to have successfully eradicated all but a few major lineages of 
mobile elements in their genomes. Hence, the piRNA machinery may have 
evolutionarily adapted to perform some other germline functions.  
 
Studies into piRNAs in mammals remain at their early stages with far less being 
understood, and far more based on extrapolation and conjecture, than for the siRNA 
and miRNA pathways. It is likely that piRNAs provide important regulatory roles, but 
whether it is specific to mobile element control, or meiosis, or alternative germline 
functions remains to be determined.  
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1.3.2 Endogenous small interfering RNAs 
Exogenous small interfering RNAs (siRNAs) have been in use as an RNAi research 
tool in mammalian systems for many years, and although the expression of 
endogenous siRNAs is well characterised in plants and C. elegans, they were not 
considered to be a feature of mammalian cells until recent years (Babiarz et al., 2008, 
Tam et al., 2008, Watanabe et al., 2006, Yang and Kazazian, 2006). Similar to 
piRNAs, endogenous siRNAs (endo-siRNAs) have mostly been studied in 
D.melanogaster and various groups have characterised many of their biogenesis and 
functional features in this system (Czech et al., 2008, Ghildiyal et al., 2008, 
Kawamura et al., 2008, Okamura et al., 2008a, Okamura et al., 2008b). In mammals,  
endo-siRNAs have been best characterised in oocytes in mice (Tam et al., 2008, 
Watanabe et al., 2006). Deletion of PIWI protein members resulted in the activation 
of transposons and subsequent loss of fertility in male mice as expected with a loss of 
piRNA, but surprisingly no effects were seen in female mice. Further characterisation 
of small RNA expression in mouse oocytes led to the identification of endo-siRNAs 
as the alternative pathway to piRNAs that could confer protection against mobile 
elements (Tam et al., 2008, Watanabe et al., 2006).  
 
Endo-siRNAs are approximately 21 nucleotides long, and can be derived from a range 
of sources including transposable elements (Tam et al., 2008, Watanabe et al., 2006). 
They share some similarities to miRNAs in their biogenesis in that Dicer and at least 
one of the argonaute proteins, Ago2, is also required (Watanabe et al., 2006). Whether 
other Ago proteins can be utilised, or if TRBP is required in partnership with Dicer, is 
currently unknown. Studies in mice have shown that endo-siRNA precursors are 
generated from long primary transcripts (Fig. 1.6), but can take on the form of long 
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hairpin precursors derived from inverted repeats in the same orientation, or bi-
directional transcripts from the same loci (cis precursor) or two separate but similar 
loci (trans precursor) (Watanabe et al., 2006).  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Generation of endogenous siRNA precursors. Endo-siRNAs can be 
transcribed from intergenic repetitive elements, pseudogenes or endo-siRNA clusters. 
The double stranded precursors can arise from sense and antisense transcription from 
the same loci or different but similar loci to form cis-dsRNA or trans-dsRNA. 
Transcription can also occur from inverted repeats in the same orientation that give 
rise to hairpin-type precursors. [Modified from Kim et al., 2009]. 
 
 
 
Pseudogene transcripts can also generate endo-siRNAs by annealing to their cognate 
functional transcripts, and some of these endo-siRNAs were perfectly complementary 
to their putative target transcripts, suggesting an Ago2 mediated slicer mechanism 
(Tam et al., 2008, Watanabe et al., 2006). Further, in Dicer and Ago2 mutants these 
functional genes are up-regulated suggesting that regulation by endo-siRNAs may be 
physiologically relevant (Tam et al., 2008, Watanabe et al., 2006). Thus, a negative 
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feedback loop appears to operate between the pseudogene derived endo-siRNA and 
its source gene via an RNAi mechanism. Another example of endo-siRNA regulation 
in human cell lines comes from the 5’ UTR of the human LINE1 (LI) element. 
Transcription from opposing promoters generates the LI-specific endo-siRNA which 
is associated with the degradation of L1 transcripts and repression of L1 transposition 
(Yang and Kazazian, 2006). Taken together, it is likely that endo-siRNAs function via 
the RNAi pathway to regulate both protein-coding genes and retrotransposons, and 
thus bridging the roles attributed to miRNAs and piRNAs.  
 
1.4 CURRENT TOPICS IN MICRORNA RESEARCH 
The advances in our understanding of small RNAs as global gene regulators has led to 
increasing studies of their effects in disease and development. In particular, the focus 
on miRNAs in cancer and stem cell research has led to significant advances in both 
areas, helping to identify both key genes that are subject to miRNA regulation for 
normal and adverse effects, as well as novel features concerning the regulation of 
certain miRNAs themselves (O'Donnell et al., 2005, Cimmino et al., 2005, Gangaraju 
and Lin, 2009, Esquela-Kerscher and Slack, 2006, Dalmay and Edwards, 2006).  
 
1.4.1 MicroRNAs in diagnostics and therapeutics 
Although many aspects of miRNA biology and function remain unclear, large scale 
profiling studies have shown that miRNAs exhibit consistently altered expression in 
various types of cancer cells compared to normal cells (Calin and Croce, 2006, 
Volinia et al., 2006, Yanaihara et al., 2006). A large proportion of known human 
miRNAs have also been reported to be mapped to fragile sites and therefore likely to 
play a role in cancer (Calin et al., 2004b). Some of the miRNAs identified from these 
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studies have experimentally validated oncogenic or tumour suppressor activity and 
thus have the potential to be developed into diagnostic, prognostic or even therapeutic 
tools. Several families or clusters of miRNAs have been well characterised for their 
roles in tumourogenesis, and among these are the let-7 family, the miR-17~92 cluster, 
the miR-15~16-1 cluster, as well as individual miRNAs such as miR-21 and miR-155 
and many others (Esquela-Kerscher and Slack, 2006). 
 
One of the first studies to identify miRNAs as potential tumour suppressors arose 
from the profiling of miRNA expression in patients with B-cell chronic lymphocytic 
leukemia (CLL), which showed that two miRNAs, miR-15a and miR-16-1, which are 
derived from the same cluster often appeared to be down-regulated or deleted (Calin 
et al., 2002). Subsequently, it was shown that miR-15a and miR-16-1 target the anti-
apoptotic gene, BCL2, which is often over expressed in many types of cancers 
(Cimmino et al., 2005). Hence it was surmised that miR-15a and miR-16-1 are 
required as tumour suppressors to prevent the over expression of BCL2 which would 
otherwise promote leukaemogenesis and lymphomagenesis in haematopoietic cells 
(Calin et al., 2005, Cimmino et al., 2005).  
 
Let-7 is another well established tumour suppressor miRNA. In animals, the 
biological function of let-7 includes the regulation of proliferation and differentiation 
(Esquela-Kerscher and Slack, 2006, Hatfield and Ruohola-Baker, 2008, Yu et al., 
2007a). This is due in part to let-7 regulation of the RAS genes, which act to stimulate 
cell growth (Johnson et al., 2005). Profiling studies have shown a similar marked 
reduction of let-7 in various cancers (Nam et al., 2008, Volinia et al., 2006), further 
validating its role as a tumour suppressor. There is also a strong correlation between 
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the expression levels of let-7 and post-operative survival in patients with lung cancer, 
where low let-7 expression corrleates with  a poor prognosis, indicating that let-7 may 
be a useful diagnostic tool (Takamizawa et al., 2004).  
 
Conversely, a number of miRNAs have been identified that act as oncogenes, many of 
which were first identified due to their association with the MYC proto-oncogene. 
MYC is a transcription factor that regulates cell proliferation and apoptosis and is 
often found to be amplified in cancers (Pelengaris et al., 2002). The translocation of 
MYC into the locus of miR-142 places it downstream of the miR-142 hairpin and 
under the control of its promoter, leading to the B cell transformation possibly as a 
result of both disrupted miR-142 processing and increased MYC activity (Lagos-
Quintana et al., 2002). Other miRNAs, such as the miR-17~92 cluster, may target 
apoptotic factors that are activated in response to MYC over expression and hence 
work co-operatively with MYC to drive cells to proliferate uncontrollably, resulting in 
cancer (He et al., 2005). The miR-17~92 cluster is also over expressed in various 
cancers (Hayashita et al., 2005), and it has been shown that MYC directly regulates 
the miR-17~92 primary transcript by binding to the first intron of its host gene 
C13orf25 (O'Donnell et al., 2005). However, the miR-17~92 cluster can also behave 
as tumour suppressors rather than oncogenes, as a target of miR-17~92 is E2F1, a 
transcription factor that functions in a reciprocal positive-feedback loop with MYC 
(O'Donnell et al., 2005), thus adding another layer to the complexities of miRNA 
mediated control in cancer.  
 
The use of miRNAs as cancer diagnostic tools has had some success with numerous 
profiling studies using distinct miRNA expression signatures to classify cancers 
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(Calin et al., 2005, Calin et al., 2004a, Takamizawa et al., 2004, Iorio et al., 2005, Lu 
et al., 2005). Lu et al., 2005 also found that miRNA signatures could be used to 
successfully categorise poorly differentiated tumours, previously considered 
histologically non-diagnostic, into their appropriate tissue specific lineages, further 
attesting to the usefulness of miRNAs in defining and enabling accurate diagnosis. 
However, the focus of deriving a use for miRNAs as administrable therapeutic agents 
remains at an early stage. There has been some success in delivering anti-miRNA 
oligonucleotides (antagomirs) conjugated with cholesterol into mice to inhibit the 
activity of select miRNAs (Krutzfeldt et al., 2005), though the effectiveness of similar 
siRNA agents have been shown to be limited by the immune response (Izquierdo, 
2005). However, a more recent study in mice with hepatic cancer has demonstrated 
effective tumour regression from the administration of a single miRNA by an adeno-
associated viral vector (Kota et al., 2009). This type of study highlights the potential 
for miRNAs in therapeutics and the continued advances being made in this field.   
 
1.4.2 MicroRNAs in human stem cells 
Stem cells are defined by their ability to self-renew and differentiate into other cell 
types, and the factors that govern these properties involve complicated networks of 
regulation at the transcriptional, post-transcriptional, epigenetic and signaling 
pathways (Evans and Kaufman, 1981, Martin, 1981, Takahashi and Yamanaka, 2006). 
MicroRNAs are predicted to regulate approximately a third of all known genes, 
therefore it is not surprising that miRNAs are also key regulators of stem cell fate and 
behaviour (reviewed in Gangaraju and Lin, 2009). The identification of stem cell 
specific miRNAs has enforced the view that miRNAs are highly important for stem 
cell specification (Houbaviy et al., 2003, Suh et al., 2004).  
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Embryonic stem cells (ESCs) are the most extensively studied stem cell model for 
miRNAs. They are derived from the inner cell mass of blastocyst stage embryos and 
under normal development will eventually give rise to all of the different cell types in 
an organism. Initial studies into the effects of miRNAs on ESCs involved the 
abolishment of miRNA activity through the generation of Dicer and DGCR8 mutants 
(Kanellopoulou et al., 2005, Wang et al., 2007, Bernstein et al., 2003). In vivo, loss of 
Dicer resulted in embryonic lethality in mice, and the derived ESCs exhibit 
differentiation and growth defects, as well as delayed cell cycle progression, but were 
viable (Bernstein et al., 2003). In vitro, Dicer-null ESCs can be induced to 
differentiate, but fail to express certain differentiation markers such as the endodermal 
marker, hepatocyte nuclear factor 4A (HNF4A); and the mesodermal markers, 
brachyury, bone morphogenetic protein 4 (BMP4) and GATA1 (Kanellopoulou et al., 
2005). DGCR8-null ESCs show similar phenotypes with delayed cell-cycle 
progression; cells arrested at the G1 phase, and differentiation defects as a result of an 
inability to regulate differentiation markers; cells continued to express self-renewal 
markers, OCT4, SOX2 and Nanog (Wang et al., 2007). The global perturbation of the 
miRNA pathway in ESCs therefore emphasized a role for miRNAs in both 
differentiation and proliferation.  
 
Subsequent cloning and sequencing studies of both mouse and human ESCs have 
identified miRNAs that are specific to this cell type, as well as subsets of miRNAs 
that were up or down regulated following differentiation (Houbaviy et al., 2003, Suh 
et al., 2004). Surprisingly, many of the ESC specific miRNAs detected were not 
conserved between human and mouse, which is now thought to be a result of 
experimental limitations as recent advances in high throughput deep sequencing 
 42 
technologies have identified better overlap between the miRNAs expressed in mouse 
and human ESCs, as well as between self-renewing and differentiating cells (Morin et 
al., 2008). Studies to characterise the role of highly expressed ESC miRNAs have 
highlighted miR-21, miR-134, miR-296 and miR-430 as important regulators of the 
pluripotency factors, SOX2, Nanog and OCT4 (Singh et al., 2008, Tay et al., 2008). 
Interestingly, key ESC specific transcription factors have been shown to bind to the 
promoters of ESC specific miRNAs to regulate their expression, hinting at multiple 
layers of ESC specific control (Marson et al., 2008).  
 
Adult multipotent stem cells are also extensively regulated by miRNAs and, similar to 
ESCs, display cell type specific expression and regulation. In hematopoietic stem 
cells, miR-128 and miR-181 are highly expressed in early stage progenitor cells and 
act to prevent differentiation, while miR-221, miR-222 and miR-223 control the 
terminal differentiation pathways (Georgantas et al., 2007). Two miRNAs, miR-1 and 
miR-133, are known to be muscle-specific miRNAs that are important for heart 
development and physiology (Chen et al., 2006, Zhao et al., 2007). The promotion of 
neuronal differentiation has also been attributed to miR-124 and miR-128, whereas 
miR-26, miR-29 and miR-23 are preferentially and specifically expressed in the 
astrocyte lineages (Cao et al., 2007, Makeyev et al., 2007, Smirnova et al., 2005). Key 
miRNAs have also been identified in the regulation of osteogenic differentiation (Luzi 
et al., 2008, Mizuno et al., 2008), and in the promotion of epidermal stem cell 
differentation (Yi et al., 2008).  
 
It is clear that miRNAs play an essential role in the complex network of gene 
regulation events that govern stem cell states. Ultimately, the identification of specific 
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miRNA expression in various stem cell types will help to elucidate the precise 
mechanisms by which stem cells normally maintain their function and identity. 
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1.5 PROJECT AIMS 
 
At the time of starting this project, there were no deep sequencing profiles of 
microRNA expression generated from human stem cells, and therefore the initial aim 
was to generate microRNA libraries from various human stem cells and subsequently 
to characterise their expression and function. In collaboration with Professor David 
Baulcombe and Attila Molnar we generated microRNA libraries from human 
mesenchmal stem cells, embryonic stem cells (hESCs) and from neuronal stem cells 
(hNSCs) that were derived by differentiation from the hESCs. These libraries formed 
the platform for all of my subsequent studies to:  
 
Assess the functional characteristics of microRNAs and their isomers 
The sequencing results from the microRNA libraries strongly indicated that individual 
microRNA genes often express a number of different mature miRNA isomer forms. 
Consequently, a major project aim that developed was to investigate whether this 
observation was of functional significance by characterising isomer expression in 
different human cell types and also assessing their ability to target mRNAs.  
 
Characterise the regulation of microRNAs during differentiation 
As expected, the hESC and hNSC libraries also allowed us to identify microRNAs 
whose expression changed markedly upon differentiation of hESCs along the 
neuronal lineage. I therefore undertook experiments that aimed to confirm the changes 
in microRNA expression indicated by the sequencing results and to investigate 
whether the observed changes in microRNA expression were regulated at 
transcriptional or post-transcriptional levels.  
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Identify messenger RNA targets of microRNAs 
In order to identify key messenger RNA (mRNA) targets of microRNAs, I also aimed 
to profile the global mRNA expression of the same cells used to generate the libraries, 
and to investigate the use of Argonaute immunoprecipitation as a means to determine 
functionally important mRNA targets.  
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CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 CELL CULTURE 
2.1.1 General cell culture 
All culture dishes (Nunc), flasks (Triple Red), and serological plugged pipettes 
(Corning) used were suitable for sterile tissue culture. Experiments were carried out in 
a Class II flow cabinet and all cells were maintained at 37°C in 10% CO2. Unless 
otherwise stated, all cell lines used were cultured in D10 media (Dulbeco’s Modified 
Medium (DMEM) supplemented with 10% (v/v) heat inactivated Foetal Calf Serum 
(FCS), 50 U/ml penicillin/streptomycin (Invitrogen, Gibco) and 200 µM glutamine 
(Invitrogen, Gibco)).  Cells were passaged twice weekly by washing in PBS and then 
incubating with 0.25% trypsin (Invitrogen, Gibco) for approximately 5 minutes at 
37oC in 10% CO2. The cells were then re-suspended in D10 media and centrifuged at 
1200 rpm for 5 mins. The cell pellet was then resuspended in D10 and plated to the 
required density.  
 
2.1.2 Human mesenchymal stem cells  
Human mesenchymal stem/stromal cells were obtained from Prof. Nick Fisk (Uni. of 
Queensland, Australia, formerly Imperial College London), from first trimester fetal 
blood, at passage 5 – 6. Cells were cultured in normal D10 medium and incubated at 
37oC in 10% CO2. Prior to total RNA extraction, the cells were split into 4 x 150 mm 
diameter dishes and grown to confluence.  
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2.1.3 Human embryonic stem cells and neuroprogenitor stem cells 
Two human embryonic stem cell (ESC) lines designated H1 and H7 were obtained 
from Dr Wei Cui (Imperial College London), along with their differentiated neuronal 
progenitor stem cells (NSC). All cells were grown on poly-L lysine (Sigma) and 
laminin (Invitrogen) coated plates. Briefly, 6-well plates were coated with 1 ml of 
16.7 µg/ml of poly-L lysine in PBS for 1 hr. The poly-L lysine solution was removed 
and 1 ml of 20 µg/ml of laminin in PBS was added to each well and incubated at 4oC 
overnight. The laminin solution was removed prior to seeding the cells.  
 
The ESCs were cultured in SR medium (knockout DMEM + knockout serum 
replacement, Invitrogen, Gibco) conditioned mouse embryonic fibroblasts (MEFs) 
and supplemented with 0.4 µl/ml basic fibroblase growth factor (bFGF) on matrigel-
coated plates, plus 50 U/ml penicillin/streptomycin (Invitrogen, Gibco), and 200 µM 
glutamine (Invitrogen, Gibco), all reagents supplied by Dr Wei Cui. The medium was 
changed daily and cells were maintained in ESC colonies at confluence. 
 
Neuroprogenitor stem cells were grown in N2B27 medium containing 1:1 of DMEM 
and neurobasal medium plus 1% B27 and 0.5% N2 supplements and 1% L-glutamine 
(all reagents from Invitrogen). The medium was changed every 2 days and 20 ng/ml 
of EGF and 20 ng/ml of bFGF were added fresh with every passage. 
 
2.1.4 Freezing cell lines 
Adherent cells were incubated with 1 ml of 0.25% trypsin, and then the trypsin was 
inactivated by adding 9 mls of D10 media. The cells were centrifuged at 1200 rpm for 
5 minutes and re-suspended in D10 media with 10% dimethyl sulfoxide and 
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immediately aliquoted into 1 ml cryotubes. The cells were frozen slowly in a cryo 
freezing container containing propan-2-ol at -80°C for at least 48 hrs and then 
removed to be stored either directly in -80oC or in liquid nitrogen.  
 
2.1.5 Total RNA extraction 
The cells were lysed and total RNA was extracted using Trizol as per manufacturer’s 
instructions. 4 x 150 mm dishes of sub-confluent to confluent cells were required to 
generate ~500 µg of total RNA. 5 mls of trizol reagent was used per 10 cm dish, and 
all the resultant total RNA extracted was pooled at the end and resuspended in 50 µl 
of water treated with 0.1% diethylpyrocarbonate (DEPC). 0.5 µl of the sample was 
removed for quality check of 28S and 18S RNA on a 1.5% agarose gel. The samples 
were quantified by measuring 1 µl on a nanodrop. All RNA samples were stored at –
80oC.  
 
The quality of RNA samples was checked on a 1.5% TBE agarose gel containing 0.1 
µg/ml of Ethidium Bromide (Sigma). The samples were run at 100 V for 1 hr and the 
quality of the 28S and 18S rRNA bands were checked under UV light.  
 
2.2 MICRORNA LIBRARIES 
The generation of the human MS, ES and NS miRNA libraries was done in 
collaboration with Prof. David Baulcombe’s group, University of Cambridge formerly 
at the Sainsbury’s laboratory (John Innes Centre, Norwich) using protocols that were 
established by Dr Attila Molnar and Miss Louise Chappell. The human MS library 
was generated in the Sainsbury laboratory using the 454 sequencing protocol, while 
the human ES and NS libraries were subsequently generated at the University of 
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Cambridge using the Solexa sequencing protocol. All of the stages of construction 
including the sequencing of the libraries were conducted under the supervision of Dr 
Attila Molnar.  
 
2.2.1 454 Sainsbury Protocol – Human MS miRNA library 
Isolating small RNAs and adapter ligations 
Approximately 500 µg of total RNA was separated on a 15% polyacrylamide 
denaturing gel (7M Urea) along with an oligonucleotide ladder with markers at 20, 
30, 40, 60 and 80 nucleotides (nt). The gel containing the RNA sample was excised 
between the 20 – 30 nt markers and cut into 1 mm cubes and eluted in 3 x volume of 
0.3 M NaCl solution, at 4oC overnight on a rotating platform. Fresh solution was 
added and the elution was repeated for another 6 - 8 hrs before both elution solutions 
were pooled and centrifuged at 3000 rpm for 20 mins at 4oC to spin down any residual 
gel. The solution was then transferred to a fresh 15 ml falcon tube and the small 
RNAs were precipitated with 3 x volume of -20oC ethanol, plus 0.1 x volume of 3 M 
sodium acetate and 1 µl of 10 mg/ml glycogen, overnight at -20oC.   
 
The small RNA sample was pelleted by centrifugation at 3000 rpm for 1 hr, and then 
washed with 80% ethanol. The pellet was resuspended in 20 µl of DEPC-treated 
water and transferred to a 1.5 ml eppendorf. The 5’ adapter was ligated to the small 
RNA sample by adding 3 µl of 100 µM oligo plus 6 µl of DMSO to the sample, and 
denaturing at 90oC for 1 min. The volume was adjusted to 32.5 µl with DEPC-treated 
water, and then 4 µl of 10 x ligation buffer, 1.5 µl of RNaseOUT, and 2 µl of T4 RNA 
ligase was added. The sample was mixed and incubated at 37oC for 1 hr.  
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1 x volume of gel loading dye was added and the sample was denatured at 65oC for 5 
mins, before being loaded onto a 15% polacrylamide denaturing gel and separated at 
250 volts (V). The gel fragment was excised between the 30 – 60 nt markers and 
eluted as previously described.  
 
The 3’ adapter was ligated to the small RNA sample as described with the 5’ adapter, 
and the gel fragment was excised between the 50 – 80 nt markers and eluted as 
previously described. The pellet was resuspended in 10 µl DEPC-treated water.  
 
RT-PCR 
To the adapter-RNA sample, 2 µl of the 3’ PCR primer (100 µM) was added, and the 
solution was denatured at 90oC for 1 min. 3 µl of 0.1 M DTT, 6 µl of 5 x first strand 
buffer, and 3 µl 10 mM dNTPs were added and the solution made up to 28.5 µl with 
DEPC-treated water. The sample was mixed and incubated at 50oC for 3 mins, before 
1.5 µl of the reverse transcriptase (Superscript II, Invitrogen) was added to the tube 
and the sample was incubated at 42oC for 30 mins, followed by 50oC for 30 mins.  
 
To hydrolyse the RNAs, 0.4 µl of 0.1 M EDTA and 1.52 µl of 1 M potassium 
hydroxide was added to 10 µl of the sample and incubated at 90oC for 10 mins, then 
left on ice for 1 min before 1.8 µl of 1 M Tris-HCL pH 1.0 and 0.4 µl of 0.2 M 
magnesium chloride was added to the tube.  
 
The PCR reaction was set up by adding 10 µl of 10 mM dNTPs, 50 µl of 10 x Taq 
polymerase buffer, 5 µl of each of the 5’ and 3’ PCR primers (100 µM) and 5 µl of 
Taq polymerase enzyme, to the sample adjusted to 500 µl with water. The PCR mix 
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S1      S2   20 bp ladder S1      S2   20 bp ladder 
200 bp 
 
 
100 bp 
was then split evenly into 5 x 0.5 ml PCR tubes and the PCR reaction set at 94oC for 2 
mins, followed by 21 cycles of 94oC for 30 sec, 50oC for 30 sec, 72oC for 30 sec, and 
terminated at 72oC for 10 mins. The PCR products were then pooled into a 1.5 ml 
eppendorf and phenol:chloroform extracted, before precipitation with 0.1 x volume of 
3 M sodium acetate, 2 µl of 10 mg/ml glycogen and 3 x volumes of ethanol at -20oC 
overnight.  
 
The PCR products were separated in a 10% native polyacrylamide gel alongside a 20 
bp step ladder (Sigma). The miRNA library was indicated by a strong band at ~100 
bp, with artefact adapter-dimers at ~80 bp (Fig. 2.1). The miRNA library was excised 
from the gel and eluted with 3 x volume of DNA elution buffer (0.5 M ammonium 
acetate, 10 mM magnesium acetate, 1 mM EDTA, 0.1% w/v SDS), at 37oC under 
agitation overnight.  
 
 
 
 
 
 
 
 
Figure 2.1. Gel separation and excision of miRNA library PCR products. The 
PCR products were separated on a 10% native PAGE along with a 20 bp ladder 
(Sigma) and the region corresponding to ~100 bp was excised for elution (right 
panel). S1 and S2 refer to experimental duplicates where only S1 gave the appropriate 
sized product.  
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The elution was repeated with fresh buffer for 6 - 8 hrs, before the solutions were 
pooled and residual gel was pelleted by centrifugation. The miRNA library was 
precipitated as previously described and resuspended in 20 µl water. 
 
Note – The majority of the hMSC miRNA library was submitted for 454 sequencing 
at this point, while a sample was taken and prepared for conventional sequencing via 
pGEM-T easy vector cloning.  
 
pGEM-T easy vector cloning 
The miRNA PCR products were cloned into pGEM-T Easy vector (Promega) as 
follows; 2 µl of the PCR sample was mixed with 1 µl of pGEM-T Easy vector, 5 µl of 
2 x rapid ligation buffer, 1 µl of T4 DNA ligase, and made up to 10 µl with water. 
The ligation reaction was incubated at room temperature for 2 hrs, and then added to 
50 µl of TOP10 competent cells and incubated on ice for 30 mins. The cells were 
subjected to heat shock for 30 sec at 42oC, and then placed immediately on ice. 500 µl 
of SOC medium was added to the cells and incubated at 37oC, agitating at 250 rpm 
for 1 hr. LB plates supplemented with ampicillin was pre-warmed at 37oC, and 100 – 
200 µl of the cells were spread evenly onto the plate and incubated at 37oC overnight.  
 
Colony PCR  
The PCR mix was prepared as follows: 200 µl of 10 x Taq polymerase buffer; 40 µl 
of 10 mM dNTPs; 20 µl of both the M13 forward and reverse primers (100 µM); 73 
µl of 1% w/v W-1 detergent (Brig-35P, Sigma) and 20 µl of Taq polymerase enzyme 
was mixed together and made up to 2000 µl with water. 20 µl of the PCR mix was 
pipetted into each well of a 96 well PCR plate. A p10 pipette tip was used to swipe 
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the edge of one of the single colonies on the plate and placed inside one of the wells. 
This was repeated for all 96 wells so that each well contained a p10 tip which had a 
sample of an individual colony. The pipette tips were mixed thoroughly with the 
solution inside each of their wells and then removed, and the plate was spun briefly to 
pool the solutions inside the wells. The PCR reaction was set at 94oC for 2 mins, 
followed by 35 cycles of 94oC for 30 sec, 55oC for 30 sec, 72oC for 30 sec, and 
terminated at 72oC for 10 mins. A sample of 5 µl of each of the PCR products was 
then checked on a 1.5% TBE agarose gel for amplification.  
 
A shrimp alkaline phosphatase (SAP) and exonuclease I (Exo I) reaction mix was set 
up by mixing 200 µl of SAP (1U/µl) with 20 µl of Exo I (20U/µl), made up to 1500 µl 
with water. To each of the 96 wells in the PCR plate, 15 µl of the mix was added. The 
plate was then incubated at 37oC for 30 mins, and inactivated at 80oC for 10 mins.  
 
Sequencing 
The colony PCR products were prepared for pre-sequencing PCR by mixing 4 µl of 
each sample with 1 µl of M13 forward primer (3.2 pmol/µl) and 1 µl of Big Dye 
Terminator (BDT), made up to 10 µl with water. The PCR reaction was set at 96oC 
for 3 mins, followed by 25 cycles of 96oC for 10 sec, 50oC for 5 sec, 60oC for 4 mins, 
ramping at 1oC/sec, and held at 4oC. 
 
Big Dye precipitation solution was made up to 8 mls with 6.25 mls of 100% ethanol, 
0.3 mls of 3 M sodium acetate and 1.45 mls of water. 40 µl of the precipitation 
solution was added to each of the pre-sequencing PCR products and left at room 
temperature for 20 mins. The samples were then centrifuged at 4000 rpm for 40 mins, 
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and the supernatant was discarded. Samples were washed with 50 µl of 70% ethanol 
and centrifuged at 4000 rpm for 5 mins. The supernatant was discarded and the 
samples were left to dry at 37oC for 30 mins. Samples were submitted for in-house 
sequencing with ABI Prism Big Dye Terminator cycle sequencing reaction kit and 
were analyzed using the 3100 Genetic analyser, 16 capillary model (Applied 
Biosystems).  
 
2.2.2 Solexa Protocol – Human ES and NS miRNA libraries 
Approximately 10 µg of total RNA was enriched for small RNAs using the miRVana 
kit (Ambion) according to the manufacturer’s instructions. Eluted small RNAs were 
precipitated with an equal volume of 100% Isopropanol and 3 µl of 15 mg/ml 
glycogen (Ambion glycoblue) and incubated at –80 C for 20 to 30 minutes. The 
RNAs were pelleted at max speed in a microcentrifuge at 4oC and then washed with 
80% ethanol. The RNA pellet was air dried then dissolved in a total of 5.7 µl of 
DEPC-treated water (Ambion).  
 
To ligate the 5’ adapter RNA, the small RNAs were denatured at 90oC for 30 seconds 
and then snap cooled on ice. A mix of 1.3 µl of 5’ adapter RNA (5 µM), 1 µl of 
RNAguard (40 U/µl) (GE Healthcare), 1 µl of 10 x RNA ligation buffer and 1 µl of 
T4 RNA ligase (10 U/µl) (Promega), was added to the 5.7 µl of small RNAs and 
incubated at 37oC for 1 hr. The reaction was stopped by the addition of 10 µl of 2 x 
formamide gel loading buffer and incubated at 65 oC for 5 mins prior to loading into a 
15% TBE denaturing polyacrylamide gel. A 40-60 nt ladder was loaded with one 
space between the ladder and sample and then run at 150V for 2 hrs until the xylene 
cyanol had run near the bottom of the gel. Only the ladder portion of the gel was 
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stained with Ethidium bromide and used as a guide to locate the approximately 40-60 
nt section from the unstained sample portion of the gel to be excised. The gel portion 
was then transferred to a 0.5 ml RNase-free microfuge tube with puncture holes in the 
bottom from a 21 gauge needle, and placed into a 2 ml RNase-free round bottom 
microfuge tube. The combined tubes were spun at max speed for 2 mins, or until all 
the gel had passed through the holes into the 2 ml microfuge tube. 500 µl of sterile 0.3 
M NaCl was added to the tube to elute the RNA, and the tube was rotated at 4oC 
overnight. To purify the eluate, the gel debris and eluate was transferred into a Spin-X 
Cellulose Acetate filter with a 2 ml collection tube and spun at max speed for 2 
minutes and then washed with 100ul 0.3 M NaCL and spun for another 2 mins. The 
RNA from the total collected eluate was precipitated with an equal volume of 100% 
propan-2-ol and 3 µl of glycogen and incubated at -80oC for 20-30 mins. The tube 
was then spun at max speed for 30 mins at 4oC, and the supernatant was removed. 
80% ethanol was added to wash the pellet before it was air dried at room temperature 
and resuspended in 6.4 µl of DEPC-treated water.   
 
To ligate the 3’ adapter, the same procedure as the 5’ adapter was used with the 
following amendments:  0.6 µl of 3’ adapter (10 uM) was added for the ligation; a 60-
80 nt ladder was loaded to gauge the area to be excised from the gel; the eluted and 
precipitated RNA pellet was resuspended in 4.5 µl of DEPC-treated water.  
 
RT-PCR of adapter ligated small RNAs 
To the 4.5 µl adapter ligated RNA sample, 0.5 µl of the 3’ PCR primer (100 µM) was 
added, and the solution was denatured at 65oC for 10 mins. 1 µl of 100 mM DTT, 2 µl 
of 5 x first strand buffer, 0.5 µl of RNAguard (40 U/µL) and 1 µl 10 mM dNTPs were 
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added. The sample was heated to 48oC for 3 min and then 1 µl of SuperScript™ II RT 
(200U/µL) was added and the sample was incubated at 42oC for 1 hr.  
 
Note – At this point, a pilot PCR was set up to test the ES and NS samples to use for 
conventional sequencing prior to performing the final PCR reaction for the Solexa 
sequencing.  
 
Pilot PCR and cloning 
The PCR reaction was set up by adding 1 µl of 10 mM dNTPs, 4 µl of 5 x Phusion 
HF buffer, 0.25 µl of each of the 5’ and 3’ PCR primers (50 µM) and 0.2 µl of 
Phusion DNA polymerase enzyme (Finnzymes), to 1 µl of the RT sample adjusted to 
20 µl with water. The PCR reaction was set at 98oC for 30 sec, followed by 20 cycles 
of 98oC for 10 sec, 58oC for 30 sec, 72oC for 20 sec, and terminated at 72oC for 5 
mins. In order to clone the PCR products, 1 µl of Taq polymerase enzyme (New 
England BioLabs) was added to the PCR reaction at the end, and the samples were 
incubated at 72oC for 15 mins to allow the incorporation of Adenosine Triphosphate 
overhangs required for pGEM-T easy vector cloning.  
 
The PCR products were purified on a 6% TBE native polyacrylamide gel and the 
band representing approximately ~90 bp was excised and eluted using the same 
protocol as with the previous adapter ligation purifications with the following 
amendments: 300 µl of 1 x buffer 2 (New England BioLabs) (10 mM Tris-HCL pH 
7.9; 10 mM MgCl2; 50 mM NaCl; 1 mM DTT) was added to the gel fragments and 
incubated at 30oC for 1 hour shaking, and then transferred to rotate at 4oC overnight; 
100 µl of 1 x buffer 2 was used for the wash step. The DNA was precipitated with 40 
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µl 3 M NaOAc pH 5.2, 1 ml 100% Ethanol and 3 µl glycoblue for overnight at -20oC. 
The tube was then spun at max speed for 30 mins at 4oC, and the supernatant was 
removed. 80% ethanol was added to wash the pellet before it was air dried at room 
temperature and resuspended in 6 µl of water.   
 
The PCR products were cloned into pGEM-T Easy vector (Promega) as follows; 3 µl 
of the PCR sample was mixed with 1 µl of pGEM-T Easy vector, 5 µl of 2 x rapid 
ligation buffer, and 1 µl of T4 DNA ligase, to make up a 10 µl total volume. The 
ligation reaction was incubated at room temperature for 1 hr or 4oC overnight, and 
then added to 100 µl of DH5a competent cells and incubated on ice for 40-60 mins. 
The cells were subjected to heat shock for 30 sec at 42oC, and then placed 
immediately on ice. 500 µl of 2 x YT medium was added to the cells and incubated at 
37oC, agitating at 250 rpm for 30 mins. LB plates supplemented with ampicillin was 
pre-warmed at 37oC, and 100 – 200 µl of the cells were spread evenly onto the plate 
and incubated at 37oC overnight.  
 
Colony PCR and sequencing was performed as described for the 454 sequencing 
protocol. Subject to the presence of clones positive for miRNA inserts as verified by 
sequencing, a scaled up PCR reaction was performed with the initial RT sample for 
Solexa sequencing.  
 
Scaled-up PCR for Solexa cloning 
A 200 µl PCR reaction was set up by adding 5 µl of 10 mM dNTPs, 40 µl of 5 x 
Phusion HF buffer, 1 µl of each of the 5’ and 3’ PCR primers (25 uM) and 2 µl of 
Phusion DNA polymerase enzyme (Finnzymes), to 4 µl of the RT sample adjusted to 
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200 µl with water. The PCR reaction was set at 98oC for 30 sec, followed by 15-20 
cycles of 98oC for 10 sec, 58oC for 30 sec, 72oC for 20 sec, and terminated at 72oC for 
5 mins. The PCR product was precipitated with 1/10 volume of 3M NaOAc, 2.5 
volumes of EtOH and 3 µl of glycoblue (Ambion), and resuspended in 20 µl of water 
and stored at -20oC.  
 
The scaled up PCR sample was purified using the same 6% native polyacrylamide gel 
as with the pilot PCR. To avoid overloading, the sample was split and loaded into two 
consecutive lanes with a gap between a 20bp ladder (Sigma). The ~90 bp band was 
excised and the DNA was eluted from the gel as described for the pilot PCR and gel 
purification. To precipitate the DNA, 1 µl of Pellet Paint (Novagen) at room 
temperature, 40 µl of 3 M NaOAc and 1000 µl of EtOH was added to the elutate and 
incubated at -20oC overnight. To pellet the DNA, the sample was spun at max speed 
for 30 mins and then washed with 1000 µl of 80% EtOH, before resuspending in 15 
µl of sterile buffer (10 mM Tris-HCL pH 8.5). 1 µl of the sample was quantified by 
nanodrop prior to submission for Solexa sequencing.  
 
2.2.3 Specific priming for individual microRNAs 
Specific miRNAs of known sequence were detected by ligating 3’ UUU-adapters or 
3’ AAA-adapters followed by RT-PCR (refer to Section 2.7.5 for primer and adapter 
sequences, and miRNA sequence specific primers). To ligate the 3’ adapter, 12 µl of 
gel isolated small RNAs were denatured with 2 µl of the 3’ adapter at 95oC for 1 min 
and then snap cooled on ice. A mix of 1 µl of RNAguard (40 U/µl) (GE Healthcare), 
2 µl of 10 x RNA ligation buffer and 2 µl of T4 RNA ligase (10 U/µl) (New England 
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Biolabs), was added and incubated at 37oC for 1 hr. The ligase was inactivated at 
65oC for 15 mins and then 95oC for 2 mins, before storing at -20oC.  
 
The 3’ adapter ligated small RNA sample was reverse transcribed by adding 10 µl of 
the sample to 1 µl of the appropriate 3’ AAA or UUU PCR primer and denaturing at 
95oC for 1 min, and then on ice. 1 µl of 100 mM DTT, 4 µl of 5 x first strand buffer, 
and 1 µl 10 mM dNTPs were added and the sample was incubated at 50oC for 3 mins. 
Then 1 µl of RNAguard and 1.5 µl of SuperScript™ II RT (200U/µL) were added and 
the sample was incubated at 42oC for 30 mins followed by 50oC for another 30 mins.  
 
The PCR reaction was set up by adding 1 µl of 10 mM dNTPs, 2 µl of 10 x Standard 
Taq buffer, 0.5 µl of each of the miRNA specific primer and 3’ PCR primer (50 uM) 
and 1 µl of Taq DNA polymerase enzyme (New England Biolabs), to 5 µl of the RT 
sample adjusted to 20 µl with water. The PCR reaction was set at 94oC for 2 mins, 
followed by 35 cycles of 94oC for 30 sec, 50oC for 30 sec, 72oC for 30 sec, and 
terminated at 72oC for 10 mins. PCR products were size fractionated on a 12% native 
PAGE and the appropriately sized fragment was eluted and cloned into the pGEM-T 
Easy vector for sequencing as described for the 454 cloning protocol.  
 
2.3 NORTHERN HYBRIDISATION 
2.3.1 Labelling of DNA probes with 32P γATP 
DNA oligonucleotides probes complementary to the target miRNAs were labelled 
with high specific activity 32P γATP as follows; 0.5 µl of the oligonucleotide probe 
(50 µM) was mixed with 1 µl of polynucleotide kinase (PNK) buffer, 1 µl of PNK 
enzyme, 1 µl of 32P γATP and made up to 10 µl with water. The sample was then 
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incubated at 37oC for 1 hr. To remove any excess 32P γATP, an ethanol precipitation 
step was performed by adding 70 µl of Tris-EDTA pH 8.0 (TE) buffer, 20 µl of 
ammonium acetate (10 M) and 1 µl of glycogen to the sample. The sample was mixed 
thoroughly before 250 µl of -20oC ethanol was added and the sample was left on ice 
for 1 hr. The sample was then centrifuged at max rpm at 4oC for 20 mins. The 
supernatant was removed and the sample was left to air dry briefly before being 
resuspended in 100 µl TE. The radioactivity of the precipitate and the removed 
supernatant were checked with a Geiger counter and the precipitate was stored at -
80oC. 
 
2.3.2 Denaturing PAGE and semi-dry blot 
30 – 50 µg of total RNA was separated on a 10% or 15% polyacrylamide denaturing 
gel (7M Urea) in 0.5 x TBE buffer at 150 V. The gel was washed with gentle agitation 
in 0.5 x TBE for 5 mins to remove excess urea. 6 pieces of Whatman filter paper, and 
1 piece of Hybond N+ nylon membrane was cut to the same size as the gel and soaked 
in 0.5 x TBE. 3 of the pieces of filter paper were then placed on the semi-dry blot 
apparatus and the membrane was layered on top. The gel was positioned on top of the 
membrane before the remaining 3 pieces of filter paper were also added to the gel 
sandwich. Bubbles within the gel sandwich were squeezed out by rolling a long 
pipette over the top, and any excess liquid surrounding the sandwich was wiped away. 
The semi-dry apparatus was run at 3.3 mA/cm2 of the gel sandwich for 35 mins (~5 
V). The membrane was washed in 0.5 x TBE for 5 mins, and then placed on top of a 
piece of filter paper and UV crosslinked at 1000 µJoules, twice.  
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2.3.3 Hybridisation 
The membrane was washed with 2 x SSC + 0.1% SDS with gentle agitation for 5 
mins at room temperature. Hybridisation buffer consisting of 15 ml of 20 x SSC, 5 ml 
of 50 x Denhardt’s solution, 2.5 ml of 10% SDS, and made up to 50 ml with water, 
was pre-warmed to 42oC. The membrane was placed inside a 15 ml falcon tube with 
the transferred RNA side facing upwards, and pre-hybridised with 3 mls of the 
hybridisation buffer, rotating at 42oC for 30 mins. The solution was removed and 
fresh hybridisation buffer was added to the tube along with 50 µl of the 32P γATP 
labelled oligonucleotide probe specific for the miRNA of interest. The probe was 
hybridised to the membrane for at least 2 hrs at 42oC, and then washed twice in 2 x 
SSC + 0.1% SDS at room temperature. The membranes were exposed at -80oC with 
an intensifying screen for a minimum of 24 hrs.  
 
2.4 WESTERN BLOTTING AND IMMUNOPRECIPATION 
All reagents, buffers and solutions described are detailed in Sections 2.7.2 (western 
blotting); 2.7.3 (immunoprecipitation) and 2.7.4 (common buffers).  
 
2.4.1 Cell lysis   
Adherent cells were plated into 6-well plates and grown to confluence. The cells were 
then washed in 1 x PBS before being lysed in 200 µl of RIPA directly in the wells.  
Using a cell scraper, the lysates were transferred into 1.5 ml eppendorfs and any 
insoluble debris was pelleted at 13,000 x g in a microfuge for 10 mins at 4°C. The 
supernatant was transferred to a new eppendorf and 20 µl of Laemlli lysis buffer was 
added.  Samples were stored at -20°C.   
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Suspension cells were grown in T25 flasks until confluent and then pelleted at 1,200 x 
g for 5 mins. The cells were then washed with PBS and spun again to pellet the cells 
before being lysed in 200 µl of RIPA lysis buffer. Lysates were spun to remove any 
insoluble debris and Laemmli lysis buffer was added as described for adherent cells.  
 
2.4.2 SDS-PAGE  
Cell lysates were run on either an 8% or 10% (w/v) resolving with 4% (w/v) stacking 
acrylamide gel based on the size of protein to be analysed. Glass plates (18.5cm x 
20cm) were assembled using 1mm spacers at the sides and the bottom.  These were 
held together using bulldog clips and sealed using 1% agarose. The bottom and top 
atrium of the tank were filled with 1 x SDS running buffer and 10 µl Laemmli loading 
dye was added to each of the wells. Samples were loaded at equal concentration and 
the gel was run at 150 volts for 5 hours. 
 
2.4.3 Nitrocellulose wet transfer  
Gels were transferred using a wet transfer blotting system (Biorad). Gels were 
carefully removed from between the glass plates and layered into the permeable 
folding apparatus in the following order; a sponge layer, 2 sheets of Whatman 
chromatography paper, the nitrocellulose sheet (0.2 µm pore size) (Amersham), the 
gel, 2 further sheets of whatman blotting paper (Whatman), and finally another 
sponge layer. The gel sandwich was soaked in a tray filled with transfer buffer and 
any air bubbles were removed by rolling a tube across the sandwich. The folding 
apparatus was closed and slotted into the transfer tank, which was then filled to the 
top with transfer buffer. The apparatus was run at 200 mA for 5 hrs.   
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2.4.4 KIT Antibody hybridisation  
Prior to antibody hybridization, the nitrocellulose membrane was stained with 
Ponceau S (Sigma) for general proteins as a loading and even transfer check. The 
membrane was scanned at this point in order to have a permanent record. The 
membrane was then washed with 1 x TBS-T buffer for 5 mins, rolling at rtp in a 150 
ml tube (Appleton Woods) to remove any residual ponceau staining. The wash buffer 
was then remove and replaced with 5 ml of 5% milk in 1 x TBS-T, and 1:1000 
dilution of the c-kit antibody (rabbit polyclonal IgG, cat. no. sc-168, Santa Cruz), and 
incubated at 4oC overnight rolling. The membrane was then washed with 1 x TBS-T 
buffer for 10 mins, before incubating for 2 hrs rolling at rtp with 10 ml of 5% milk 
and 1:10000 dilution of the anti-rabbit IgG secondary antibody (Sigma). The 
membrane was then washed with 1 x TBS-T buffer for 10 mins.  
 
Membranes were developed using the ECL plus reagents (Amersham). The 
membrane was laid flat on cling film and the ECL plus was left on the membrane for 
5 minutes before being covered with the cling film. The membrane was incubated 
with GRI biomax film and developed with a developing machine (Kodak). 
 
 
2.4.5 Argonaute Immunoprecipitation  
A confluent flask of T75 cells were washed with PBS and lysed with 10 ml of NP-40 
lysis buffer. The cells were spun at 3,000 x g for 30 mins at 4oC, and the supernatant 
was added to a fresh 15 ml falcon tube. 2 mls of Argonaute1 (Ago1) and Argonaute2 
(Ago2) hybridoma supernatants were added, this was supplied by Gunter Meister, 
Max-Planck Institute, Germany. HRAS (Y13259) hybridoma supernatant was 
supplied by Steve Dilworth, Imperial College London).  The tubes were rolled at 4oC 
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overnight and then 80 µl of protein-G beads (Autogen Bioclear) was added to the 
lysate and rolled at 4oC for 1 hr. The beads were then spun down at 3,000 x g for 5 
mins and washed with 3 x 10 mls of NP-40 wash buffer and 1 x 10 mls of PBS, before 
resuspending in 200 µl of Tris-EDTA pH 8 buffer. Next the beads solution was 
transferred to a 1.5 ml eppendorf and an equal volume of phenol pH 8 was added. The 
tube was vortexed for 1 min and then spun at max speed for 2 mins at rtp. The 
resultant aqueous phase was pipetted into a fresh 1.5 ml tube and ethanol precipitated 
with 1 µl of glycoblue (Ambion), 1/10 volume of 3M NaOAc and 3 x volumes of 
EtOH, overnight at -20oC.  
 
Following precipitation and resuspension of the Ago bound RNAs in DEPC-treated 
water, the sample was either loaded onto a 15% denaturing PAGE and Northern 
blotted for specific miRNAs (refer to section 2.3), or used directly for RT-PCR (refer 
to section 2.5).  
 
2.5 GENERAL RT-PCR AND CLONING 
2.5.1 RT-PCR of genes  
To reverse transcribed from total RNA samples, 20-100 ng of RNA was used. For 
RNA extracted from immunoprecipitation, at least half of the total resultant volume of 
RNA was used.  
 
The sample of RNA and 0.1-0.5 µg of random hexamers were made up to 4.5 µl with 
water and the solution was denatured at 65oC for 10 mins. 1 µl of 100 mM DTT, 2 µl 
of 5 x first strand buffer, 0.5 µl of RNAguard (40 U/µL), 1 µl of 10 mM dNTPs, and 
finally 1 µl of SuperScript™ III RT enzyme (200U/µL) were added. The sample was 
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incubated at 42oC for 30 mins and then 50oC for 30 mins. For gene specific RT, 
substitute the random hexamers for 1 µl of 10 µM gene specific reverse primer. 
 
The PCR reaction was set up using the gene specific primers (refer to section 2.7.5 for 
all primers). Briefly, 1 µl of the RT sample was added to 1 µl of each of the forward 
and reverse primers (10 uM), 1 µl of 10 mM dNTPs, 2 µl of 10 x buffer and 1 µl of 
Taq polymerase (New England Biolabs) and made up to 20 µl with water. The PCR 
reaction was set at 94oC for 2 mins, followed by 35 cycles of 94oC for 30 sec, 55oC 
for 30 sec, 72oC for 30 sec, and terminated at 72oC for 5 mins (Note – extension time 
was determined based on a rate of extension of 1 kb/min).  
 
All PCR products were run on TBE agarose gels to check the product sizes. Briefly, 1 
- 2% (w/v) agarose, depending on fragment sizes, was dissolved in 1x TBE and left to 
cool before adding 0.1 µg/ml ethidium bromide (Sigma-Aldritch). Samples were 
mixed with 1/3 volume of 3 x loading dye containing bromophenol blue and xylene 
cyanol and then loaded into the wells of the gel alond with a 1 Kb ladder (Invitrogen) 
or a 50 bp ladder (New England Biolabs). Gels were run at 100 V for 1-2 hours and 
then visualised for bands on a UV light box.   
 
2.5.2 Transcriptional start site 5’ RACE assay  
The 5’ RACE assay was carried out with the Ambion FirstChoice RLM-RACE kit 
(cat.no. AM17000) as per manufacturer’s instructions and using reagents supplied by 
the kit unless otherwise specified. All primers were either supplied by the kit, or are 
listed in section 2.7.5 under 5’ RACE primers.  
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Briefly, total RNA (10 µg) was treated with Calf Intestinal Phosphatase for 1 hr at 
37oC. The reaction was terminated with the addition of ammonium acetate, prior to 
acid phenol-chloroform extraction. RNA from the aqueous phase was precipitated 
with an equal volume of isopropanol for 10 mins on ice and pelleted at max speed for 
20 mins at 4oC. The pellet was washed with 70% ethanol and air dried before being 
resuspended in 10 µl of water. Half of the sample was then treated with Tobacco Acid 
Pyrophosphatase for 1 hr at 37oC and then stored at -20oC. 
 
The RNA was ligated to the 5’ RACE adapter with T4 RNA ligase for 1 hr at 37oC 
and then a quarter of the sample was reverse transcribed with M-MLV Reverse 
Transcriptase for 1 hr at 42oC and stored at -20oC. The sample was then subjected to 
nested PCR involving two rounds of PCR; first with the 5' RACE gene-specific outer 
primer and subsequently with the 5' RACE gene specific inner primer. Both cycles 
consisted of an initial denaturating step at 94oC for 3 mins, then 35 repeats of 94oC for 
30 sec, 60oC for 30 sec, 72oC for 30 sec, and a final extension of 72oC for 7 mins. 
PCR products were then visualised on a 2% agarose gel stained with ethidium 
bromide and then excised for sequencing.  
 
2.5.3 Generating PCR fragments for cloning  
To generate fragments from BAC clones or any other vectors for cloning purposes, 
the previously described method was used with the following substitutions; 20-50 ng 
of the relevant vector was used as the base for amplification. Phusion High fidelity 
Taq polymerase (Finnzymes) was used with its 10 x HF buffer, or the 10 x GC buffer 
for fragments with high GC content. The extension time is adjusted to a rate of 0.5 
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kb/min. Forward and reverse primers should include restriction site overhangs for 
later cloning steps (refer to section 2.7.5). 
 
2.5.4 Preparation of inserts and vectors for cloning  
Restriction enzyme digests were performed using NEB restriction enzymes (Biolabs) 
with the recommended buffers and at the recommended reaction temperatures. All 
reactions were carried out in a final volume of 20 µl and contained 1-2 µg of 
plasmid/vector or 5 µl of the PCR product, 2 µl enzyme buffer and 1 µl enzyme and 
were incubated for 2-3 hrs at the suggested temperature. The reactions were stopped 
by adding 1/5 of 5 x orange G loading dye and fragments were then isolated on an E-
gel (refer to section 2.5.5).  
 
2.5.5 E-Gel extraction  
To isolate digested fragments for subsequent ligations, the samples were run on small 
(3 mm x 75 mm x 75 mm) 1% (w/v) agarose E gels (1% E buffer containing 0.1µg/ml 
ethidium bromide).  Samples were loaded into the E-gel with a lane between each 
sample along with a 1 kb ladder (Invitrogen). Gels were run at 30 volts for 
approximately three hours in 1 x E-buffer. To isolate the required fragment, a section 
corresponding to the width of the fragment was cut out of the gel above the DNA 
band, leaving a well inside the gel. The gel was then placed back into the tank in the 
opposite direction on a raised block. The empty well next to the DNA fragment was 
washed and then filled with fresh buffer. The gel was then run for 15 seconds (small 
DNA fragment) or 20 seconds (larger DNA fragment) at 150 V. During this step the 
DNA enters the cut well and the solution is removed with a pipette and placed into a 
1.5 ml eppendorf. Fresh buffer was then added to the well, and the previous step was 
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repeated four times until all of the required DNA was removed as seen by the 
disappearance of the band under UV light. The eluate tube was then spun for 2 
minutes and the supernatant removed to a fresh tube. DNA was ethanol precipitated 
by adding 1 µl of glycogen, 1/10 of the volume of NaOAc pH 5.2 and 2.5 times the 
volume of -20°C ethanol and then incubated on ice for 1 hr (or overnight at -20°C) 
and spun for 20 minutes at max speed in a microfuge at 4oC. The supernatant was 
removed and tubes washed with 70% ethanol at rtp. Pellets were air dried before 
being re-suspended in 10-20µl of TE buffer.  
 
2.5.6 Ligation and transformation  
DNA inserts and vectors with matching restriction cut ends were ligated together by 
adding T4 DNA ligase (New England Biolabs) and 10 x ligation buffer to the insert 
and vector. The insert and vector ratio was titrated to ensure optimum ligation 
efficiency, e.g. 1 µl of vector to 1, 3 and 5 µl of insert in separate tubes. To the vector 
and insert mix, 1 µl of T4 DNA ligase and 1 µl of 10 x ligation buffer were added, 
and the total volume was made up to 10 µl with water. A negative control containing 
no insert was also made. The samples were then incubated at rtp for 5 hrs in the dark, 
before 100 µl of DH5α competent cells were added to each tube and incubated on ice 
for 40 mins. The samples were then heat shocked at 42oC for 30 secs and placed on 
ice for a further 1 min. 500 ul of YT medium was added to each sample before they 
were incubated at 37oC shaking at 250 rpm for 30 mins. Each sample was then plated 
onto separate pre-warmed agar plates containing 100 µg/ml ampicillin, at the same 
volume (200 µl) and left to incubate overnight at 37oC.  
 
The number of colonies visible on each plate was counted and compared against the 
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negative control plate to determine the ligation and transformation efficiency. Colony 
PCR may be performed at this stage to determine if colonies contain the correct 
plasmid with insert (refer to Colony PCR in section 2.2.1). Alternatively, colonies 
may be selected immediately for small scale plasmid preperation (refer to section 
2.5.7). 
 
2.5.7 Plasmid preparation 
For small scale plasmid purification, a singly colony was picked from the transformed 
DH5α plate and inoculated with 1 ml of YT media containing 100 µg/ml ampicillin 
and placed at 37oC shaking overnight. The resultant broth containing proliferated cells 
was spun at max speed in a microfuge for 1 min. The supernatant was removed and 
the plasmids were purified using the QIAprep miniprep plasmid Purification Kit per 
manufacturer’s instructions (Qiagen).     
 
For large scale plasmid purification, transformed DH5α cells from the agar plate were 
scraped into a conical flask with 250 mls of YT media containing 100 µg/ml 
ampicillin. The flask was placed into a 37°C shaker overnight and the cells were 
harvested by spinning at 3,000 x g at 4oC for 30 mins. Plasmids were isolated from 
the cells using the QIAGEN Maxi plasmid purification kit as per manufacturer’s 
instructions (Qiagen). The concentrations of the plasmids were measured by nanodrop 
spectrophotometer and the samples were stored at -20oC. 
 
Plasmids were checked for the correct insert by restriction enzyme digests or PCR and 
sequencing (concentration of plasmids adjusted to 100 ng) as described in sections 
2.5.4 and 2.2.1 respectively. 
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2.6 CELL TRANSFECTION 
2.6.1 Transient plasmid transfection  
Cell lines to be transfected were grown to 80% confluence in their usual media 
without the addition of penicillin/streptomycin.  Cells were transfected with ESCORT 
V lipid based transfection reagent (Sigma) as per manufacturer’s instructions.  
Briefly, for the transfection of plasmid DNA into a 6 well plate, 300 µl of Escort V 
buffer was mixed with 3.5 µg of plasmid and in a separate tube, 300 µl of Escort V 
buffer was mixed with 10 µl of Escort V transfection reagent and incubated for 5 mins 
at rtp. The two mixtures were combined, inverted 3 times and incubated at room 
temperature for 25 mins.  The mixture was then added to cells drop wise and 
incubated for 48 hours before assaying by western blotting (refer to section 2.4).  
 
2.6.2 Luciferase assay  
All of the constructs used for luciferase assays were prepared as detailed in section 
2.5, and a list of the primers and vectors used for cloning are given in the primer list 
in section 2.7.5. 
 
MicroRNA targeting analysis was performed by the insertion of predicted target sites 
downstream of the gene encoding for firefly luciferase in the pGL3-Control vector 
(Promega). Assays were performed in 96-well plates using HEK293 cells at ~60% 
confluence at the time of transfection, and incubated for 48 hrs. Renilla luciferase was 
used as the internal control. The total concentration of transfected DNA plasmids was 
made up to 50 ng with a green fluorescent protein (GFP) expressing vector driven by 
the pGK promoter to enable visualization of transfection efficiency. All experiments 
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were performed with a negative control pGL3 vector which contains no insert, and 
transfected in triplicates, as follows: 
 
For each well of a 96-well plate, the following 5 components were each made up to 1 
ul before being mixed to a final transfection volume of 5 ul: 20 ng of the target firefly 
luciferase construct; 2 ng of the renilla luciferase vector; 25 ng of a pGK-GFP vector; 
0.15 ul of FuGene transfection reagent (Roche) and synthetic microRNAs (known as 
pre-miRs, Ambion) diluted to a range of 0.1 – 20 pmol, all diluted in Optimem 
(Invitrogen). The mixture was then incubated at rtp for 25 mins before being added to 
the wells dropwise gently.  
 
Promoter analysis was performed by the insertion of predicted promoter regions 
upstream of the gene encoding for firefly luciferase in the pGL4.10 vector (Promega). 
Assays were performed in 24-well plates using HEK293, MSC, early and late NS 
cells at between 60-80% confluence at the time of transfection, and incubated for 48 
hrs. Renilla luciferase was used as the internal control. The total concentration of 
transfected DNA plasmids was made up to 1.3 µg with a green fluorescent protein 
(GFP) expressing vector driven by the pGK promoter to enable visualization of 
transfection efficiency. All experiments were performed with a negative control pGL4 
vector which contains no insert and transfected as follows:  
 
For each well of a 24-well plate, the following was added; 1 µg of the target firefly 
luciferase construct, 150 ng of the renilla luciferase vector, 150 ng of a pGK-GFP 
vector, and 2.5 µl of FuGene transfection reagent (Roche) diluted to 30 µl total 
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volume in Optimem (Invitrogen). The mixture was then incubated at rtp for 25 mins 
before being added to the wells drop wise gently.  
 
To assay the results of luciferase transfections, an equal volume of SteadyLite Plus 
reagent (PerkinElmer) was added to the wells and incubated in the dark for 10 mins. 
Lysis of the cells was confirmed by microscopy before 100 ul of the medium was 
transferred to a white walled 96-well plate. Next the firefly luciferase reading was 
taken using the Partha Luminescence program on a plate reader (Wallac 1420 Victor2, 
PerkinElmer). 25 ul of RenLite (0.5 M HEPES, 0.5 M EDTA and 1 mg/ml 
coelenterazine) was then added to each well and the plate was incubated in the dark 
for 25 mins. The renilla luciferase reading was then read using the same program on 
the plate reader and the two datasets were combined to allow the standardization of 
the firefly luciferase reading against the renilla luciferase reading for the final result.  
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2.7 REAGENTS, PRIMERS AND CONSTRUCTS 
2.7.1 Cloning reagents 
15% denaturing PAGE: 21 g urea, 2.5 ml 10 x TBE, 18.75 ml of 40% (w/v) 19:1  
    acrylamide:bis-acrylamide, Adjust volume to 50 ml  
with water. Add 350 µl of 10% (w/v) ammonium  
persulphate (APS) and 17.5 µl of TEMED 
10% denaturing PAGE: As above but with 12.5 ml of 40% (w/v) 19:1  
    acrylamide:bis-acrylamide 
10% native PAGE:  As above but without urea. Samples loaded with non- 
denaturing gel loading dye 
Denaturing loading dye: 10 ml deionized formamide, 200 µl 0.5 M EDTA  
pH 8.0, 1 mg xylene cyanol FF, 1 mg bromophenol 
blue,  
Non-denaturing loading dye: 0.02% w/v 1 M EDTA pH 8.0, 0.25% w/v xylene  
cyanol FF, 0.25% w/v bromophenol blue,  
15% Ficoll in water.  
 
2.7.2 Western blotting reagents 
Antibodies: 
• KIT Primary - c-Kit rabbit polyclonal IgG (Santa Cruz) 
• Secondary - Peroxidase conjugated Goat anti-rabbit IgG (Sigma Aldrich) 
 
Polyacrylamide 8% gel: 16.95 ml Deionised water, 13.4 ml 30% Acrylamide  
/Bis solution (Biorad), 18.75 ml 1 M Tris (pH 8.8),  
0.5 ml 10 % SDS, 0.5 ml 10% ammonium  
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persulphate, 30 µl TEMED    
Polyacrylamide 10% gel: 18.75 ml Deionised water, 13.25 ml 30% Acrylamide  
/Bis solution (Biorad), 18.75 ml 1 M Tris (pH 8.8),  
0.5 ml 10 % SDS, 0.5 ml 10% ammonium  
persulphate, 30 µl TEMED    
Polyacrylamide stacking gel:  6.8 ml Deionised water, 1.7 ml 30% Acrylamide / 
Bis solution (Biorad), 1.25 ml 1 M Tris (pH 6.5),  
0.1 ml 10 % SDS, 0.1 ml 10 % ammonium  
persulphate, 10 µl TEMED    
RIPA/SDS lysis buffer: 1% Nonidet P-40, 1% Triton X-100, 1% Sodium  
Deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM  
 Tris pH 8.0, 2 nM NaF 
(RIPA/SDS was stored at 4°C and 10µl per ml of 
protease inhibitor mix and Aprotinin was added before 
use.) 
Protease inhibitor mix: 20 mg/ml phenyl methyl sulfonyl fluoride (PMSF),  
20 mg/ml 1-10 phenanthroline, 20 mg/ml Benxamine. 
Dissolved in ethanol and stored at -20°C 
Laemmli lysis buffer:   20% Glycerol, 2% SDS, 0.1 M Tris pH 6.8,  
10% ß-Mercaptoethanol, 7 M Urea 
Laemmli loading dye:   20% Glycerol, 2% SDS, 0.1 M Tris pH 6.8,  
7 M Urea, 10% w/v bromophenol blue  
10x Running buffer:   121g Tris base, 578g Glycine, 40g SDS, Water to 4  
litres 
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Transfer buffer:  25 mM Tris base, 0.2 M Glycine, 20% Methanol, 0.05% 
SDS 
Ponceau S:    0.2 % Ponceau Red, 5% Acetic acid 
Blocking buffer:   5% non fat milk/TBS plus 0.15% TWEEN 20 
 
2.7.3 Immunoprecipitation reagents 
NP-40 lysis buffer: 25 mM Tris HCl pH 7.4, 150 mM KCl, 0.5% NP-40,  
2 mM EDTA. Add fresh 1mM NaF, 0.5 mM DTT and 
1% proteinase inhibitors 
NP-40 wash buffer: 300 mM KCl, 50 mM Tris-HCl pH 7.4, 1 mM MgCl2, 
0.1 % NP-40 
 
2.7.4 Other commonly used reagents 
10 x PBS:  0.5 M NaH2P04 (30g/500ml), 0.5 M Na2HP04 (35.5g/500ml) 
Add the Na2HP04 to NaH2P04 until pH 7.2 to give the stock 
solution. Take 200ml of this stock and add 8.76 g NaCl and 
make up to 1 litre with distilled water. 
10 x TBE:   432 g Tris, 220 g Boric acid, 37.2 g EDTA, Water to 4 litres 
20 x TAE (E-buffer):  0.8 M Tris, 0.4 M Sodium acetate, 20 mM EDTA, adjusted to  
pH 8 with acetic acid 
TE Buffer:  10 mM Tris-HCL pH 7..4, 1 mM EDTA 
YT medium:  16 g Tryptone, 10 g Bacto-yeast extract, 5 g NaCl, Water to  
1 litre 
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2.7.5 Primers 
MicroRNA cloning primers 
454 5’- ADAPTER  - 5’ TGGGAATTCCTCACTrArArA 3’ 
454 3’- ADAPTER    - 5’ P-rUrUrUCTATCCATGGACTGTidT 3’ 
454 PCR 5’ primer   - 5’ CATGGGAATTCCTCACTAAA 3’ 
454 PCR 3’ primer    5’ TACAGTCCATGGATAGAAA 3’ 
M13 forward primer   5’ TTCCCAGTCACGACGTT 3’ 
M13 reverse primer    5’ CAGGAAACAGCTATGAC 3’ 
(Key: A, C, G, T = DNA residues; rA, rU = RNA residues; P = 5’ phosphate; idT = 
3’-inverted deoxy thymidine) 
 
MicroRNA sequence specific primers 
3’- UUU-ADAPTER   - 5’ P-rUrUrUCTATCCATGGACTGTidT 3’ 
3’- AAA-ADAPTER   - 5’ P-rArArACTATCCATGGACTGTidT 3’ 
UUU PCR 3’ primer    - 5’ TACAGTCCATGGATAGAAA 3’ 
AAA PCR 3’ primer    - 5’ TACAGTCCATGGATAGTTT 3’ 
miR-221 specific primer - 5’ ACCCAGCAGACAATGTAGCT 3’ 
miR-222 specific primer - 5’ ACCCAGTAGCCAGATGTAGCT 3’ 
miR-23a specific primer - 5’ GGAAATCCCTGGCAATGTGA 3’ 
 
MicroRNA editing primers 
miR-376c forward primer - 5’ TGCACCTATCCTGTGCTGTC 
miR-376c reverse primer - 5’ TCTTCCCTGATGGTGGTTTC 
miR-376a-2 forward primer - 5’ TCCGGGATGAAACCTTCTTT 
miR-376a-2 reverse primer - 5’ GCCCACCATCTTTCCACTTA 
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MicroRNA target site primers 
KIT forward primer  - 5’ GGACCACTGCATGAGCTTTT 3’ 
KIT reverse primer  - 5’ CCTGAATCTTTCAAGACAACACA 3’  
 
CSF1R forward primer (XbaI):   
- 5’ ATTCACTCTAGATGCAGCCCAACAACTATCAG 3’ 
CSF1R reverse primer (FseI): 
- 5’ ACGCGGCCGGCCTTAATGCTGTTAGTTTAATGTGG 3’ 
 
Sequencing primers 
pGL3 forward sequencing primer  – 5’ GGAAAGACGATGACGGAAAA 3’ 
pGL3 reverse sequencing primer  – 5’ CCCCCTGAACCTGAAACATA 3’ 
pGL4 forward sequencing primer  – 5’ TTCTACCCACTCGAAGACGG 3’ 
pGL4 reverse sequencing primer  – 5’ GGGGACAGCCTATTTTGCTA 3’ 
 
5’ RACE primers 
5’ RACE gene specific inner primer  – 5’ TTCTCTCATCCCACCTTTAATCA 3’ 
5’ RACE gene specific outer primer  – 5’ GCAACAACCCCTCTCAAGAC 3’ 
 
Promoter primers 
9-2 EST forward primer (KpnI):  
- 5’ ATGGTACCCGGGCTGCATTTACATACG 3’  
9-2 EST forward primer (XhoI):  
- 5’ ATCTCGAGCCTCGGAGTGGAGAGTGAAG 3’  
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9-3 EST forward primer (KpnI):  
- 5’ ATGGTACCACTCCCAAGCTCTGCGTCT 3’  
9-3 EST forward primer (NheI):  
- 5’ ATGCTAGCCCGCTTCTCTGGGCTCTG 3’ 
 
9-1 miRNA forward primer (KpnI):  
- 5’ ATGGTACCTTCTTCAGCACCATATTATCATCC 3’ 
9-1 miRNA reverse primer (XhoI):  
- 5’ ATCTCGAGGATAACCAAAGATAACAACCAACC 3’ 
9-2 miRNA forward primer  - 5’ AGCACGGAGGAGGTAAAAGG 3’ 
9-2 miRNA reverse primer  - 5’ CCAAAGATAACAACTCGCTTCC 3’  
9-3 miRNA forward primer (KpnI):   
- 5’ ATGGTACCGGAGGAAGACGGAGGAGTTT 3’ 
9-3 miRNA reverse primer (NheI):  
- 5’ ATGCTAGCAGAAACGGGCCTCCCTTAG 3’  
 
pGK left primer   - 5’ TATCATCGATCACGAGACTAGC 3’ 
pGK right primer (BglII) - 5’ ATAGATCTCTCGCCCTTGCTCACCAT 3’ 
 
Gene expression primers 
F2R forward primer   - 5’ AGAAAGTTGCAAGGCAAATG 3’ 
F2R reverse primer   - 5’ GATGGAGTCTTGCTCTGTTGC 3’ 
ROCK2 forward primer  - 5’ TGCTGGCTACCCTAGATGTG 3’ 
ROCK2 reverse primer  - 5’ GCCTGGCCAGATGATGTATT 3’ 
BGN forward primer   - 5’ TTCTCGCTTCTGAGCTTGGT 3’ 
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BGN reverse primer   - 5’ CACGTTGCACGGTGTTTCT 3’ 
IGFBP7 forward primer  - 5’ CAAGAGGCGGAAGGGTAAAG 3’ 
IGFBP7 reverse primer  - 5’ GGCAGGAGTTCTGTCCTTTG 3’ 
CTHRC1 forward primer  - 5’ GCTCACTTCGGCTAAAATGC 3’ 
CTHRC1 reverse primer  - 5’ CGAGAAACTGAATTCCATCCA 3’ 
ACTG2 forward primer  - 5’ CAGGGAAAAGATGACCCAGA 3’ 
ACTG2 reverse primer  - 5’ TGGAGAGAGAGGCCAGGATA 3’ 
COL6A3 forward primer  - 5’ CGAAAGACGAAGGAACTTGC 3’ 
COL6A3 reverse primer  - 5’ GGGCAGGGAATGAAAAAGTT 3’ 
CRABP1 forward primer  - 5’ GATCCACTGCACCCAAACTC 3’ 
CRABP1 reverse primer  - 5’ AAGCCAGCTGCCTTCATTCC 3’ 
CRABP2 forward primer  - 5’ ATGCCCAACTTCTCTGGCAA 3’ 
CRABP2 reverse primer  - 5’ CGTCATGGTCAGGATCAGTT 3’ 
GFAP forward primer  - 5’ CTGTTGCCAGAGATGGAGGTT 3’ 
GFAP reverse primer   - 5’ TCATCGCTCAGGAGGTCCTT 3’ 
ID3 forward primer   - 5’ ACTCACTCCCCAGCATGAAG 3’ 
ID3 reverse primer   - 5’ AAGCTCCTTTTGTCGTTGGA 3’ 
NANOG forward primer  - 5’ AGCCTCTACTCTTCCTACCACC 3’ 
NANOG reverse primer  - 5’ TCCAAAGCAGCCTCCAAGTC 3’ 
NODAL forward primer  - 5’ CGACCAACCATGCATACATCC 3’ 
NODAL reverse primer  - 5’ GTGACTTCATCCCACCTCCAA 3’ 
HES5 forward primer   - 5’ GGAAGCCGGTGGTGGAGAAGAT 3’ 
HES5 reverse primer   - 5’ TCCTGCAGGCACCACGAGTAGC 3’ 
Novel miR-A forward primer  - 5’ GGAGTCCAACTTGCCTGGA 3’ 
Novel miR-A reverse primer   - 5’ TTACCCAAGCAAGTCATCCA 3’ 
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Novel miR-D forward primer  - 5’ AAGACATGGCCACTCCAGTC 3’ 
Novel miR-D reverse primer   - 5’ GAACGCATGGCGATTACTTT 3’ 
miR-23b/27b/24-1 gene cluster forward primer   
- 5’ TGTACCTCTACGGGGAGCTG 3’ 
miR-23b/27b/24-1 gene cluster reverse primer   
- 5’ ATGTCCAGGGTCAGTTCGAG 3’ 
miR-302 gene cluster forward primer - 5’ TGCCATTTTGTTTTCTTTCTCC 3’ 
miR-302 gene cluster reverse primer  - 5’ CCCATGTCTTAACGGAGAGC 3’ 
miR-9-1 gene forward primer  - 5’ TCACAGAAGCCTGGAGCTG 3’ 
miR-9-1 gene reverse primer   - 5’ GGTGCTGGATGTGGCTCTAT 3’ 
miR-9-2 gene forward primer  - 5’ TAACGCTGCCGGAGATTACT 3’ 
miR-9-2 gene reverse primer   - 5’ GCAACAACCCCTCTCAAGAC 3’ 
miR-9-3 gene forward primer  - 5’ CCCAGCCTAACCAACACCT 3’ 
miR-9-3 gene reverse primer   - 5’ AATGAATAACCGGGCATCTG 3’ 
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2.7.6 Constructs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Luciferase expression vectors, pGL3 (A) and pGL4.10 (B) (Promega) for 
miRNA targeting and promoter analysis (reproduced from Promega technical 
manual).  
 
 
The pGL3-Control vector (Fig. 2.2, cat. no. E1741, Promega) was used generate the 
following constructs: 
• pGL3-Kit - KIT 3’UTR cloned into XbaI site at position 1934. 
• pGL3-CSF1R - CSF1R 3’UTR cloned into XbaI and FseI sites at 
positions 1934 and 1953 respectively.  
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The pGL4.10[luc2] vector (Fig. 2.2, cat. no. E6651, Promega) was used generate the 
following constructs: 
• pGL4-9-1-miR – 2895bp sequence upstream of the miR-9-1 hairpin 
was cloned into KpnI and XhoI sites at positions 18 and 34 
respectively. 
• pGL4-9-2-miR - 744bp sequence upstream of the miR-9-2 hairpin was 
cloned into NheI and BglII sites at positions 28 and 47 respectively.  
• pGL4-9-3-miR - 600bp sequence upstream of the miR-9-3 hairpin was 
cloned into KpnI and NheI sites at positions 18 and 28 respectively. 
• pGL4-9-2-EST - 2729bp sequence upstream of a putative miR-9-2 
EST was cloned into KpnI and XhoI sites at positions 18 and 34 
respectively. 
• pGL4-9-3-EST - 2875bp sequence upstream of a putative miR-9-3 
EST was cloned into KpnI and NheI sites at positions 18 and 28 
respectively. 
• pGL4-pGK - 575bp sequence encompassing the pGK promoter was 
cloned into XhoI and BglII sites at positions 34 and 47 respectively. 
 
2.7.7 Bioinformatic progams 
miRBase - http://microrna.sanger.ac.uk/sequences/ 
piRNA database - http://pirnabank.ibab.ac.in/index.shtml 
TargetScan - http://www.targetscan.org/ 
PicTar - http://pictar.mdc-berlin.de/ 
miRGen - http://www.diana.pcbi.upenn.edu/cgi-bin/miRGen/v3/Targets.cgi 
Diana Lab TarBase - http://diana.cslab.ece.ntua.gr/tarbase/ 
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Sloan-Kettering miRNA targets - http://cbio.mskcc.org/cgi-
bin/mirnaviewer/mirnaviewer.pl 
MicroRNAdb - 
http://bioinfo.au.tsinghua.edu.cn/micrornadb/browse_seq.php?ID=hsa-mir-23a 
UCSC Genome Browser - http://genome.cse.ucsc.edu/cgi-bin/hgBlat 
Ensembl Genome Browser - http://www.ensembl.org/index.html 
NCBI Blast - http://blast.ncbi.nlm.nih.gov/Blast.cgi 
MFOLD - http://mobyle.pasteur.fr/cgi-bin/MobylePortal/portal.py?form=mfold 
RNAfold - http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi 
MethPrimer - http://www.urogene.org/methprimer/index1.html 
Primer3 - http://frodo.wi.mit.edu/ 
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CHAPTER 3 – MicroRNAs and isomers in human 
mesenchymal stem cells 
 
3.1 INTRODUCTION 
3.1.1 Human mesenchymal stem cells  
Human mesenchymal stem or mesenchymal stromal cells (MSCs) are multipotent 
stem cells with a fibroblast-like morphology that can differentiate into cells of the 
mesenchymal lineage, namely bone, cartilage, muscle and fat cells (Uccelli et al., 
2008).  MSCs are of medical interest for a number of reasons including their stem 
cell-like properties; immunosuppressive properties; relative ease of isolation and 
expansion and their ability to support the growth of other cell types (Uccelli et al., 
2008). MSCs can be isolated from a variety of sources, most commonly from adult 
bone marrow (Friedenstein et al., 1970); but also from maternal origins, such as 
amniotic fluid (In 't Anker et al., 2003), placenta (In 't Anker et al., 2004), and cord 
blood (Bieback et al., 2004). There are also increasing reports of MSCs derived from 
fetal origins that have been shown to exhibit good efficacy in therapy (Guillot et al., 
2008a, Guillot et al., 2008b), demonstrating the widespread distribution of viable 
sources. To address ambiguity issues related to variations in extraction and 
methodologies of isolation of MSCs, the defining characteristics have been set out as 
based on adherence to plastic, expression of specific surface antigens, and 
differentiation potential (Dominici et al., 2006).  
 
Studies into miRNA expression in MSCs have highlighted the presence of several 
miRNAs important for lineage specification (Schoolmeesters et al., 2009, 
Lakshmipathy and Hart, 2008). MiR-143 for example, has been shown to be 
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important for adipogenic differentiation (Esau et al., 2004), while miR-148b, miR-27a 
and miR-489 may be required for osteogenic differentiation (Schoolmeesters et al., 
2009). However, the total amount of published data on MSC miRNAs remains 
relatively low in comparison to studies done on embryonic stem cells, and mainly 
consists of miRNA microarray data (Goff et al., 2008, Sorrentino et al., 2008, Esau et 
al., 2004). As a result, global miRNA expression analysis using deep sequencing 
technology may provide a more in-depth characterisation of miRNAs in this cell type 
than previous reports.  
 
3.1.2 MicroRNA isomers 
Large scale cloning studies in various cell types have identified mature miRNAs that 
vary in size, though usually only one form is most dominant (Landgraf et al., 2007, 
Morin et al., 2008). These miRNA variants (miRNA isomers or isomiRs), are most 
probably generated by  Drosha and Dicer, which determine the exact 5’ and 3’ ends of 
the mature miRNAs respectively, and have also been demonstrated to be associated 
with endogenous Argonaute proteins (Azuma-Mukai et al., 2008).  
 
It has been reported that a miR-142-5p isomer with two additional nucleotides at the 
5’ end can affect the cleavage position of a completely complementary target in vitro, 
and thus has the potential to exhibit slightly different target specificities (Azuma-
Mukai et al., 2008). However, the majority of endogenous human miRNAs do not 
bind with perfect complementary for target inhibition, and are thought to focus 
instead on binding at the 5’ seed region (Brennecke et al., 2005). As the most 
abundant variations are often observed at the 3’ end of the mature miRNA, without 
affecting the 5’ seed region, this indicates that there may be little gene expression 
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effects due to differences in functionality of different isomers for endogenous 
miRNA-target binding scenarios. Nevertheless, additional reports based on the 
identification of miRNA targets from immunoprecipitated components of the miRNP 
have indicated that for many of those miRNA-target pairs, 5’ seed binding is neither 
necessary or sufficient for effective targeting  (Beitzinger et al., 2007, Easow et al., 
2007). Crystallographic studies also illustrate that all of the bases of a microRNA, 
with the possible exception of the very first and last bases, are capable of binding to 
target mRNA (Wang et al., 2008). Furthermore, the sequence of double nucleotide 
overhangs can influence the stability of oligonucleotide duplexes (O'Toole et al., 
2006), which may in turn influence the loading of microRNA into the RISC complex 
(Khvorova et al., 2003, O'Toole et al., 2006).           
 
3.1.3 Argonaute proteins 
Argonaute proteins form the core component of gene silencing complexes, containing 
a PAZ domain that binds to the 3’ end of small RNAs, and a catalytic PIWI domain 
that can cleave complementary RNA targets (Liu et al., 2004, Ma et al., 2004, Song et 
al., 2004). However, in mammals, only Ago2 demonstrates endonuclease activity in 
RNAi (Liu et al., 2004, Meister et al., 2004). Other members such as Ago1 and Ago4 
have more diverged catalytic motifs (Tolia and Joshua-Tor, 2007), though most 
mammalian miRNA mediated repression does not actually require cleavage. All 
argonaute proteins are functionally equivalent and are thought to bind to miRNAs 
indiscriminately (Liu et al., 2004, Meister et al., 2004, Su et al., 2009), though binding 
of mRNA transcripts may be more selective (Beitzinger et al., 2007). Analysis of 
Ago-associated mRNAs by immunoprecipitation of endogenous protein has been 
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demonstrated as an efficient means of identifying target mRNAs of a given cell type 
(Weinmann et al., 2009).  
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3.2 RESULTS 
3.2.1 Human mesenchymal stem cell microRNA library 
A representation of overall miRNA expression in hMSCs was generated by deep 
sequencing using the 454 sequencing technique. Cells derived from first trimester 
fetal bone marrow and cultured in vitro through 6 passages were used to isolate small 
RNAs from which the hMSC miRNA library was cloned. A total of 253,791 
unfiltered sequence reads were extracted, of which 25,724 were between 15 and 28 
nucleotides in length. After filtering for redundancy, the resultant database contained 
6043 unique reads, from which a total of 162 individual annotated mature miRNAs 
(miRBase v13.0) could be identified, along with an additional 9 non-annotated mature 
miRNAs (Supplementary Table S1.). This equates to just under a quarter of all 
currently known human miRNAs (706 in miRBase v13.0). The total sequencing 
numbers for each miRNA ranged from 1 to 2,686 including any isomers. 
 
Seven of the non-annotated miRNAs were mapped to the opposite strand of known 
miRNAs and were annotated in this library with the * suffix attached to their 
precursor miRNA designation. Two additional potential novel miRNAs, which did 
not match any known miRNA precursors were also sequenced 47 and 9 times, and 
designated novel-1 and novel-2 respectively. Analysis of the two sequences on the 
UCSC Genome Browser indicated that both sequences were mapped to single 
locations within the human genome and did not constitute part of any annotated 
genes. Subsequently, both sequences were subjected to RNAfold analysis (Hofacker, 
2003) which indicated that they could be folded into hairpin-like precursors (Fig. 
3.1A), confirming that these sequences are likely to be novel miRNAs. Sequence 
conservation analysis was also done between various mammalian species for the full  
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Figure 3.1. Analysis of novel miRNAs designated novel-1 and novel-2. (A) Hairpin 
fold was generated by the RNAfold program. Arrows indicate the 5’ and 3’ ends of 
the novel miRNAs. (B) Sequence conservation of the predicted novel miRNA 
hairpins were analysed with the Blat program on the UCSC Genome Browser (Human 
March 2006 assembly).  
A 
B 
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predicted hairpin sequence of novel-1 and novel-2 but indicated that there was only 
mild homology across the speices (Fig. 3.1B), which may explain why these potential 
novel miRNAs were not detected by previous bioinformatic searches (Weber, 2005, 
Xu et al., 2008).  
 
             
3.2.2 MicroRNA isomers are differentially expressed  
Northern blotting was used to confirm the expression of many of the miRNAs 
sequenced and to optimise the detection of miRNA isomers. Isomer detection was not 
limited to hMSCs and could be found in the human cell lines; K562, HEK293, 
HepG2, and HeLa (Fig. 3.2). Detection of miRNA isomers, if any, was not uniform 
across the different cell lines. Interestingly, in the case of miR-151-5p, although 3 
isomers could be detected in every cell line, the dominant isomer differed between 
them, as determined by the strongest visible band. In contrast, for miR-26a, the lower 
band appeared most dominant regardless of whether any isomers were detected in 
those cell lines.  Repeated northern blotting revealed the same isomer dominance 
pattern for all of the miRNAs tested in Fig 3.2. 
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Figure 3.2. Detection of miRNA isomers. Different human cell lines; K562, 
HEK293, HepG2, HeLa and hMSC express varying amounts of miRNA isomers. 
Total RNA containing the 5.8S rRNA was stained with ethidium bromide as a loading 
control. XC = xylene cyanol dye.  
 
 
Figure 3.3 shows that miRNA isomer expression can vary in hMSCs with the changes 
that occur upon differentiation. Freshly isolated hMSCs that were cultured in vitro for 
no more than 3 passages were differentiated through the osteogenic lineage by 
switching to osteogenic medium for 14 days (work done by Pascale Guillot, Imperial 
College London). Differentiation to osteoblasts was monitored by the increasing 
formation of mineral deposits on the cells (Fig. 3.3A). RNA was isolated from the 
cells at days 0, 3, 7 and 14, from the onset of culturing in differentiation medium, for 
northern blotting of let-7a, miR-15a and miR-151-5p (Fig. 3.3B). The results show 
that at least two distinct isomers were visible for miR-151-5p and less clearly two 
bands for miR-15a can be seen at Day 0, while only one band was detected for let-7a 
but whose expression increased steadily with differentiation. For miR-151-5p the 
dominant isomer was initially the top higher molecular weight band, but this 
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gradually switched to the lower molecular weight band by day 7, indicating a shift in 
isomer preference with differentiation.  
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miR-151-5p
5.8S rRNA
hMSC differentiation
0      3       7      14
Day 3 Day 7 Day 14
A
B
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Figure 3.3. Isomer expression changes with differentiation of hMSC. (A) hMSC 
were differentiated through the osteogenic lineage for 14 days, and differentiation was 
confirmed by increasing mineral deposition. Arrows indicate areas of concentrated 
mineral deposition. (B) Northern blots for the expression of let-7a, miR-15a and the 
isomers of miR-151-5p, at 0, 3, 7 and 14 days of differentiation. Total RNA 
containing the 5.8S rRNA was stained with ethidium bromide as a loading control.  
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3.2.3 Isomer validation by miRNA specific sequencing  
To further verify the expression of miRNA isomers as detected by deep sequencing 
and northern blotting by a different technique, several miRNAs were sequenced 
independently by using specific primers and adapters for individual miRNAs. Two 
different 3’ adapter RNAs were designed, designated 3’ AAA-RNA adapter and 3’ 
UUU-RNA adapter (A = adenosine, U = uracil). The 3’ AAA-RNA adapter was 
preferably used when the isomers of the miRNA of interest contained 3’ terminal 
uracil bases, as the use of a 3’ UUU-RNA adapter may lead to the detection of false 
isomers due to ligation with potential degraded adapters. Likewise, 3’ UUU-RNA 
adapters were used for the detection of isomers containing 3’ terminal adenosine 
bases. Figure 3.4A shows the sequencing traces of miR-221 ligated to 3’ AAA-RNA 
adapters and 3’ UUU-RNA adapters separately for the detection of miR-221 3’ 
isomers. Both adapters were used because the hMSC miRNA library indicated the 
presence of both terminal adenosine and uracil isomers for miR-221. The miRBase 
predicted pre-miRNA hairpin is shown in figure 3.4B, with the mature form in red. 
Sequencing numbers for each isomer from the hMSC library and the specific 
sequencing are listed also. The most common isomer detected by specific sequencing 
did not match with the library which may be an indication of insufficient total 
numbers or some bias in PCR amplification. Nevertheless multiple isomers were 
detected by both approaches. Specific priming results for miR-23a and miR-222 are 
given in supplementary figures S1-2.  
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Sequence Library      Specific priming
AGCTACATTGTCTGCTG                1                -
AGCTACATTGTCTGCTGG   1                -
AGCTACATTGTCTGCTGGGT  7                5
AGCTACATTGTCTGCTGGGTT 1                1
AGCTACATTGTCTGCTGGGTTT 7 6
AGCTACATTGTCTGCTGGGTTTA - 1
AGCTACATTGTCTGCTGGGTTTC 17                1
AGCTACATTGTCTGCTGGGTTTT          - 1
AGCTACATTGTCTGCTGGGTTTCA         2                1
AGCTACATTGTCTGCTGGGTTTCT         - 1
AGCTACATTGTCTGCTGGGTTTAT         - 2
miR-221        3’ UUU-RNA 
adapter
miR-221      3’ AAA-RNA 
adapter
A
B
-U     ----       CUGG   A    -  UG   U         AUUU    -   C  
  GAACA    UCCAGGU    GGC UGAA CC  GCA ACAAUGUAG    CUGU GUU G 
  |||||    |||||||    ||| |||| ||  ||| |||||||||    |||| ||| U 
  CUUGU    AGGUCCA    UCG ACUU GG  CGU UGUUACAUC    GACA CGG U 
CU     ACAA       ----   G    U  GU   C         ----    A   A  
 
 
 
 
 
Figure 3.4. Detection of miR-221 isomers by specific priming. Sequencing of miR-
221 using 3’ AAA-RNA adapters or 3’ UUU-RNA adapter by specific priming (A). 
Arrows indicate the site of adapter ligation. (B) miRBase annotation of the miR-221 
hairpin, sequenced hMSC library and specific priming numbers for each isomer are 
listed. Red denotes the mature form deposited in miRBase.  
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3.2.4 Target analysis of miR-221 isomers  
Previously published data had shown that miR-221 can downregulate the expression 
of KIT, a transmembrane receptor tyrosine kinase, in vitro by binding to the 3’ UTR 
of the c-kit mRNA (Felli et al., 2005). From the results of the hMSC miRNA library 
and specific sequencing data, miR-221 does express a number of isomer forms, 
though in differing amounts, and further validation by northern blotting of these 
isomers in hMSCs, human bone marrow (hBM), HeLa, HepG2, HEK293, K562, and 
mo7e, are given in figure 3.5A. In order to assess whether miRNA isomers may be 
incorporated in RISC or even possibly differ in their ability to bind to and inhibit the 
same target, the predicted 3’ UTR c-kit target was cloned downstream of a firefly 
luciferase gene in a reporter plasmid and transfected into HEK293 cells. Synthetic 
miRNA mimics of two of the miR-221 isomers, differing in only one base at the 3’ 
end were selected based on library sequencing numbers (Fig. 3.5B) and were 
designated 221-UUC and 221-UU as denotes the 3’ base composition. The c-kit 
3’UTR expressing reporter plasmid was then co-transfected with each miR-221 
isomer at 20, 10, 5, 2, 1, 0.5 and 0.1 pmol concentrations, and the luciferase 
expression after 48 hrs was recorded (n = 9) (Fig. 3.5C). Transfection efficiency was 
monitored by the expression of a co-transfected gfp expressing plasmid and a Cy3-
labelled scrambled RNA was used as the negative control (Fig. 3.5D). All data was 
standardised against Renilla as an internal control and total knockdown was 
calculated as a percentage in comparison to the negative control. Target mRNA 
knockdown was achieved by both isomers of miR-221 at up to 35%, indicating no 
discrimination by endogenous RISC incorporation for either isomer. No obvious 
difference in targeting ability by the two isomers of miR-221 was observed suggesting 
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that, at least in the case of c-kit targeting, a single nucleotide difference at the 3’ end 
is insufficient to alter specificity.  
 
3.2.5 Target analysis of miR-193a-3p and miR-193b  
During the process of validating miR-221 targeting of KIT, bioinformatic analysis 
revealed that miR-193a-3p and miR-193b, which are encoded by separate miRNA 
genes, may also be able to down regulate KIT (further described in Chapter 5, section 
5.2.1). Both miR-193a-3p and miR-193b were detected in the hMSC miRNA library 
and northern blotting for both miRNAs in the human cell lines; HeLa, MDA-MB-453, 
mo7e, HEK293, K562, HepG2, and human bone marrow (hBM) indicated expression 
in only HepG2 cells (Fig. 3.6A). Regardless of isomer expression, these two miRNAs 
naturally share a high level of homology with differences in only a total of four 
nucleotides at the centre and 3’ end (Fig. 3.6B). To determine if these internal 
nucleotide differences were sufficient to affect binding affinity to a target mRNA, the 
synthetic miRNA mimics of miR-193a-3p and miR-193b along with the previously 
described c-kit 3’ UTR luciferase construct, were transfected in HEK293 cells. The 
concentrations of the miRNAs were fixed at 10, 5, 1, 0.5, and 0.1 pmol, per well of a 
96 well plate, and the cells were incubated for 48 hrs (n = 8). All other experimental 
conditions and data analysis were similar to the miR-221 isomer luciferase assay. The 
results showed that, as predicted by bioinformatics, miR-193a-3p and miR-193b were 
able to bind to and affect knockdown of luciferase. The total percentage knockdown is 
also higher overall with both miRNAs than the previously tested miR-221 isomers 
(Fig. 3.5C). However, there was no significant difference in inhibition between the 
two miRNAs, indicating that four nucleotide differences in the centre and 3’ end of 
the miRNAs are not important for effective miRNA:KIT-target binding.  
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Figure 3.5. Target analysis of miR-221 isomers. (A) Northern blot of isomers of 
miR-221 in different human cell lines. 5.8S rRNA was stained with ethidium bromide 
as a loading control. Two of the most commonly cloned isomers of miR-221 from 
hMSCs (B), were transfected into HEK293 cells at different concentrations along with 
a target Luciferase construct (C) (n = 9). (D) Transfection efficiency was monitored 
by co-transfecting with a gfp-expressing plasmid (center) and Cy3-labelled scrambled 
miRNA mimic (right). 
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Sequenced
miR-193a-3p    AACTGGCCTACAAAGTCCCAGT 107
miR-193b AACTGGCCCTCAAAGTCCCGCT 4
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Figure 3.6. Target analysis of miR-193a and miR-193b. (A) Northern blot of miR-
193a-3p and miR-193b in different human cell lines. 5.8S rRNA was stained with 
ethidium bromide as a loading control. (B) Sequencing numbers from the hMSC 
miRNA library of miR-193a-3p and miR-193b, nucleotides in grey denotes the 
differences. Synthetic RNA mimics of miR-193-3p and miR-193b were transfected 
into HEK293 cells at different concentrations along with a target Luciferase construct 
(C) (n = 8).  
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3.2.6 MicroRNA isomers in Argonaute  
To test whether isomers of miRNAs can be incorporated into the miRNP complex in 
hMSCs, and are therefore likely to be functional, immunoprecipitations of the human 
Argonaute proteins 1 and 2 (Ago1 and Ago2) were performed and their associated 
RNAs were size selected on a 15% denaturing PAGE for northern blotting. An 
antibody for the k-RAS protein, which is not expected to associate with any RNAs, 
was used as the negative control. MicroRNAs with previously detectable levels of 
isomers from total RNA northern blots were probed for on the Argonaute blots under 
the same conditions, with the exception of a longer exposure time under an 
intensifying screen at -80oC (up to 10 days). Figure 3.7 shows that isomers of let-7a, 
miR-23a, miR-26a, miR-221, miR-222 and miR-151-5p can be detected in the Ago1 
and Ago2 immunoprecipitations from MSCs under conditions that maintain the 
integrity of the complex between Argonaute proteins, microRNA and target mRNA 
(Beitzinger et al., 2007). The results for miR-23a reveal that Ago2 is more strongly 
associated with one of the minor isoforms (20mer) and is poorly associated with the 
dominant isoform (21mer) compared to Ago1. Strikingly the dominant isoform of 
miR-151-5p (22mer) was not immunoprecipitated by antibodies against either Ago1 
or Ago2, whereas the minor isoforms (21 and 23mers) were apparent. The shorter 
22mer isoforms of miR-222 were evidently enriched following Ago1 and Ago2 
immunoprecipitation compared to the other isoforms. The results for let-7a, miR-26a 
and miR-221 are more difficult to interpret as relatively little isoform was 
immunoprecipitated in either Ago1 and/or Ago2 samples. Some of the observed bands 
in figure 3.7 may represent more than one isomer of identical length. Ago1 and Ago2 
expression levels appear to be similar in MSCs according to microarray analysis 
(Supplementary Table S2). 
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Figure 3.7. Isomer association with Ago1 and Ago2. Isomers of let-7a, miR-23a, 
miR-26a, miR-221, miR-222 and miR-151-5p could be detected by northern blotting 
of total RNA immunoprecipitated by anti-Ago1 and anti-Ago2 from hMSCs. Lane 1 – 
northern blotting prior to immunoprecipitation. Sizes are indicated by the arrows on 
the right and are estimated from size markers (not shown), ? = size unknown.  
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3.2.7 Microarray data for hMSC total RNA and Ago2 associated RNA  
A representation of overall messenger RNA expression and Ago2 associated RNA in 
hMSCs was generated by microarray analysis using the HumanWG-6 V3 beadchip 
(Illumina Inc) (performed by Peter Ellis, Sanger Institute). Briefly, Ago2 was 
immunoprecipitated from hMSCs with a monoclonal antibody (gifted by Gunter 
Meister) (Beitzinger et al., 2007), and following clean up, any associated RNAs 
(coding or non-coding) were extracted by phenol and precipitated in ethanol. The 
Ago2 associated RNAs were then submitted to Sanger directly, along with total RNA 
from hMSCs for microarray analysis. The readings obtained from the HumanWG-6 
V3 beadchip platform ranged from a signal of 61.70 to 63796.70 (arbitrary units), and 
a threshold of 150.00 was selected to eliminate background signals.  
 
Out of 37,804 analysed transcripts from the beadchip platform, 12,903 scored higher 
than the threshold signal from the overall mRNA array (Supplementary Table S2), 
and 119 from the Ago2 associated RNAs array (Supplementary Table S3). There was 
a very good correlation in mRNA expression values between two repeats 
(Supplementary Table S3). As expected, the top hMSC expressed genes included 
genes encoding ribosomal protein subunits as well as members of the actin, myosin 
and tubulin families. The mesenchymal marker, vimentin, was also highly expressed 
on the microarray. Interestingly, the osteoblast marker, osteonectin, was also detected 
at significant levels, though osteocalcin was not. In comparison, the results of the 
Ago2 microarray revealed that under the conditions that were used for 
immunoprecipitation only a very small proportion of overall hMSC RNAs were 
associated with Ago2 and therefore likely to be regulated by miRNAs. Figure 3.8A 
shows a scatter plot of the average microarray signal for overall mRNA versus Ago2 
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associated RNA. As expected, the average signals are lower for Ago2 associated RNA 
and there is no correlation between the two datasets, indicating that the Ago2 
immunoprecipitations are specific. Several randomly selected mRNAs (F2R, ROCK2, 
BGN) that exhibited a signal above the threshold from the Ago2 IP microarray could 
also be detected in repeat Ago2 immunoprecipitation experiments by RT-PCR 
(Fig.3.8B). RNAs not detected above threshold from the Ago2 IP microarray were 
also retested by Ago2 immunoprecipitation and RT-PCR and were confirmed not to 
be immunoprecipitated. All tested mRNAs could be detected by RT-PCR in the 
absence of Ago immunoprecipitation, which supports the microarray analysis 
(denoted by + in Fig 3.8B). A non-RNA binding protein IP (kRAS) was used as the 
negative control (-).  
 
To further test whether the genes detected on the Ago2 microarray were genuine 
miRNA targets, the predicted targets of the top 30 expressed miRNAs from the hMSC 
miRNA library was matched to the top mRNA detected by the overall mRNA 
microarray and by the Ago2 microarray (Fig. 3.9). From the overall mRNA 
microarray, the top 10 mRNAs were selected; FTL, EEF1A1, RPL27, MYL6, OAZ1, 
MT2A, ACTA2, MRCL3, TUBA1C, RPL24. Whilst from the Ago2 microarray, the 
top 5 mRNAs were selected; LAIR1, F2R, IMAA, C19ORF31, CLUAP1. The lines 
linking miRNAs and genes represent one or more predictions from 3 different 
programs; PicTar, TargetScan and miRanda, which are 3 of the most commonly 
utilised prediction algorithms currently available. As indicated by the number of 
adjoining lines, there are a greater number of Ago2 microarray genes matching 
predicted miRNA targets than total hMSC expressed genes (Fig. 3.9).  
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Figure 3.8. Comparison of microarray data from hMSC total RNA and Ago2 
associated RNA. (A) Microarray signals for each mRNA from the total RNA array 
for hMSCs plotted against the microarray signals following Ago2 
immunoprecipitation. (B) RT-PCR validation of the Ago2 microarray with total RNA 
(+), Ago2 IP associated RNA (A) and a negative antibody control (-). Genes detected 
in Ago2 microarray are shown on the left panel, negative control genes are on the 
right panel.  
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mRNA hMSC 1 miRNA cloned no. mRNA Ago2 IP miRNA cloned no.
mir-151-5p 2686 mir-151-5p 2686
FTL 58112.60 let-7a 2052 let-7a 2052
mir-23a 1967 LAIR1 3986.1 mir-23a 1967
let-7d 1324 let-7d 1324
EEF1A1 56198.00 mir-21 880 mir-21 880
mir-26a 740 mir-26a 740
mir-191 637 mir-191 637
RPL27 53570.50 mir-376c 454 mir-376c 454
mir-22 429 F2R 1894.1 mir-22 429
let-7f 289 let-7f 289
MYL6 53094.80 mir-376a 251 mir-376a 251
mir-495 238 mir-495 238
let-7b 211 let-7b 211
OAZ1 51675.20 mir-29a 179 mir-29a 179
let-7g 171 IMAA 1499.2 let-7g 171
mir-376b 167 mir-376b 167
MT2A 50277.00 let-7e 151 let-7e 151
mir-130a 151 mir-130a 151
mir-15b 141 mir-15b 141
ACTA2 49299.60 mir-17 127 mir-17 127
mir-493* 119 C19ORF31 1326.4 mir-493* 119
mir-24 118 mir-24 118
MRCL3 49030.20 mir-145 113 mir-145 113
mir-16 113 mir-16 113
mir-23b 110 mir-23b 110
TUBA1C 48961.30 mir-337-3p 109 mir-337-3p 109
mir-193a-3p 107 CLUAP1 918.2 mir-193a-3p 107
mir-125b 97 mir-125b 97
RPL24 48951.00 mir-143 96 mir-143 96
mir-130b 93 mir-130b 93
 
 
 
 
Figure 3.9. Comparison of target predictions for the top genes from the overall 
mRNA and Ago2 associated RNA microarrays. The top 30 expressed miRNAs are 
plotted against the 10 most highly expressed mRNAs (left column) and against the top 
5 Ago-specific mRNAs (right column) from hMSC. Lines indicate microRNA target 
predictions (from TargetScan, PicTar and miRBase). The number of target predictions 
is greater for the Ago-specific mRNAs (more lines on the right panel) than the total 
mRNA (left panel) indicating that the Ago-specific mRNAs are more likely to be 
functional miRNA targets.  
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3.2.8 MicroRNAs in hMSCs are subject to ADAR editing  
The raw data from the hMSC miRNA library indicated that internal editing may occur 
in several of the miRNAs. In accordance with previous reports, two miRNAs in 
particular stood out as being strong candidates for adenosine to inosine (A to I) 
editing by ADAR (adenosine deaminase that acts on RNA) enzymes; miR-376c and 
miR-376a-2 (Kawahara et al., 2007b). There were 41 and 203 examples of possible 
ADAR editing of miR-376c and miR-376a-2 respectively sequenced in the hMSCs 
miRNA library in addition to the unedited versions that were detected (Supplementary 
Table S1). To confirm the occurrences of editing in these miRNAs in hMSCs, specific 
priming was used to selectively amplify and sequence the primary transcripts 
containing miR-376c and miR-376a-2. Figure 3.10 shows the sequence traces of both 
the edited and unedited versions of miR-376c and miR-376a-2 detected, and the 
sequencing numbers are indicated (n = 8). Edited inosine registers as a guanine (G) by 
sequencing. As detected by the miRNA library and verified by RT-PCR of the 
primary transcripts, both miRNAs are readily subject to ADAR editing in hMSCs.  
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Figure 3.10. ADAR editing of miRNAs. miR-376c (A) and miR-376a-2 (B) were 
sequenced by specific priming for A to I (G) editing. Mature forms are highlighted in 
orange, the arrows indicate the site of editing and the sequencing numbers as detected 
by miRNA specific-priming are indicated on the right (n = 8).  
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3.3 DISCUSSION 
3.3.1 MicroRNA expression in hMSCs 
Previous reports of miRNAs in hMSCs through microarray analysis have highlighted 
the expression of miR-21, miR-145, miR-125b, miR-143, as well as the let-7 family 
in this cell type (Bae et al., 2009, Lakshmipathy and Hart, 2008), all of which are also 
present at high levels in the deep sequencing library generated in this study. 
Interestingly, the most abundant miRNA that was detected was miR-151-5p, for 
which there is little published data. No specific links of miR-151-5p to hMSCs have 
been made, though interestingly this miRNA maps to the intron of the Protein 
Tyrosine Kinase 2 (PTK2) mRNA and this protein has been implicated in the 
osteogenic differentiation pathway of hMSCs (Salasznyk et al., 2007).  
 
In addition to known miRNAs, 9 novel miRNAs were also detected; 7 of which 
mapped to the opposite arm of existing miRNA hairpins, and 2 to unique locations in 
the human genome. Current nomenclature criteria in miRBase recognises that both 
strands of a miRNA precursor may be equally functional, and are now most 
commonly differentiated by the suffix -5p (5' arm) and -3p (3' arm) in relation to their 
hairpin strand position (Griffiths-Jones et al., 2006). For ease of classification of the 7 
novel miRNAs that mapped to opposite arms, a * suffix was used after their miRNA 
precursor given name. As a result of their location, no folding analysis was required, 
and only the 2 remaining novel miRNAs that mapped to unique locations were 
submitted for RNAfold analysis. Both novel miRNAs could be folded into precursor 
hairpins as shown in figure 3.1, and exhibited a number of isomer forms as seen with 
existing miRNAs.  
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Additionally, two of the miRNAs isolated from hMSCs, miR-376a-2 and miR-376c, 
appeared to be frequently subject to ADAR editing (Supplementary Table S1). These 
editing events were also subsequently detected in the primary transcripts encoding 
these miRNAs (Fig. 3.10). This indicates that editing can take place before the action 
of Drosha, as has been previously reported (Yang et al., 2006, Kawahara et al., 2008). 
Interestingly, the frequency of editing occurrences on the pri-miRNA, as detected by 
RT-PCR and conventional sequencing, indicates a 1:1 ratio of edited and unedited pri-
miRNA for miR-376c, while deep sequencing of the mature form indicates an editing 
ratio of 1:9. Conversely for miR-376a-2, there is a 1:3 ratio of edited to unedited pri-
miRNA, but a 1:1 ratio for the mature miRNA. While it was noted that the two 
detection methods are not precisely comparable, especially given the low sequencing 
numbers of the pri-miRNAs (n = 8) compared to the deep sequencing numbers of the 
mature miRNA (n > 200), it has been reported that ADAR editing can affect Drosha 
and Dicer processing (Yang et al., 2006, Kawahara et al., 2008, Kawahara et al., 
2007a) which may provide an explanation for the discrepancy in the expression of 
edited pri- and mature miRNAs. Previous reports have also shown that editing events 
exhibit a degree of tissue specificity, particularly miR-376a-2 and miR-376c which 
are nearly 100% edited in human cortex and medulla tissue (Kawahara et al., 2007b). 
Evidence from this study now indicates that these miRNAs may also be edited up to 
50% in hMSCs.  
 
3.3.2 Messenger RNAs and Argonaute  
For profiling mRNAs, microarray techniques are commonly used and have become 
increasingly more discriminative and authentic in their ability to detect and determine 
expression levels. Conversely, though increasingly improved microarray methods are 
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being developed for the detection of miRNAs (Castoldi et al., 2008, Shingara et al., 
2005), their small sizes and potentially high homology within family members leads 
to issues regarding hybridising specificity, and means that deep sequencing remains 
the preferred method of identifying miRNAs. Thus, with the generation of the hMSC 
miRNA library by deep sequencing, the subsequent use of microarrays to profile the 
expression of overall mRNA and Argonaute bound mRNA provides a firm platform 
for the analysis of miRNA-target interactions in hMSCs.  
 
The global mRNA profile generated by the microarray for hMSCs in this study has 
many matching attributes to previously published microarray data for this cell type in 
its undifferentiated form (Silva et al., 2003, Tanabe et al., 2008). Most notably, the 
mesenchymal marker, vimentin, was highly expressed on the microarray. While the 
majority of markers which indicate increasing osteogenic differentiation, Osteocalcin, 
EPHA5 and NOV (Tanabe et al., 2008), were not detected at high levels. One 
exception was the expression of the osteoblast marker, osteonectin, which was 
detected at significant levels and may be an indication that the cells were close to the 
onset of their default osteogenic differentiation pathway when isolated for analysis.  
 
In addition to the mRNA microarray, an identical microarray was performed using 
RNA extracted from immunoprecipitated Ago2 from the same cells (Supplementary 
table S3). These Ago2-specific mRNAs were not easily detectable by microarray, as 
evidenced by their generally low signals, and showed no correlation to overall mRNA 
expression (Fig. 3.8A), emphasising that those that were detected may be of some 
significance. Further validation of some of the Ago2-specific mRNAs by RT-PCR, 
with repeated Ago2 immunoprecipitations, supports the association of these mRNAs 
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in the miRNP making them subject to miRNA targeting (Fig. 3.8B). Target 
predictions using programs; TargetScan, miRanda and PicTar, shows that there is a 
far greater propensity for the predicted targets of the hMSCs library miRNAs to 
match Ago2 mRNAs than overall mRNA, despite the lower number of Ago2 mRNAs 
analysed. The lack of matches to the most highly expressed miR-151-5p is possibly 
due to the limitations of all of the target prediction programs tested (further discussed 
in Chapter 5), but may also be a result of uncharacterised post-transcriptional 
regulation (further discussed in section 3.3.2). Validation of these Ago2 mRNAs as 
likely miRNA targets may not equate to how important or even necessary they are in 
hMSCs, only that they appear to be the most abundantly regulated genes. Many of the 
mRNAs identified have uncharacterised functions, making it difficult to interpret the 
effects of any repression by miRNAs, and would require further investigation. In 
summary, this microarray method of identifying Ago2 associated mRNAs generates a 
clear overview of mRNAs likely to be subject to miRNA targeting and provides the 
foundation to enable strong candidates for further target analysis to be selected.  
 
3.3.3 Isomers and function 
The hMSC miRNA library that was generated in this study has strongly indicated that 
miRNA isomer expression is not only common for many miRNAs, but also that these 
isomers are functional (Figs 3.2, 3.3 and Supplemenatary Table S1). Additionally, 
some miRNA isomers were selectively associated with Argonaute proteins (Fig. 3.7), 
suggesting that their roles may potentially differ from one another. Northern blotting 
data has shown that different cell types may express different isomers and at varying 
intensities of expression (Fig. 3.2), and that isomer expression may also be subject to 
the changes brought on by differentiation (Fig. 3.3). Taken together, these results have 
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provided a preliminary indication that isomer expression may not simply be due to 
unspecific processing by Drosha and Dicer, and that each isomers’ prevalence may 
signify a potential alteration in that miRNA’s overall functional specificity. However, 
the degree of functional change, if any, is likely to be subtle given what is known 
about miRNA target recognition and binding. Ultimately, the 5’ seed region is 
considered to be the most important factor for miRNA-target binding (Brennecke et 
al., 2005), and is a definite criteria in all target prediction algorithms. Since the 
majority of isomer variation exists at the 3’ end of the miRNA, it is likely that any 
changes in function between isomers of the same miRNA may be relatively subtle, if 
existing at all. However, previous reports have suggested that 5’ seed binding may not 
be necessary or sufficient in the case of certain targets (Grosshans et al., 2005, 
Johnson et al., 2005). In these cases, it is possible that the differences between 
isomers of a particular miRNA may be sufficient to alter that miRNA’s ability to 
affect the target. 
 
The initial detection of isomers bound to Argonaute proteins is in support of isomers 
being functional and targeting studies using two of the most abundantly expressed 
isomer forms of miR-221 and the c-kit 3’ UTR has confirmed that endogenous RISC 
is able to utilise both forms for translational repression in HEK293 cells (Fig. 3.5). 
Nonetheless, no changes were noticed in the ability of either miR-221 isomers to 
target KIT, which indicated that at least for this miRNA-target binding pair, a single 
nucleotide deletion at the miRNA’s 3’ end does not affect its ability to down regulate 
its target. This was not surprising given that even a miRNA isomer with 2 additional 
nucleotides at the 5’ end has only been demonstrated to alter cleavage site specificity 
rather than efficiency against a completely complementary target (Azuma-Mukai et 
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al., 2008). The attempt to determine if a naturally occurring miRNA-target pair in this 
study can be differentially influenced by isomers may not have been successful for the  
miR-221-KIT targeting pair because the predicted binding site on the c-kit 3’ UTR 
indicates only strong 5’ seed region binding with a large number of mismatches at the 
3’ end of the miRNA (Felli et al., 2005). Future studies using validated miRNA 
targets with better complementarity at the 3’ end may be more promising candidates 
for this analysis.  
 
Interestingly, bioinformatic analysis indicated that miR-193a and miR-193b may also 
be able to down regulate KIT. MiR-193a and miR-193b are naturally homologous 
miRNAs with only 4 bases that differ between them, two at positions 9 and 10, and 
another two at positions 20 and 21 from the 5’ end. All four bases are thus situated 
outside of the seed region of the miRNA, near the middle and 3’ end respectively. 
Target binding reporter assays for both of these miRNAs confirmed their ability to 
down regulate the reporter gene expression, though both miRNAs performed equally 
well at various concentrations (Fig. 3.6).  
 
The selective incorporation of miRNA isomers in Ago1 and Ago2 indicates a level of 
regulation in the usage of mature miRNAs present in human cells post-processing that 
has not been previously characterised. The examples shown in figure 3.7 has 
highlighted that isomers associated with Argonaute proteins may differ from profiled 
isomer expression, showing selective preference for different isomers (e.g. miR-221, 
miR-222, miR-151-5p). Furthermore, miRNAs and their isomers may associate 
differently with different Argonaute proteins, indicating another level of specificity 
(e.g. miR-23a). Considering that only Ago2 has the ability to cleave mRNA targets of 
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miRNAs (Liu et al., 2004, Meister et al., 2004), selective incorporation in Ago2 may 
be indicative of this unique function. In plants, it has been shown that the two bases at 
the 5’ end of a microRNA can direct miRNAs to different Argonaute complexes (Mi 
et al., 2008). Though generally miRNAs are not thought to be differentially 
incorporated in endogenous human Argonaute proteins (Liu et al., 2004, Meister et 
al., 2004, Su et al., 2009), at least one report has indicated that there may be a slightly 
greater preference of miR-24 for Ago2 over Ago3 (Azuma-Mukai et al., 2008). As 
was observed in this study, this suggests that miRNAs can exhibit a degree of specific 
incorporation with human Argonaute proteins, though sequencing of the isomers 
associated with each would be required to determine if, like plants, the 5’ terminal 
nucleotides are a factor. 
 
Of additional interest from these experiments was the result that miR-151-5p was not 
incorporated into Ago1 or Ago2 at proportionate amounts to its level of expression as 
indicated by deep sequencing. This may possibly provide an explanation as to why the 
Ago2 associated mRNAs were not predicted to be targeted by miR-151-5p (Fig. 3.9). 
It is also possible that miR-151-5p may be preferentially incorporated into Ago3 and 
Ago4, which were not immunoprecipitated in this experiment, though mRNA data 
from the microarray indicates that neither of these Ago proteins is expressed at high 
levels above background in hMSCs (Supplementary Table S2). Interestingly, this also 
indicates that the profiling of general miRNA expression may not necessarily be a 
good representation of miRNA functional significance, and that profiling all 
Argonaute associated miRNAs may be a better method for determining their 
importance.  
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The fact that miRNAs express a number of isomer forms has been previously reported 
(Kuchenbauer et al., 2008, Morin et al., 2008), though their functional significance 
remains unknown. The main evidence in this study for isomer function is their 
abundant and specific expression levels in various cell types and their presence bound 
to endogenous Argonaute proteins, which is also potentially highly selective. The 
clarification of whether isomers contribute to increasing the range of miRNA targets, 
or simply fine-tune repression of specific targets, may depend on further future 
insights into the mechanisms governing miRNA incorporation into RISC in addition 
to miRNA-target interaction.  
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CHAPTER 4 – MicroRNAs in human embryonic stem 
cells pre- and post-differentiation into neuronal 
progenitor stem cells 
 
4.1 INTRODUCTION 
4.1.1 Embryonic to neuronal stem cell microRNAs 
In recent years the advances in deep sequencing technologies have enabled in-depth 
profiling of miRNA expression in various cell types (Creighton et al., 2009). A 
number of deep sequencing miRNA libraries generated from human embryonic stem 
cells (ESCs) undergoing differentiation have already been reported (Bar et al., 2008, 
Landgraf et al., 2007, Morin et al., 2008), but so far no study has focused on deep 
sequencing miRNAs from human ESCs differentiating along the neuronal lineage. 
General studies of miRNA expression in neuronal cell types have already identified a 
number of important miRNAs, including miR-9, miR-9*, and miR-124 that confer 
neuronal specificity (Krichevsky et al., 2006, Miska et al., 2004, Sempere et al., 
2004). Studies into miRNA expression and miRNA mediated gene regulation that 
govern self-renewal and lineage commitment in ESCs are of great interest because of 
the ultimate potential for advancing stem cell therapy. Similarly, a better 
understanding of miRNA regulation in neuronal stem cells is likely to offer insights 
that may aid the treatment of neurological diseases.  
 
4.1.2 Regulation of microRNA expression 
The importance of miRNA mediated gene regulation has been investigated in a 
number of cell systems, but far fewer studies have been able to characterise the 
mechanisms that regulate miRNAs themselves. Genome-wide chromatin 
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immunoprecipitation (ChIP) based predictive analysis and bioinformatics have been 
used to identify a number of promoter regions and common features of miRNA 
promoters, but have also indicated the lack of a general rule governing transcriptional 
control (Corcoran et al., 2009, Ozsolak et al., 2008, Zhou et al., 2007, Marson et al., 
2008). This is particularly evident for the regulation of intragenic miRNAs, many of 
which are now believed to be independently transcribed from their host genes 
(Corcoran et al., 2009, Ozsolak et al., 2008). While features such as binding sites for 
transcription factors has been shown to be important for regulating certain miRNAs 
(O'Donnell et al., 2005, Barroso-delJesus et al., 2008), specifically, experimental 
validation of core promoters for miRNA genes in mammals remains limited to only a 
few examples; such as the miR-302 family cluster (Barroso-delJesus et al., 2008), the 
miR-23a~27a~24-1 cluster (Lee et al., 2004), and the miR-290 – 295 cluster 
(Houbaviy et al., 2005). Further work in characterising individual core promoters of 
miRNAs is essential to understand the mechanisms that govern miRNA function and 
cell type or stage specific expression.  
 
The generation of miRNA expression profiles by deep sequencing in human ESCs 
and their differentiated NSCs in this study shows how the miRNA signature varies 
with differentiation, and highlights the specific miRNAs that might be essential for 
this process. MicroRNA expression was demonstrated to exhibit a degree of cell type 
specificity and comparative analysis of miRNA and mRNA data in ESCs, NSCs and 
mesenchymal cells suggest the likely importance of post-transcriptional regulation of 
miRNA expression.  
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4.2 RESULTS 
4.2.1 Human embryonic and neuronal progenitor stem cell microRNA libraries 
Cells were obtained and differentiated by the Wei Cui lab, Imperial College London 
(Gerrard et al., 2005). Undifferentiated human embryonic stem cells (ESCs), 
designated H1, were maintained at sub-confluence to confluence and formed compact 
colonies in culture (Fig. 4.1A, colonies indicated by white arrows). Neuronal 
progenitor stem cells (NSCs) differentiated from the same line of H1 ESCs were also 
maintained at confluence but grew as a monolayer of cells and exhibited altered 
morphology (Fig. 4.1B).  
 
A representation of overall miRNA expression in undifferentiated ESCs and their 
differentiated NSCs was generated by deep sequencing using the Solexa sequencing 
technique in collaboration with Dr Attila Molnar and Professor David Baulcombe. A 
total of 1,697,514 and 2,345,364 unfiltered sequences were extracted from ESCs and 
NSCs respectively, of which 1,276,916 (ESCs) and 1,274,244 (NSCs) were between 
15 and 28 nucletides in length. After filtering for redundancy, the resultant databases 
contained 24,534 and 23,426 unique sequence reads for ESCs and NSCs respectively, 
from which a total of 92 ESCs and 100 NSCs individual annotated mature miRNAs 
(miRBase v13.0) with a sequencing frequency of n ≥ 5 could be detected 
(Supplementary Tables S4 and S5). All of the miRNAs that were preferentially 
expressed with n>50 in either the ESC and NSC libraries (and <5 in the other library), 
are listed in Table 4.1. Additionally, one non-annotated potentially novel mature 
miRNA, plus 25 individual annotated piRNAs (piRNABank v2) could also be 
detected (Supplementary Table S6). The total sequencing numbers for each miRNA is 
inclusive of any isomers.  
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Figure 4.1. Human embryonic stem cell colonies and neuronal progenitor stem 
cells. H1 human embryonic stem cells (left panels) and differentiated neuronal 
progenitor stem cells (right panels) were cultured in 6-well plates coated in laminin 
and poly-L-lysine and maintained at confluence. Embryonic stem cells formed tightly 
packed colonies in culture (white arrows), whereas neuronal progenitor stem cells 
grew as a monolayer and have a different morphology.  
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Northern blotting was used to validate the expression of several of the miRNAs that 
were sequenced in either or both ESC and NSC libraries (Fig. 4.2). The miRNAs 
specific to either the ESCs (miR-302a* and miR-182) or NSCs (miR-9 and miR-9*), 
as indicated by Solexa sequencing, could only be detected in their specific cell types. 
Two miRNAs with similar sequencing values in both ESCs and NSCs (miR-222 and 
miR-340) were also detected at equivalent levels by northern blotting. Isomer 
expression is visible for miR-222 and miR-182, and faint additional bands could also 
be detected for miR-9* and miR-302a* (Fig. 4.2).  
 
miRNA ES   miRNA NS 
302a* 2370 
  
let-7f 4356 
182 905 
  
let-7a 3701 
183 350 
  
9* 1299 
302b 115 
  
92b 885 
302a 105 
  
9 870 
31 83 
  
29a 559 
302d 75 
  
let-7c 481 
302c 68 
  
26a 393 
1323 58 
  
let-7b 371 
  
  
let-7e 326 
  
  
125b 297 
  
  
24 297 
  
  
210 209 
  
  
let-7g 199 
  
  
100 197 
  
  
let-7d 190 
  
  
27b 170 
  
  
181a 168 
  
  
let-7i 153 
  
  
7 150 
  
  
146b 88 
  
  
23a 53 
 
4.2.2 Novel microRNA and piwi-interacting RNAs 
One potential novel miRNA (miR-1839), homologous to the canine cfa-miR-1839 
miRNA, was discovered and mapped to a single location within the human genome 
and could be folded into a hairpin structure resembling pre-miRNA by MFold 
analysis (Fig. 4.3A).  
Table 4.1. MicroRNAs that 
were both highly and 
preferentially expressed in 
the human embryonic and 
neuronal progenitor stem 
cells libraries. All miRNAs 
that were sequenced n>50 
and preferentially expressed 
in either the ESC (red) or 
NSC (blue) libraries (not 
detected n>5 in the other 
library) are listed with their 
sequencing frequencies.  
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Northern No. seq.
ES      NS ES       NS
miR-302a*
miR-182    
miR-340    
miR-222       
let-7a           
let-7f             
miR-9*          
miR-9            
5.8S rRNA
8700
12990
43560
369120
4228
682474
0905
02370
 
 
 
 
 
Figure 4.2. Northern blot confirmation of ES and NS miRNA sequencing results. 
30 ug of total RNA was run on a 15% denaturing PAGE and northern blotted for ES 
and NS specific miRNAs. Sequencing numbers for both libraries are indicated on the 
right. Total RNA containing the 5.8S rRNA was stained with ethidium bromide as a 
loading control.  
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5.8S rRNA
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----^        ca-        tt  ata     
 
 
 
 
 
 
Figure 4.3. Novel microRNAs and piR-018780. (A) Potential novel miRNA, 
designated Novel miR-1839 was cloned from the ES and NS miRNA libraries and its 
putative hairpin structure is shown as determined by Mfold. This miRNA is 
homologous to the miRBase annotated canine cfa-miR-1839 (insert box). (B) ES and 
NS total RNA was northern blotted for piR-018780, and the sequencing frequencies 
are shown above. 5.8S rRNA was stained with ethidium bromide as a loading control. 
(C) The transcript encoding for piR-018780 was also detected by RT-PCR and 
sequenced, the double bands represent splice variants.  
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MiR-1839 was cloned from both human ESCs and NSCs libraries. The mature 
sequence of miR-1839 maps to chromosome 15 in the human genome and is 
homologous to its cfa-miR-1839, which maps to chromosome 3 of the Canis 
familiaris genome (Fig. 4.3A, shown in insert box).  
 
In the current version of piRNABank (v2) there are 23,439 listed human piRNAs 
mapping to unique or multiple loci. Of these, a total of 11 individual annotated human 
piRNAs were identified from the ESCs and NSCs libraries, sequenced up to 435 times 
(Supplementary Table S6). An additional 14 individual piRNAs not annotated in 
humans but matching annotated piRNAs of various other species including mouse, 
rat, zebrafish, platypus and flies were also detected, indicating the discovery of human 
piRNAs that are well conserved in other species and previously undetected in human 
cell types.  
 
4.2.3 Microarray analysis 
A representation of overall messenger RNA expression in human ESCs and NSCs 
was generated by microarray analysis using the HumanWG-6 V3 beadchip (Illumina 
Inc) (performed by Peter Ellis, Sanger Institute). The readings obtained from the 
HumanWG-6 V3 beadchip platform ranged from a signal of 67.10 to 65461.10 for 
ESCs, and 63.0 to 64372.70 for NSCs (arbitrary units), as illustrated by heatmaps 
(Fig. 4.4). The expression levels of some of the ESC or NSC mRNAs were tested and 
validated by RT-PCR (Fig. 4.5). Total mRNA from MSCs (discussed in Chapter 3.) 
was included as an additional control. All bands shown were isolated and sequenced 
for verification (data not shown).  
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All of the mRNAs that were either up-regulated or down-regulated by a minimum of 
10-fold between the ESC and NSC microarrays were identified (Supplementary Table 
S7). As expected, in the ESC microarray, among the up-regulated mRNAs detected 
were several encoding for previously identified pluripotency factors, such as Oct4, 
Nanog and Lin28 (Yu et al., 2007b). Also in this up-regulated subset were two 
members of the transforming growth factor-beta (TGFβ) family of cell-cell signalling 
factors, Nodal and Lefty1, as well as the transcription factor, Myc. The up-regulated 
mRNAs in the NSCs detected by microarray included some regulators of neural 
development: hairy and enhancer of split 5 (Hes5); neurocan (NCAN); distal-less 
homeobox 5 (DLX1); tectonic 1 (TCTN1); and Ephrin receptor A3 (EPHA3). 
Surprsingly, neuronal markers, NCAM and MAP2, were only detected at low levels 
above background, but the astrocyte marker, glial fibrillary acidic protein (GFAP), 
was among the most abundantly expressed mRNAs, which is indicative of long term 
culture of NSCs and may indicate that the cells were beginning to lose their neuronal 
progenitor status (Gerrard et al., 2005). Interestingly, the transcript containing miR-9-
1, C1orf61, lists as the second most abundantly detected transcript in the microarray. 
 
Figure 4.4 Messenger RNA heatmap of embryonic and neuronal progenitor stem 
cells. Total mRNA expression in human embryonic stem cells (ES) and neuronal 
progenitor stem cells (NEURO) were analysed by microarrays. 
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Figure 4.5. RT-PCR validation of mRNA microarray. Specific ES, NS and MS up-
regulated genes were amplified by RT-PCR to validate the microarray data.  
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4.2.4 Transcription unit and promoter analysis of miR-9 and miR-9* 
The miRNA libraries highlighted miR-9 and miR-9* as neuronal specific, and the 
miR-302 family of miRNAs as embryonic specific (Table 4.1). MiR-9 and miR-9* are 
derived from the same hairpin which is conserved at 3 genomic locations in humans. 
In all 3 locations the mature sequence of both miR-9 and miR-9* remains identical, 
and are separated individually by a -1, -2 or -3 suffix. MiR-9-1 is intragenic and maps 
to the intron of the host transcript, C1orf61, for which the expression levels is > 10-
fold up-regulated in the NSCs microarray. Both miR-9-2 and miR-9-3 do not map to 
any known host transcript, and have thus been classified as intergenic. The expression 
of the transcripts encoding miR-9-1 and miR-9-2 was detected only in NSCs by RT-
PCR (Fig. 4.6A), validating that miR-9-1 and miR-9-2 were NSCs specific due to 
regulation at the transcriptional level. Similarly, the transcript containing the miR-302 
family of miRNAs could also only be detected in ESCs. None of the primers tested 
could detect expression of the miR-9-3 transcript in either cell types (data not shown), 
but this is not conclusive due to the lack of a positive control.  
 
Both miR-9-1 and its host mRNA, C1orf61, are highly up-regulated in NSCs, which 
strongly indicates co-transcription and regulation in these cells. Though miR-9-2 is 
not located within an annotated mRNA, EST data from the UCSC genome browser 
indicates that it is contained within an unidentified transcriptional unit (Fig. 4.6B). To 
determine the transcriptional start site (TSS) of the transcriptional unit encoding miR-
9-2, a 5’ RACE assay was performed and the resultant 5’ adapter ligated transcript 
was sequenced (Fig. 4.6C).  
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Figure 4.6. Detection of miRNA genes. (A) ES and NS specific miRNA-containing 
transcripts were amplified by RT-PCR. (B) Four putative transcriptional start sites 
(indicated by the red arrows 1-4) based on EST data from the UCSC genome browser 
for miR-9-2. (C) 5’ RACE assay was used to determine the transcriptional start site 
(TSS) for miR-9-2 in NS cells, as marked by the upper band (left panel). The 
sequence of the TSS matches closely to the start of the BC036480 EST as marked by 
arrow 1 in (B). Aproximately 1 kb upstream of the TSS was selected to test for 
promoter activity. 
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The end result showed that the TSS detected mapped to position Chr5(-):88004906 on 
the human genome, approximately 70 bases upstream of the start of the BC036480 
EST (Fig. 4.6B, shown by red arrow 1), indicating that the transcriptional unit of miR-
9-2 identified best corresponds with this EST. 
 
To try to identify the promoter regions for miR-9-1, miR-9-2 and miR-9-3, sections 
upstream of both their predicted TSS and the miRNA hairpins themselves were 
subjected to preliminary analysis for promoter elements and tested for promoter 
activity by luciferase assays. Figure 4.7 shows possible promoter regions (indicated 
by black bi-directional arrows) and the predicted CpG islands (shaded blue regions on 
graphs, as determined by the program, MethPrimer) and TATA sites (T) associated 
with each. The degree of conservation across mammals (UCSC genome browser) is 
also shown in the lower graphs under each region, represented by dark blue peaks. For 
miR-9-1, a 3 kb region upstream of the miRNA hairpin was selected which contained 
multiple CpG rich sections and one TATA box (Fig. 4.7A). The region upstream of 
the TSS could not be cloned and therefore has not been analysed here. For miR-9-2, a 
700 bp region upstream of the miRNA and a 1 kb region upstream of the TSS as 
identified previously (Fig.4.6B-C) revealed no CpG islands for the former, and no 
TATA boxes for the latter (Fig. 4.7B). For miR-9-3, owing to a lack of detection in 
the NSCs, a putative TSS taken from the CR612213 EST was used from which 3 kb 
from the upstream region was analysed, along with 600 bp upstream of the hairpin 
(Fig. 4.7C). No TATA boxes were found in the 600 bp region upstream of the hairpin 
but the entire region is a predicted CpG island. For the region upstream of the 
predicted TSS taken from EST data, two TATA boxes were found and multiple 
smaller CpG islands were also present. An Inr-like motif with a consensus sequence 
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of CCCCACCTCC, reported to be present in the putative promoters of many human 
miRNAs, was considered but not found in any of the regions analysed (Zhou et al., 
2007).  
 
All 5 regions analysed in Figure 4.7 were cloned upstream of the firefly luciferase 
expression vector, pGL4.10 (Promega) for which there is no internal promoter (Fig. 
4.8A). HEK293 cells were used as controls to represent a generic highly transfectable 
cell line, along with MSCs to represent a more difficult to transfect primary cell line 
(hESCs were not available at this time).  The NSCs used were taken from two 
different stages of differentiation, an earlier stage of differentiation (ENS) as 
determined by passage number (<14) and the later stage differentiation (LNS) (~ 
passage 40) which correlates better with the stage used to derive the miRNA library 
and mRNA microarray data. The mammalian pGK promoter was cloned into pGL4 as 
a positive control while a random genomic sequence was cloned as a negative control. 
All individual luciferase activity readings taken were standardised against their renilla 
luciferase levels as internal controls. Transfection of the negative control into all 4 
cell types gave no increase in luciferase activity above transfection of the unmodified 
pGL4 vector (data not shown). Transfection of the positive control resulted in an 
almost 100-fold increase in luciferase activity in HEK293 cells, but only a ~60-fold 
increase in MSCs, and less than 12-fold increase in both ENS and LNS (Fig. 4.8B). 
Figure 4.8C shows the promoter activity based on luciferase expression for all 5 miR-
9 regions tested upstream of the miRNA hairpins (pre-mir) and upstream of their 
putative TSS (pre-EST) (n ≥ 6). The results of the pGK expression (Fig. 4.8B) 
indicated that overall transfection efficiency was much lower for ENS and LNS than 
HEK293 and MSCs, and this was also observed in the GFP expression as visualised 
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by microscopy (<10% in ENS and LNS, data not shown). Hence, the results obtained 
for the luciferase assays for promoter activity for each cell type (Fig. 4.8C) was also 
analysed as a percentage of their positive pGK control (Fig. 4.8D). Following this 
standardisation, all regions tested appeared to give slightly higher luciferase 
expression in the neuronal cell types than the control cell types. For the miR-9-1 pre-
mir vector, only ~5% of the positive control luciferase expression was observed, 
indicating that there is no promoter activity in this region. For miR-9-2, ~10-22% 
expression was observed for both pre-mir and pre-EST vectors in ENS and LNS in 
comparison to the <5% observed for the control cell types, indicating potential 
neuronal specific activity. Similarly, for both miR-9-3 vectors, there is higher 
induction of luciferase in ENS (~30%) and LNS (~45%) in comparison to the control 
cells (<16%) but no difference is observed between luciferase expression induced by 
the pre-mir region and the pre-EST region.  
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Figure 4.7. Promoter analysis of miR-9 family. Regions upstream of the miRNA 
hairpins for miR-9-1 (A), miR-9-2 (B) and miR-9-3 (C), and the predicted 
transcriptional start site (TSS) derived from EST data for miR-9-2 (B) and miR-9-3 
(C), were analysed for promoter activity (sequence lengths are indicated by the red 
arrows). Exons are denoted by the blue boxes. The graphs below each cloned region 
shows the approximate locations of CpG islands (shaded blue) and TATA sites (T), 
and also the sequence conservation across mammalian species (dark blue).  
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Figure 4.8. Luciferase assay for promoter activity. Regions upstream of the 
miRNA hairpins for miR-9-1, miR-9-2 and miR-9-3, and the predicted transcriptional 
start site derived from EST data for miR-9-2 and miR-9-3 (see Fig. 4.7B-C), were 
cloned upstream of the firefly luciferase gene in the pGL4 reporter vector (A). The 
pGK promoter was cloned as a positive control and was transfected into HEK293, 
mesenchymal stem cells (MSC), early (ENS) and late (LNS) differentiated neuronal 
progenitor stem cells (B). The ability of each of the promoters for driving luciferase 
activity was measured (C), and also analysed as a proportion of the pGK positive 
control in each cell type (D). All measurements were taken as the fold increase of 
Luciferase activity measured after 48 hrs and standardised against Renilla luciferase 
and the negative insert control (n>6). 
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4.2.5 Intragenic microRNAs and host mRNAs expression 
Approximately half of all of the miRNAs isolated from human ESCs and their 
differentiated NSCs in the miRNA libraries were intragenic miRNAs (Supplementary 
Tables S4 and S5). The majority of the host transcripts containing these miRNAs 
were also detected on the microarray. With the exception of any intragenic miRNAs 
that can map to more than one genomic location, the sequencing values (number of 
times sequenced) of all of the intragenic miRNAs identified from both the ESC and 
NSC libraries was plotted against their host mRNA expression levels as determined 
by microarray analysis (Fig. 4.9A and Supplementary Table S8). No overall 
correlation was observed between miRNA and host mRNA expression levels in either 
cell types. A number of the intragenic miRNAs appeared to be highly expressed 
irrespective of the lack of their host mRNA expression, and furthermore were up- or 
down-regulated in the differentiated NSCs compared to ESCs in the absence of any 
changes in the host mRNA levels (Fig. 4.9B).  
 
One of these examples is miR-27b, which is located within a host mRNA, C9orf3 
whose expression is not much above background in either ESCs or NSCs. MiR-27b is 
also part of a cluster of 3 miRNAs, which includes miR-23b and miR-24-1 that map 
within 700 bp of each other (designated here as the miR-23b cluster). It should be 
noted that although miR-24 was detected in the ESCs library, this miRNA maps to 
two genomic locations, miR-24-1 and miR-24-2, and it was not possible to fully 
elucidate which location the isolated miR-24 in each library is derived from. In both 
the miR-23b and miR-302 clusters, despite being within 700 bp apart, the expression 
of individual miRNAs can vary up to 50-fold (Fig. 4.10A).  
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Figure 4.9. Comparison of miRNA and host mRNA expression levels. (A) 
MicroRNA expression levels based on Solexa sequencing numbers plotted against 
their host mRNA expression levels based on average microarray signal for both the 
human embryonic stem cells (ES) and neuronal progenitor stem cells (NS). (B) 
Examples of miRNAs with expression levels that differ from their host mRNA 
expression levels in ES and differentiated NS.  
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Figure 4.10. Variable expression of clustered and hairpin microRNAs. (A) 
Sequencing frequency of individual miRNAs from the miR-302 cluster and the miR-
23b cluster. The numbers in gray indicate the miRNAs sequenced can be derived from 
an alternate location. (B) Sequencing frequency of miR-151-5p and miR-151-3p in 
embryonic, neuronal and mesenchymal stem cells.  
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In the miR-23b cluster in NSCs, there is an 8-fold higher expression of miR-27b over 
miR-23b, but preference for miR-27b in this cell type is not reflected in the MSC 
library (refer to Chapter 3.), which instead predominantly expresses miR-23b from 
this cluster.  
 
Incidentally, differences in the preferences for specific miRNAs in different cell types 
are also seen between two miRNAs from the same hairpin. In both the ESC and NSC 
libraries, the miRNA derived from the 3’ arm of the miR-151 hairpin (miR-151-3p) is 
predominantly expressed. However, in the MSC library, it is the 5’ arm (miR-151-5p) 
which is selectively expressed from this miR-151 hairpin (Fig. 4.10B).  
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4.3 DISCUSSION 
4.3.1 MicroRNA signatures of embryonic and neuronal progenitor stem cells 
In the sequenced human ESC library, initial observations of miRNA expression 
highlights the abundance of the well characterised embryonic specific miR-302 family 
members (Barroso-delJesus et al., 2008, Lin et al., 2008). In addition, there is little 
expression of the let-7 family of miRNAs more commonly associated with 
development. The miRNA profile of this library is therefore mostly consistent with 
the expected miRNA signature of ESCs (Houbaviy et al., 2003, Lakshmipathy et al., 
2007, Suh et al., 2004). However, additional miRNAs that were highly up-regulated 
in this ESCs library include the miR-182~96~183 cluster and miR-31. Aside from one 
report by Langraf et al., 2007, which mentions the expression of the miR-182~96~183 
cluster in embryonic tissues and cell lines, none of these miRNAs have been 
previously associated specifically with human ESCs. Conversely, some of the 
previously identified ESCs enriched miRNAs such as the miR-371~372~373 cluster 
(Suh et al., 2004, Laurent et al., 2008) were also not observed in this library. 
Nonetheless, mRNA data supports the genotype of the ESCs used in this study as 
pluripotent cells expressing high levels of Oct4, Nanog and Lin28, suggesting that 
these discrepancies are more likely to be due to the variations in the sourcing and 
conditions of generating individual ESCs and their miRNA profiles.  
 
Fewer studies have characterised miRNA expression specifically in NSCs, but those 
that have screened for miRNAs in various brain tissues have identified miR-9, miR-
9*, miR-125a, miR-125b and miR-138 as brain enriched miRNAs (Sempere et al., 
2004, Miska et al., 2004, Krichevsky et al., 2003, Le et al., 2009), all of which were 
also detected in the NSC library, and not the ESC library. The NSCs library also 
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expressed abundant let-7 family of miRNAs, characteristic of more developed cells 
and in direct contrast to ESCs (Fig. 4.2). Though similar, there are discrepancies in 
this library compared to other published miRNA profiles for this cell type. The 
reported brain specific miR-124 (Krichevsky et al., 2006) was not only present at low 
levels in the NSCs library, but also present at equivalent levels in the ESCs library. 
Two miRNAs, miR-132 and miR-137, with reported roles in neuronal cell 
differentiation and maturation (Klein et al., 2007, Vo et al., 2005, Silber et al., 2008), 
were also not detected, though the majority of these studies were not conducted with 
human cells. The expression of the astrocyte marker, GFAP, and lack of neuronal 
markers, NCAM and MAP2, from the microarray analysis of the NSCs has hinted at 
the possibility that the NSCs used were beginning to undergo astrocytic 
differentiation, possibly as a consequence of long-term culture (Gerrard et al., 2005). 
This would explain the lack of miR-124, which is preferentially expressed in 
embryonic neurons (Smirnova et al., 2005). Interestingly, there is some evidence to 
suggest that the over-expression of miR-9/miR-9* along with miR-124 in neural 
precursor cells leads to a decrease in GFAP positive cells, and conversely, blocking 
miR-9 function with antagomirs leads to an increase in GFAP cells (Krichevsky et al., 
2006). The high levels of GFAP and miR-9/miR-9* is therefore somewhat 
contradictory and indicates that the cells may constitute a mixed population of 
neuronal and astrocyte progenitors, or alternatively be of a common progenitor that 
has not committed to either lineage.  
 
Overall, the miRNA signatures of both the ESCs and NSCs profiled in this study has 
displayed many commonalities with other similar libraries, as well as expressing a 
degree of individual identity. This highlights that while there are some miRNAs that 
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can constitute a robust cell type signature, such as miR-302 for ESCs, the majority are 
likely to be more variable or reflective of minor differences in the individually 
profiled cells. Further characterisation of the roles that specific miRNAs play in 
regulating the genetic changes that occur with differentiation will enable the use of 
miRNA libraries such as the ones generated in this study to become better tools for 
unravelling the features of the stem cells that they represent.  
 
4.3.2 PIWI-interacting RNAs in embryonic and neuronal stem cells 
Typically piRNAs are most commonly associated with germline cell types but their 
expression has been reported from deep sequencing libraries generated from human 
embryonic stem cells pre- and post-differentiation into embryoid bodies (Morin et al., 
2008), and in Jurkat cells (Azuma-Mukai et al., 2008). It is therefore not surprising 
that both the ESCs and NSCs libraries generated in this study also included a number 
of piRNAs. The precise sequencing numbers vary between 2 and 435 for the piRNAs 
detected. Three of the piRNAs show >5-fold differential expression between ESCs 
and NSCs (hsa-piR-000045, dr-piR-0029287, dr-piR-0038184), but mostly there is 
little difference between the expressions of individual piRNAs between the two cell 
types. The only tested piRNAs could be detected faintly in NSCs by northern blotting 
(Fig. 4.3B), though the encoding transcript was detectable by RT-PCR in both (Fig. 
4.3C). It is difficult to infer functional relevance, if any, for these piRNAs in ESCs 
and NSCs. Additionally, mRNA microarray data indicates, as expected (Aravin et al., 
2007, Girard et al., 2006), that none of the PIWI encoding mRNAs are expressed in 
these cells. Taken together, it is possible that the presence of these piRNAs does not 
constitute any functional significance in these cells at this point. However, as there is 
still clearly much about the piRNA pathway and mechanisms of function that have yet 
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to be discovered in humans, it cannot be ruled out that alternative functional 
properties currently unidentified may exist, which would better explain their presence.   
 
4.3.3 Regulation of miR-9 and miR-9* expression 
The NSC miRNA library generated in this and previous studies have highlighted the 
expression of the miR-9 hairpin of miRNAs as highly neuronal specific miRNAs 
(Krichevsky et al., 2006). Similar to miR-302 family regulation by pluripotency 
factors (Barroso-delJesus et al., 2008), miR-9/miR-9* may be regulated by neuronal 
factors such as the TLX nuclear receptor, which is an important regulator of neural 
stem cell self-renewal (Zhao et al., 2009), and the transcriptional repressor RE1-
silencing transcription factor (REST) (Conaco et al., 2006, Packer et al., 2008). 
Intriguingly, miR-9/miR-9* has also been shown to target components of the REST 
repressor complex, thus constituting a negative feedback loop (Packer et al., 2008). 
While these studies have indicated that the expression of miR-9/miR-9* are affected 
by changes in the expression of these factors, the precise associations that trigger 
transcription of miR-9/miR-9* genes have thus far not been elucidated. Reasons for 
this may be due to the fact that the same mature sequence of miR-9/miR-9* is located 
in 3 different transcripts, and identifying specifically which transcripts encodes miR-
9/miR-9* in a given cell type has not been done in this or any previous studies. The 
precise transcriptional units and promoter elements at all 3 locations have also not 
been fully defined.  
 
Initial analysis of the miR-9/miR-9* transcript expression in the NSCs showed that at 
least 2 of the 3 transcripts, miR-9-1 and miR-9-2, were only expressed in NSCs and 
not ESCs (Fig. 4.5A). RT-PCR analysis of miR-9-1 and miR-9-2 expression  
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indicated that regulation of these miRNA encoding transcripts was at the 
transcriptional level, which suggested possible NSCs specific promoter activity. In the 
case of miR-9-1, this was accentuated by the fact that it is located within a host 
mRNA, C1orf61, whose expression was also highly neuronal specific according to 
microarray data. It was speculated that regions containing the promoter for miR-
9/miR-9* would thus only exhibit promoter activity in neuronal cell types. Assuming 
that core promoters lie upstream of the transcript encoding the miRNA, regions 
upstream of the miR-9-2 and miR-9-3 containing transcripts (as inferred by EST data 
and verified by RT-PCR and 5’ RACE assay for miR-9-2 (Fig. 4.5B-C) were tested in 
in vitro luciferase studies to assess promoter activity. The region upstream of the miR-
9-1 containing C1orf61 mRNA transcript was not tested in this study due to 
experimental difficulties, but given the NSC specific expression of C1orf61 it is likely 
that any promoter region identified would also be NSC specific. Additionally, regions 
upstream of all 3 miR-9/miR-9* hairpin locations were also assessed for promoter 
activity due to findings from a previous report that indicated ~26% of intragenic 
miRNAs may utilise their own promoters over the promoter of their host gene  
(Corcoran et al., 2009), and that intergenic miRNA promoters are often ~500 bp 
upstream of the miRNAs themselves (Zhou et al., 2007),.  
 
The overall results from this analysis indicated that while all but the miR-9-1 putative 
promoter regions exhibited a degree of neuronal cell type specific ability to drive 
luciferase, none of the regions particularly stood out as having strong core promoter 
activity (Fig. 4.6). For both miR-9-2 and miR-9-3, interestingly, the regions upstream 
of the EST and upstream of the miRNA hairpin tested gave similar activity. Despite 
the relatively low levels of activity observed for miR-9-2, and the indication that none 
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of the regions tested constitutes in itself the core promoter; the fact that two different 
regions of the putative miR-9-2 and miR-9-3 transcripts can drive luciferase activity 
specific to NSCs to similar degrees is suggestive of the presence of possibly 
uncharacterised elements that aids, if not forms part of, the core promoter. Zhou et al. 
(2007) previously characterised ~500 bp regions upstream of the miR-9-2 and miR-9-
3 hairpins as being their putative promoters, and these regions are encompassed in the 
regions cloned and tested in this study. They also specified that according to their 
algorithm for locating putative promoters, some miRNA genes may be predicted to 
contain multiple putative promoters, though they did not specifically detail other 
putative promoters for miR-9-2 and miR-9-3. The experimental analysis conducted in 
this study confirms the potential promoter activity of the regions specified by Zhou et 
al. (2007) and also highlights that for any given miRNA core promoter there may also 
be other regions with promoter- or enhancer-like activity.  
 
4.3.4 Regulation of intragenic and clustered microRNA expression 
The ESCs and NSCs that were used to generate the miRNA libraries were also 
submitted for mRNA microarray analysis. Aside from aiding the characterisation of 
gene expression in the ESCs and NSCs respectively, this also enabled comparisons of 
miRNA and mRNA expression pre- and post-neuronal differentiation to be studied. 
While the general concept of co-expression of miRNAs with their host mRNA 
transcripts has not been negated, studies characterising various levels of post-
transcriptional regulation (Heo et al., 2008, Lee et al., 2008, Rybak et al., 2008), as 
well as the potential of intragenic miRNA promoters (Corcoran et al., 2009, Ozsolak 
et al., 2008), has highlighted the complexity of issues governing the regulation of 
miRNA expression.  
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The initial assessment of whether the intragenic miRNAs expressed in either library 
correlated with their host mRNAs expression showed that there was no overall 
positive correlation between the two (Fig. 4.8A). Some miRNAs did correlate well 
with their hosts, such as the equivalent expression of miR-151-3p in PTK2 for both 
ESCs and NSCs, and miR-9-1 in C1orf61 in NSCs (Supplementary Table S8). 
However, a number of miRNAs were identified that appeared to be expressed in 
excess of their hosts’ expression and also, to a lesser degree, negatively correlate with 
changes in their hosts’ expression following differentiation (Fig. 4.8B). These 
observations strongly suggest either that these miRNAs are regulated by their own 
promoters, or that there are factors regulating their maturation and expression 
downstream of their initial transcription. Of course, it is important to confirm the 
mRNA expression levels indicated by microarray analysis by RT-PCR. The limited 
number of RT-PCR tests performed indicated a good correlation with the microarray 
data (Fig. 4.5) and in general micrroarray analysis of mRNA expression is held to be 
reliable.    
 
In the instances of the examples shown in Figure 4.8B, miR-15a, miR-27b and miR-
503 are most likely to be regulated at the transcriptional level by their own promoters, 
given the low background expression of their host transcripts in both the ESCs and 
NSCs. The fact that miR-15a and miR-27b increase in abundance with neuronal 
differentiation, while the host mRNAs remain essentially unexpressed, indicates cell 
specific expression for the putative miR-15a and miR-27b promoters, although 
possible post-transcriptional regulation cannot be excluded. The inverse correlation 
between the expression of miR-744 and miR-140-3p with their hosts, albeit at an 
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average of 2-3-fold only, also indicates cell type specific regulation at the 
transcriptional level via internal promoters but may also be attributed to post-
transcriptional regulation. As both miR-744 and miR-140-3p host mRNAs are 
expressed at slightly higher levels in ESCs, it is possible to speculate that far more of 
the miR-744 and miR-140-3p precursors are being generated than being processed 
until the onset of neuronal differentiation by mechanisms synonymous to Lin28 
regulation of let-7 pre-cursors (Heo et al., 2008, Newman et al., 2008, Rybak et al., 
2008, Viswanathan et al., 2008). However, as the fold changes observed here are not 
as dramatic as those in the Lin28/let-7 studies, any such mechanism is unlikely to 
constitute the main regulatory factor of these miRNAs.  
 
The presence of post-transcriptional regulatory mechanisms is most strongly indicated 
in examples where individual miRNAs located within a close cluster exhibit variable 
expression levels. In both the miR-302 and miR-23b clusters, all of the miRNAs in 
each cluster are located within a 700 bp distance of each other (Fig. 4.9B). The close 
proximity of these miRNAs, rather than their relative homology, is the main reason 
that clustered miRNAs are expected to be subject to co-transcriptional control. For the 
miR-302 cluster, while the encoding transcript appears to be ESCs specific like the 
miRNAs themselves (Fig. 4.9A), the sequencing numbers indicate a greater 
preference for the expression of miR-302a*, and thus the miR-302 hairpin precursor, 
than any of the other miRNA precursors in this cluster (Fig. 4.9B). Given that 
previous studies have characterised these miRNAs as expressed as a single polycystic 
transcript (Suh et al., 2004) regulated by a single core promoter (Barroso-delJesus et 
al., 2008, Card et al., 2008), it is most likely that the discrepancy in expression is due 
to regulation of precursor processing and/or the turnover of the mature miRNAs. This 
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is seen more prominently in the preference for the miR-27b miRNA over miR-23b in 
the same cluster observed in NSCs which is switched in MSCs (Fig. 4.9B). Further 
studies to detect the expression levels of the precursors of these miRNAs will be 
required before accurate predictions can be made to determine at which point these 
miRNAs are differentially regulated.  
 
Interestingly, the preferential expression of miR-302a over other miRNAs in the same 
cluster (Fig. 4.10A) was also observed in a previous study (Morin et al., 2008), 
However, the libraries differ in that we found that miR-302a* was more abundant 
than miR-302a (Table 4.1), indicating a difference in strand selection between the two 
libraries. Similarly, there is a switch in the most abundantly sequenced arm of the 
miR-151 hairpin of miRNAs between the ESC/NSC and MSC libraries (Fig. 4.9C). 
The observed differences in the proportionate expression of two miRNAs within the 
same hairpin precursor indicate that cell or stage type specific regulation of strand 
selection is another mechanism of post-transcriptional regulation.  
 
The use of deep sequencing technology to generate miRNA libraries from human 
ESCs pre- and post-differentiation enables a depth of insight into miRNA expression 
that is arguably not achievable with other profiling methods. The fact that other small 
RNA species, such as piRNAs, can be identified from the same library with no 
additional effort demonstrates the wealth of information that is available from this 
resource. Coupled with the mRNA microarray data, the ESCs and NSCs libraries 
constitutes a platform in which studies into miRNA targeting and miRNA regulation 
can also be investigated. Initial attempts to look into aspects of miRNA regulation 
during neuronal differentiation have already highlighted the complexity of the post-
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transcriptional regulatory mechanisms that are likely to be at work for various 
miRNAs in this system. Further experimentation will be required to fully elucidate the 
factors that may be involved in these processes, but the databases generated in this 
study as well as the insights gained from the work described here will help to support 
any future investigations.  
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CHAPTER 5 – MicroRNA target predictions and 
microarrays 
 
5.1 INTRODUCTION 
5.1.1 Target prediction programs  
While biological validation is both ideal and required for miRNA target identification, 
the development and use of predictive tools in recent years has greatly aided this 
process. Target prediction programs arose as a consequence of a series of discoveries 
that highlighted several apparent features of identified miRNA targets (reviewed in 
Bartel, 2004); such as the 5’ seed region (Lewis et al., 2003, Stark et al., 2003), and 
binding sites in the 3’UTR (Lai, 2002). Currently, the most commonly used programs 
include TargetScan (Lewis et al., 2005), PicTar (Krek et al., 2005) and miRanda 
(Enright et al., 2003), the last of which has also been adapted and incorporated into 
other prediction programs, such as microRNA.org (Betel et al., 2008) and RegRNA 
(Huang et al., 2006). Differences between these programs tend to stem from the 
individual authors’ bias in interpretation and categorising of the various identified 
criteria, such as strict complementarity (TargetScan) or single mismatch allowances 
(PicTar) at the 5’ seed region. Any differences in the algorithms can generate great 
diversity in the predicted targets (Sethupathy et al., 2006, Dalmay, 2008), and thus it 
is commonplace to use more than one algorithm to generate a list of candidate targets 
for further analysis. Whether it is for preliminary screening or validation of any 
putative miRNA-target interactions, the use of these programs now constitute a basic 
part of any miRNA targeting studies.  
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5.1.2 Microarray detection of microRNAs 
Various groups have developed specialised microarrays for the identification of 
miRNAs over the years (reviewed by Li and Ruan, 2009), in addition to numerous 
companies, such as Exiqon, LC Sciences, Dharmacon and more. Figure 5.1 shows the 
basic principles of miRNA profiling by microarray.  
 
 
 
 
Figure 5.1. Schematic of microRNA detection by microarray. Amine-modified 
miRNA probes consisting of a linker sequence (purple) and the capture sequence 
(green) are immobilised onto amine-reactive glass slides. Isolated miRNAs are 
labelled with fluorescence dye and then hybridised to the microarray. The expected 
hybridisation is shown for has-miR-31. The emission of fluorescence from the 
labelled miRNAs bound at specific positions is then detected. [Modified from Li and 
Ruan, 2009]. 
 
 
The obvious advantages in using microarrays over other miRNA detection methods 
are the quantities of samples that can be analysed in parallel, reduced costs, and 
efficiency. Hence, microarrays are frequently used in profiling miRNA expressional 
changes across multiple cell types, particularly in the screening of normal and disease 
                 Probe hybridisation 
             microRNA preparation 
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cells (Mrozek et al., 2009, Tili et al., 2008, Calin and Croce, 2006). However, due to 
their size and the relative homology of many miRNAs, it is often not possible to 
guarantee perfect specificity in miRNA-probe hybridisation in the microarrays. Issues 
regarding accuracy as well as their potential lack of comparability to other techniques 
is a recognised limitation in the use of many currently available microarrays (Li and 
Ruan, 2009, Yin et al., 2008). Nevertheless, use of microarrays has enabled large 
scale comparative studies to be done (Ramkissoon et al., 2006, Lu et al., 2005), as 
well as validate novel miRNA discoveries (Berezikov et al., 2005), and provides 
promise for use in diagnostic and prognostic assessments (Esquela-Kerscher and 
Slack, 2006). 
 
The use of predictive tools for miRNA targeting studies and microarray platforms for 
the detection of miRNA expression is briefly assessed in this chapter. Both of these 
tools were used in this study as part of the analysis of the MSC, ESC and NSC 
miRNA libraries discussed in Chapters 3 and 4. Predictions were also generated for 
miRNAs that may target two human receptors, KIT and CSF-1R, and candidate 
miRNAs were assessed for their ability to knockdown these receptors in a pilot 
screen. We collaborated with Peter Ellis and Cordelia Langford, from the microarray 
facility at the Sanger Institute for the analysis of miRNAs by microarrays. A number 
of considerations arise from the resulting data which highlight that care should be 
taken when analysing microarray and target prediction outcomes.  
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5.2 RESULTS 
5.2.1 MicroRNA target predictions for KIT 
A luciferase expression vector containing the 3’ UTR of c-kit (v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog) previously used to assess 
miRNA targeting (Figs. 3.5 and 3.6) was also used in this experiment to assess 
miRNA target prediction accuracy. In order to experimentally validate miRNAs 
predicted to target the c-kit 3’UTR, 4 target prediction programs were used; 
TargetScan (v4.0), Pictar (2007 release), miRBase targets (v5.0), and microRNA.org 
(2008 release). Figure 5.2A shows the number of predicted miRNAs generated by 
each program and also the numbers that overlap between the 4 programs. Out of the 4 
programs, microRNA.org gave the highest number of predicted miRNAs to target 
KIT (101), while miRBase gave the lowest (2), despite the fact that both programs 
utilise variations of the same core algorithm, miRanda (Enright et al., 2003). The 
proportion of predicted targets to overlapping targets is greatest between TargetScan 
and PicTar.   
 
A total of 22 miRNAs, representing miRNAs predicted by 3 in 4 programs, as well as 
2 in 4, 1 in 4 and none of the programs, were then selected for a pilot screen to test 
their ability to bind to the c-kit 3’UTR via in vitro reporter assays. Briefly, an ~700bp 
region of the 3’UTR of c-kit, containing the predicted binding sites for all of the 
miRNAs to be tested, was cloned downstream of a firefly luciferase reporter vector 
and transfected into HEK293 cells along with the predicted targeting miRNA mimic 
at 10 pmol concentration (Applied Biosystems). Firefly luciferase activity was 
measured after 48 hrs and standardised to the internal control, renilla luciferase 
activity. The ability of the co-transfected miRNA mimics to knockdown luciferase 
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activity was then calculated as a percentage of the negative control (scrambled 
miRNA mimic). Figure 5.2B shows the results of the preliminary target screen.  
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Figure 5.2. MicroRNA target predictions for KIT. (A) The number of microRNAs 
predicted to target KIT by each of the 4 programs tested are indicated inside the gray 
boxes. Adjoining lines indicate the number of predictions that match between any two 
programs. (B) Preliminary assessment of KIT targeting miRNAs, predicted by 3 (red), 
2 (orange), 1 (yellow) and 0 (blue) out of the 4 programs. MicroRNA mimics were 
transfected at 10 pmol into HEK293 cells and incubated for 48hrs before assaying for 
luciferase expression. Knockdown was calculated as a percentage of the scrambled 
RNA negative control (black bar C). All miRNAs tested at n = 2, except miR-221, 
miR-222, miR-193a and miR-193b which have n > 3.  
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With the exception of miR-193a and miR-193b, all of the tested miRNAs, regardless 
of the prediction frequency for targeting KIT, gave less than 50% knockdown. The 
reported KIT targeting miRNAs, miR-221 and miR-222 (Felli et al., 2005) also did 
not give obvious knockdown compared to the other miRNAs tested. For miR-193a, 
miR-193b and miR-221, there were a greater number of repeats due to previous 
studies described in Chapter 3, section 3.2.4-5. Up to 35% knockdown was observed 
readily for many of the miRNAs tested in this pilot study, and interestingly one of the 
unpredicted miRNAs, miR-145, appeared to up-regulate luciferase activity by almost 
2.5-fold, though the significance of these results cannot be ascertained at this point 
due to the lack of experimental repeats.  
 
5.2.2 MicroRNA target predictions for CSF-1R 
MicroRNAs predicted to target human CSF-1R (colony stimulating factor 1 receptor) 
were also identified using the same 4 target prediction programs listed in Section 
5.2.1, and 4 of these predicted miRNAs were subsequently selected for further 
analysis by in vitro reporter assays (Fig. 5.3A-B). The selected miRNAs include miR-
155 which was predicted by all four programs; miR-22 by three of the programs; 
miR-34a by two and miR-449a/miR-449b by one of the programs (Fig. 5.3A). Co-
transfection of 10 pmol of each miRNA mimic with the firefly luciferase reporter 
vector containing a ~700bp region of the 3’UTR with predicted binding sites in CSF-
1R, did not result in any obvious knockdown of luciferase expression by any of the 
miRNAs tested (Fig. 5.3B). The miR-22 and miR-34a mimics in combination gave 
slightly greater luciferase knockdown than their separate counterparts, though the 
level achieved was <20%.  
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Figure 5.3. Target analysis for microRNAs predicted to target CSF-1R. (A) The 
most commonly predicted miRNAs to target CSF-1R were tested in in vitro reporter 
asays. (B) The percentage luciferase knockdown was assayed for the predicted 
CSF1R targeting miRNAs, miR-22, miR-34a, miR-155 (n = 9) and miR-449a, miR-
449b and miR-22/miR-34a mix (n = 3). MicroRNA mimics were transfected at 10 
pmol into HEK293 cells and incubated for 48hrs, C = scrambled RNA negative 
control.  
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5.2.3 Comparison of deep sequencing and microarrays for microRNA detection 
After generating miRNA deep sequencing libraries from human mesenchymal (MSC), 
embryonic (ESC) and neuronal (NSC) stem cells (refer to Chapters 3 and 4), total 
RNA from all 3 cell types were also submitted to Peter Ellis, Sanger Institute, for 
analysis on their Illumina miRNA microarray platform as part of a collaborative study 
to aid their development of miRNA microarray assays. The resulting miRNAs 
detected by the microarrays were then compared to those identified by deep 
sequencing, and their expression levels, as indicated by the average signal intensity 
(arbitrary units) and sequencing frequencies respectively, were plotted on scatter 
graphs (Fig. 5.4). The microarray spotted for 470 human miRNAs, and only these 
miRNAs were analysed against the deep sequencing databases (Supplementary Table 
S9). Four technical repeats were performed (Arrays 1-4) for each sample (work done 
by Peter Ellis). For the ESC and NSC scatter plots, the line of dots towards the bottom 
of each graph represents sequencing numbers <5 by Solexa deep sequencing.  
 
For all 3 cell types, each of the microarrays displayed a mild positive correlation with 
their respective deep sequencing library for detecting miRNA expression (Fig. 5.4). 
None of the miRNAs detected by deep sequencing were missed by the microarray, 
though conversely many of the miRNAs detected by microarray were either not 
sequenced in the MSC library, or sequenced n < 5 in the ESC and NSC libraries. 
MicroRNAs from this category are shown below tick 1 on the y-axis, and in all cases 
they span the entire range of signal intensities detected by the microarrays.  
 
The expression of miRNAs from the let-7 family, miR-302 family, miR-9, miR-9*, 
miR-23b and miR-27b were compared across the cell types, MSC, ESC and NSCs by  
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Figure 5.4. Comparison of deep sequencing and microarrays for microRNA 
detection. RNA from human mesenchymal, embryonic and neuronal stem cells were 
submitted for microRNA microarray analysis (x-axis), and compared to the 
microRNA deep sequencing numbers (y-axis). Four technical repeats were generated 
on separate arrays (Array 1-4), performed by Peter Ellis, Sanger.  
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deep sequencing (Fig. 5.5A) and by microarray analysis (Fig. 5.5B). The average of 
the 4 technical repeats of the microarrays was used, and the standard errors are shown 
(Fig. 5.5A). Cell type specific expression of the let-7 family in MSC and NSC, as well 
as specific expression of the miR-302 family in ESC, is visible from both the deep 
sequencing and the microarray results. However, the disproportionate levels of 
expression between members of the let-7 family as well as members of the miR-302 
family are more pronounced from the deep sequencing libraries than from the 
microarray data, indicating that there may be a degree of cross-hybridising of highly 
homologous miRNAs during microarray analysis.  
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Figure 5.5. Detection of cell specific microRNAs by deep sequencing and 
microarray. (A) Deep sequencing shows that the let-7 family of miRNAs are up-
regulated in human mesenchymal (MSC, yellow) and neuronal (NSC, blue) stem 
cells, while the miR-302 family is up-regulated in embryonic (ESC, red) stem cells, 
and miR-9/miR-9* is specific to NSCs. (B) Microarray analysis of these same 
miRNAs indicate similar specificity in miRNA expression, but proportionate 
expression between members of the same family is less pronounced.  
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5.3 DISCUSSION 
5.3.1 Target prediction and experimental validation 
Programs that have been developed specifically for the prediction of miRNA:mRNA 
target interactions have become commonplace tools in miRNA functional studies, 
used to provide bioinformatics support for recognised miRNA-target relationships, as 
well as for the initial identification and subsequent experimental validation of possible 
targets (reviewed in Dalmay, 2008). In cases where there is a specific gene of interest, 
there is a degree of reliance on these programs to identify the best candidate targeting 
miRNAs for subsequent testing. In this study, having generated reporter constructs 
with the 3’UTRs of both KIT and CSF-1R downstream of luciferase, preliminary 
analysis of the miRNAs predicted to target these mRNAs was carried out. Four target 
prediction programs were chosen for this analysis; TargetScan (Lewis et al., 2005), 
PicTar (Krek et al., 2005), miRBase targets (Enright et al., 2003), and microRNA.org 
(Betel et al., 2008), where the former 3 utilise individually developed algorithms, and 
the last uses the same core algorithm as miRBase targets, known as miRanda (Enright 
et al., 2003).  
 
In order to identify candidate miRNAs for down-regulating KIT, the number of 
miRNAs as well as the overlap of miRNAs predicted by each program was compared 
(Fig. 5.2A). The actual number of miRNAs predicted by each program varied 
considerably, and surprisingly two programs that utilise the same miRanda core 
predictive algorithm, miRBase targets and microRNA.org, predicted 2 and 101 targets 
respectively. The key difference between these two programs is the extension of the 
miRanda algorithm, by the authors of microRNA.org, to include a weighted alignment 
that takes into account mismatches, G:U pairing and gaps, that reflect the relative 
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importance of both the 5’ seed and the 3’ complementary binding regions (Betel et al., 
2008), while miRBase targets maintains the use of the original miRanda with its 
stricter complementarity and conservation requirements. The stringency of the 
miRanda algorithm in the miRBase targets program versus the more relaxed 
adaptation in the microRNA.org program is reflected in the number of predictions 
generated (2 and 101 respectively), and highlights how predictions can alter 
drastically with any changes applied to a given algorithm. Interestingly, while the 
TargetScan and PicTar programs were developed separately, they exhibit the best 
degree of overlap in predictions observed for KIT, which has been previously noted 
for other targets (Rajewsky, 2006). While the convergence of algorithms does not 
guarantee the accuracy of their predictions, it is nonetheless an indication that variable 
assessments and ranking for certain criteria have been considered, and thus 
theoretically highlights stronger candidates. This is seen in the pilot screen of 
predicted KIT targeting miRNAs tested to knockdown luciferase expression (Fig. 
5.2B). While it is noted that the lack of experimental repeats for the majority of the 
miRNAs tested means that only preliminary conclusions can be drawn, it would 
appear that the best miRNAs tested to knockdown KIT includes miR-193a and miR-
193b for which 3 out of the 4 target prediction programs identified. Interestingly, 
miR-193a/miR-193b appeared to perform better than miR-221 and miR-222 which 
were experimentally validated to target KIT (Felli et al., 2005). In vivo knockdown of 
KIT in mo7e cells transfected with miR-193a, miR-193b and a negative control 
miRNA mimic was assayed by western blotting, but difficulties encountered with 
transfection efficiency in this cell line meant that the results were inconclusive (data 
not shown).  
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These results highlight the limitations of predictive programs. Although miRNA 
target predictions generated by these programs may demonstrate good inhibition in 
reporter assays, this may have no bearing on endogenous activity. Difficulties in 
experimentally validating predicted targets is exacerbated by the fact that it has also 
becoming increasingly clear that not all miRNA:mRNA interactions conform to a 
fixed set of rules, such as the emergence of 5’UTR and exonic targets (Lee et al., 
2009, Lytle et al., 2007, Orom et al., 2008, Tay et al., 2008) and miRNAs acting as 
up-regulators (Vasudevan et al., 2007). Balancing flexibility with accuracy in target 
predictions is a challenge that should be considered when using these programs.  
 
5.3.2 Use of microarrays to detect microRNA expression 
As with the use of target prediction programs for miRNA functional studies, the 
development and use of microarrays to both identify miRNAs expressed in certain 
cell types as well as characterise changes in miRNA expression profiles between cell 
types, is frequently reported (Volinia et al., 2006, Goff et al., 2008, Iliopoulos et al., 
2009, Ji et al., 2009). Having generated 3 miRNA deep sequencing libraries from 
undifferentiated human mesenchymal stem cells (MSCs) and also embryonic stem 
cells (ESCs) pre- and post-differentiation to neuronal stem cells (NSCs), RNA from 
these 3 cell types were also provided to aid the development of miRNA microarrays 
through a collaboration with the Sanger Institute, Cambridge.  
 
The results from the microarray analysis indicated that there was a degree of positive 
correlation for those miRNAs that were mutually detected by both the microarray and 
deep sequencing (Fig. 5.4). However, the scatter plots also indicate that there is a 
greater tendency for overall higher signal intensities, for every microarray performed, 
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for many of the miRNAs that were detected at only low frequencies by deep 
sequencing, resulting in the skew of dots to the bottom right hand side of the graphs. 
Additionally, many miRNAs not detected by deep sequencing were detected by the 
microarrays at the full range of signal intensities (Fig. 5.4, line of dots below 1 on the 
y-axis), indicating the presence of many potential false positives. Some of these 
miRNA ‘false positives’ were detected at extremely high levels by microarray, but not 
at significant levels in any of the 3 cell types by deep sequencing (Supplementary 
Table S9), suggesting that cross-contamination of samples is unlikely to be the cause. 
The detection of additional miRNAs as well as the overall greater signal strength for 
existing miRNAs otherwise not detected or detected at low levels by deep sequencing 
is possibly indicative of non-specific hybridisation. However, it is also possible that 
deep sequencing technology may also enable false negatives. Further experimental 
validation to determine how many of these miRNAs are genuinely expressed or not, 
possibly by RT-PCR or northern blotting, will be required before any conclusions can 
be made. 
 
The direct comparison of specific miRNAs between the 3 cell types from the 
microarray data (Fig. 5.5) echoes the propensity for overall higher expression of 
miRNAs detected by this method compared to deep sequencing. The microarray 
analysis also records specific expression of the miR-302 family of miRNAs by ESCs, 
and specific expression of miR-9/miR-9* by NSCs as well as the up-regulation of the 
let-7 family in NSCs and MSCs. However, the proportionate expression of individual 
miRNAs within these subsets is less pronounced than observed for deep sequencing. 
No more than a 3-fold variation in expression of different members of the let-7 family 
for NSCs was detected by microarray (Fig. 5.5A), while there is >20-fold variation 
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for several of the let-7 miRNAs in NSCs detected by deep sequencing (Fig. 5.5B). 
The same can also be seen with regards to the miR-302 family in ESCs. Given the 
high homology between miRNAs within these families, it is likely that the reduced 
definition of expression between these miRNAs is a result of cross-hybridisation of 
miRNA family members within the microarray. While it cannot be discounted that the 
quantification of miRNAs by deep sequencing may also contain errors, homology 
between miRNAs is unlikely to be a problem. Furthermore, comparisons of the 
expression of some of the miRNAs analysed here (miR-302a*, let-7a and miR-9*) 
between ESC and NSC by northern blotting agrees with the deep sequencing libraries 
over the microarray results (Chapter 4, figure 4.2).  
 
The results of this study have highlighted the potential areas in the detection of 
miRNA expression that require further optimisation in the Sanger microarrays. While 
the microarrays used here may currently lack the ability to discern subtle variations of 
individual miRNA sequences, they were nonetheless able to generate miRNA profiles 
that for the most part matched existing data for these cell types. Furthermore, 
technical reproducibility is relatively high between each array performed (Fig. 5.4), 
suggesting that this microarray may be reliable for comparative studies to highlight 
dramatically up- or down-regulated miRNAs between samples. In summary, 
microarrays remain a useful tool for providing initial overall insights into miRNA 
expression, but should be subject to secondary experimental validation, such as 
northern blotting.  
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CHAPTER 6 – GENERAL DISCUSSION 
 
 
Small regulatory RNAs contribute to the maintenance and organisation of almost 
every aspect of normal development, and in particular miRNAs are involved in the 
vast majority of these processes. The sheer numbers of miRNAs that can be found in 
the human genome has led to their classification as one of the largest gene families,  
functioning to regulate almost a third of all known genes (Krek et al., 2005, Lewis et 
al., 2005, Bartel, 2004). Over the past decade, the numbers of novel miRNAs being 
discovered has continued to increase (Fig. 6.1), and this is in part due to advances in 
miRNA isolation techniques and the explosion of miRNA profiling studies in a host 
of cell types and species (Landgraf et al., 2007, Molnar et al., 2007, Morin et al., 
2008, Rathjen et al., 2009, Szittya et al., 2008).  
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Figure 6.1. MicroRNA entrees in miRBase. Since its establishment in 2002, the 
public access microRNA database (miRBase, Sanger Institute) has been updated 26 
times, and the latest version (v13.0) comprises a total of 9539 microRNA hairpin 
precursor entrees across 103 species (Griffiths-Jones et al., 2008).  
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Near the start of this project, the development of deep sequencing technology had 
demonstrated massive potential for the identification of both known and new miRNAs 
in plants (Nakano et al., 2006, Lu et al., 2006). The initial aim was to extend the use 
of these techniques for miRNA profiling in human stem cells, ultimately to enable the 
characterisation of miRNA expression in these cells and also to investigate aspects of 
their biology and function. Additionally, conventional cloning and sequencing had 
already identified numerous miRNAs expressed in human and mouse embryonic stem 
cells, and a subset of these were stem cell specific (Houbaviy et al., 2003, Suh et al., 
2004). Identifying features that regulate the changes in miRNA expression during 
stem cell differentiation was another objective of this project.  
 
6.1 PROFILING MICRORNAS 
Through collaboration with Prof. David Baulcombe’s lab, Cambridge, we generated 
deep sequencing libraries of miRNAs, firstly in human mesenchymal stem cells by 
454 sequencing, and subsequently human embryonic and neuronal stem cells by 
Solexa sequencing. Analysis of the miRNAs isolated from human embryonic stem 
cells showed that their general profile matched existing reports from these cell types, 
and these results were further validated by northern blotting. The mesenchymal and 
neuronal stem cell libraries generated in this project represent the first deep 
sequencing libraries for these cell types. In addition to known miRNAs, potentially 
novel miRNAs and both known and potentially novel piRNAs were also discovered 
(Fig. 3.1 and 4.3).  
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6.1.1 MicroRNAs and their isomers  
An immediately outstanding feature of the MSC miRNA library was the abundance of 
isomer forms for the majority of miRNAs sequenced. These isomers were also 
subsequently detected in the ESC and NSC miRNA libraries, and in 2008 it was 
reported that not only are they regularly expressed, but they are associated with 
endogenous Argonaute proteins (Azuma-Mukai et al., 2008, Morin et al., 2008). 
Parallel studies conducted in this project gave results that concurred with the findings 
of these reports and additionally showed that there is cell type specific expression of 
certain miRNA’s isomers (Fig. 3.2), and this was also reflected in differentiating 
MSCs (Fig. 3.3). Furthermore, there is evidence to suggest that isomers may also be 
preferentially incorporated into specific Argonaute proteins, and that this preference is 
not always a reflection of the abundance of the isomers (Fig. 3.7). The significance of 
these results remains to be determined, but they imply that isomer expression might 
be a factor for consideration in miRNA targeting studies. The proof of this would be 
in the discovery of an endogenous miRNA target that can be demonstrated to be 
variably targeted by different isomers of the miRNA. It would also be interesting to 
further assess the potential specificity of isomer incorporation within individual 
Argonaute proteins; for example, if Ago2 does preferentially incorporate the 20mer 
isoform of miR-23a (Fig. 3.7), then presumably due to the specific endonucleolytic 
potential of Ago2 it follows that the 20mer isoform might be preferentially used for 
target cleavage, thus conferring a potentially specific role for the 20mer isoform. 
Profiling miRNA isomers associated with endogenous Argonaute proteins, rather than 
all isomers that are present, may provide a clearer picture of functionally important 
miRNA isomers. The techniques that were set up in this project ensure that these 
additional studies can be performed.  
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6.1.2 Cell type specific expression of microRNAs  
From the deep sequencing libraries of human embryonic stem cells pre- and post-
neuronal differentiation, it was clear that there are a number of miRNAs that are 
dramatically switched on or off (e.g. miR-9/miR-9* and miR-302 family respectively) 
presumably in association with the changes that also drive neuronal differentiation. 
Embryonic stem cell specific expression of the miR-302 family is due to regulation by 
equally specifically expressed pluripotency factors (Barroso-delJesus et al., 2008), 
and while it was not possible to fully elucidate the mechanism responsible for 
regulating miR-9/miR-9*, there was evidence of neuronal specificity in the 
transcription of their primary transcripts (Fig. 4.6).  
 
Only a handful of mammalian miRNA promoters have been experimentally validated 
to date (Barroso-delJesus et al., 2008, Houbaviy et al., 2005, Lee et al., 2004), and the 
difficulties experienced in determining the precise core promoter regions of miR-
9/miR-9* in this study is perhaps reflective of the issues that hinders advancement in 
this area. Had a potential promoter region been identified, further experiments to 
identify and validate the factors that actually associate with the promoter to confer 
neuronal specificity would also have been required. Hence, an alternative approach to 
this problem may be to first identify candidate neuronal specific transcription factors, 
as well as known regulators of miR-9/miR-9* such as REST (Conaco et al., 2006, 
Packer et al., 2008), and specifically test regions that encompasses their binding sites 
for promoter activity.   
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6.2 PROFILING MESSENGER RNAS  
In parallel to the miRNA libraries generated by deep sequencing, total mRNA profiles 
for each of the stem cell types used in this project were also generated by microarray 
analysis, and validated by RT-PCR (Fig. 4.5). Additionally, potentially important 
mRNA targets of miRNAs were identified by immunoprecipitation of endogenous 
Argonaute2 protein in human mesenchymal stem cells and microarray profiling of 
assoicated mRNAs (Fig. 3.8 and 3.9). Though none of the identified putative target 
mRNAs were analysed further in this project, there is potential for developing this 
technique as a means to profile the widespread changes that may occur to miRNA 
targeting with any manipulations to the cell system (Weinmann et al., 2009). It would 
be interesting to use this endogenous target profiling method to compare the 
differences in the isolated Argonaute associated mRNAs between ESCs and NSCs in 
order to highlight the changes in the genes regulated by miRNAs during 
differentiation that are thus likely to have potentially important affects on neuronal 
differentiation. 
 
Similar studies could be conducted for normal and disease model cell types, with the 
aim of identifying additional or missing mRNA targets of microRNAs in diseased 
cells. The identification of mRNA targets in model disease cell types will allow the 
use of traditional therapeutic approaches against the proteins encoded by such target 
mRNAs. This is probably a better approach than targeting specific miRNAs 
themselves, which currently do not demonstrate good efficacy as therapeutic agents 
(Izquierdo, 2005, Krutzfeldt et al., 2005). Co-profiling of miRNAs and mRNAs may 
also be more advantageous than either profile alone for diagnostic purposes. 
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6.3 REGULATORY ASPECTS OF MICRORNAS  
The creation of both miRNA and mRNA profiles representing 3 human stem cell 
types has proven useful in providing insights into aspects of miRNA regulation, 
particularly in the case of intragenic miRNAs. Many intragenic miRNAs, previously 
believed to be regulated by their host, are now more commonly believed to be 
regulated by their own promoters (Corcoran et al., 2009, Ozsolak et al., 2008), and the 
findings of this project also agrees with this assessment (Fig. 4.9).  
 
The importance of post-transcriptional regulation of miRNAs is also reiterated from 
the analysis of the differential expression of individual miRNAs within a cluster. 
Though it is unclear at which stage this regulation may act upon, there is evidence in 
previous reports as well as hints from the observations in this project (Fig. 4.10B), 
that post-transcriptional regulatory factors are involved and that these are likely to be 
influenced by cell state (Guil and Caceres, 2007, Michlewski et al., 2008, Newman et 
al., 2008, Viswanathan et al., 2008). To further assess, in the case of the miR-
23b~27b~24-1 cluster, at which stage the preference for miR-23b in MSCs and miR-
27b in NSCs is conferred (e.g. Drosha processing, nuclear export, or Dicer 
processing) it would be useful to verify and compare the expression of both the pri-
miRNA transcript and the pre-miRNA hairpin in these two cell types.  
 
Another surprising observation made in this project was the discovery that one of the 
miRNAs derived from a common hairpin precursor, such as miR-151-5p, may be 
preferentially expressed in one cell type, while the other miRNA, miR-151-3p is 
preferentially expressed in a different cell type (Fig. 4.10B). This finding was 
unexpected as presumably the thermodynamic stability and sequence of this miRNA 
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duplex does not alter, and thus additional external factors determined by the cell must 
be influencing strand selection. The fact that many miRNAs derive from both strands 
of the same hairpin precursor is an observation that has risen with the increase in deep 
sequencing data and new miRNAs being discovered, and was also observed readily in 
this project in the 3 stem cell libraries. Thus, in retrospect, it is perhaps not surprising 
that not always the same strand will be preferentially active, as this would imply that 
the remaining strand could never be generated in higher quantities. That additional 
factors may be involved does not negate the currently known rules governing miRNA 
strand selection (Khvorova et al., 2003, Schwarz et al., 2003). Indeed models to 
predict guide and active strand selection based on aspects of sequence and secondary 
structure alone have demonstrated efficiency (Ahmed et al., 2009). However, if strand 
preference is influenced by external factors, this may also have implications on the 
models of biogenesis of miRNAs, as there is evidence that pre-miRNA processing 
and Argonaute2 RISC-mediated silencing is functionally coupled (Gregory et al., 
2005). Hence, characterising the mechanisms involved in altering strand selection has 
the potential to produce far reaching effects for the field of miRNA research.  
 
6.4 CONCLUSIONS  
Comprehensive libraries of miRNA expression in 3 human stem cell types have been 
generated in this project, along with their corresponding mRNA profiles as well as an 
endogenous Argonaute2 associated mRNA profile. All of these profiles have been 
experimentally validated and a number of novel insights were also gained from their 
analysis. Among these was the discovery that miRNA isomers are both differentially 
expressed and differentially associated with Argonaute proteins. There is also strong 
evidence that multiple layers of regulation are involved in determining the global 
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expression of miRNAs in these cells, including a previously uncharacterised layer at 
the miRNA strand selectivity stage. Together, all of the data generated in this project 
provides a strong platform for future studies into miRNA biology, regulation and 
function in human stem cells.  
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SUPPLEMENTARY DATA 
 
   
miR-222           3’ AAA-RNA  
adapter
Sequence Library      Specific primning
AGCTACATCTGGCTACTG 1 -
AGCTACATCTGGCTACTGG  1 -
AGCTACATCTGGCTACTGGGT 5 3
AGCTACATCTGGCTACTGGGTC            5 8
AGCTACATCTGGCTACTGGGTCT          12 3
AGCTACATCTGGCTACTGGGTCTC         21 3
AGCTACATCTGGCTACTGGGTCTCC         - 1 
AGCTACATCTGGCTACTGGGTCTCT         4 1
A
B
GCU           UAGGUA  C   AU              -     AUC   UCUU  
   GCUGGAAGGUG      CC UCA  GGCUCAGUAGCCAG UGUAG   CUG    U 
   |||||||||||      || |||  |||||||||||||| |||||   |||    C 
   CGAUCUUCUAC      GG AGU  CUGGGUCAUCGGUC ACAUC   GAC    G 
--U           ------  U   CU              U     GAC   UAAU  
 
C
hMSC HeLa hBM K562   mo7e     HepG2  M-453   HEK
miR-222
5.8S rRNA
 
 
 
Supplementary Figure S1. Detection of miR-222 isomers by specific-
priming. (A) Northern blot of miR-222 in human cell lines. (B) Sequencing of miR-
222 using 3’ AAA-adapters by specific priming. Arrows indicate the site of adapter 
ligation. (C) miRBase annotation of the miR-222 hairpin, sequenced hMSC library 
and specific priming numbers for each isomer are listed. Red denotes the mature 
form.  
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Sequence Library     Specific primning
ATCACATTGCCAGGGATTT 7 -
ATCACATTGCCAGGGATTTC 101 -
ATCACATTGCCAGGGATTTCC 632 -
ATCACATTGCCAGGGATTTCCA 782 9
ATCACATTGCCAGGGATTTCCAA          307 8
ATCACATTGCCAGGGATTTCCAAT - 2 
ATCACATTGCCAGGGATTTCCAAC         136                1
ATCACATTGCCAGGGATTTCCAATA         - 1 
ATCACATTGCCAGGGATTTCCAATT         - 1
A
C
  C   C     -       G    G      CUUC  
GG CGG UGGGG UUCCUGG GAUG GAUUUG    C 
|| ||| ||||| ||||||| |||| ||||||      
CC GCC ACCUU AGGGACC UUAC CUAAAC    U 
  A   A     U       G    A      ACUG  
 
miR-23a            3’ UUU-RNA  
adapter
hMSC mo7e    Hep     HEK    K562    HeLa
B
miR-23a
5.8S rRNA
 
 
Supplementary Figure S2. Detection of miR-23a isomers by specific-priming. 
(A) Northern blot of miR-23a in human cell lines. (B) Sequencing of miR-23a using 
3’ UUU-adapters by specific priming. Arrows indicate the site of adapter ligation. (C) 
miRBase annotation of the miR-223a hairpin, sequenced hMSC library and specific 
priming numbers for each isomer are listed. Red denotes the mature form.  
 192 
Supplementary Table S1. Human mesenchymal stem cell miRNAs and 
isomers. A list of all microRNAs cloned from human mesenchymal stem cells by 454 
deep sequencing. The sequencing numbers and all matches to human miRNA hairpins 
are given (miRBase v13.0). Sequences in bold represent the miRBase annotated 
isomer form. Novel miRNAs and potential ADAR edited miRNAs are listed also.  
 
 
  sequence seq. no. microRNA hairpin 
let-7a ATGAGGTAGTAGGTTGTATAGTT 2 hsa-let-7a-1 
 
 TGAGGTAGTAGGTTGTATAGTTTT 3 hsa-let-7a-1 
 TTGAGGTAGTAGGTTGTATAGT 1 hsa-let-7a-2 
 TTGAGGTAGTAGGTTGTATAGTT 1 hsa-let-7a-2 
 GTGAGGTAGTAGGTTGTATAGT 4 hsa-let-7a-3 
 
 TGAGGTAGTAGGTTGTATAGTTT 37 
hsa-let-7a-1, hsa-let-7a-2, hsa-
let-7a-3 
 
 TGAGGTAGTAGGTTGTATAG 55 
hsa-let-7a-1, hsa-let-7a-2, hsa-
let-7a-3 
 
 TGAGGTAGTAGGTTGTATA 15 
hsa-let-7a-1, hsa-let-7a-2, hsa-
let-7a-3 
 
 TGAGGTAGTAGGTTGTATAGT 712 
hsa-let-7a-1, hsa-let-7a-2, hsa-
let-7a-3 
   TGAGGTAGTAGGTTGTATAGTT 1222 
hsa-let-7a-1, hsa-let-7a-2, hsa-
let-7a-3 
let-7b TGAGGTAGTAGGTTGTGTGGTTT 41 hsa-let-7b 
 TGAGGTAGTAGGTTGTGTG 3 hsa-let-7b 
 TGAGGTAGTAGGTTGTGTGGT 58 hsa-let-7b 
 TGAGGTAGTAGGTTGTGTGG 15 hsa-let-7b 
 
 GAGGTAGTAGGTTGTGTGGTT 1 hsa-let-7b 
 TGAGGTAGTAGGTTGTGTGGTT 90 hsa-let-7b 
  TGAGGTAGTAGGTTGTGT 3 hsa-let-7b 
let-7c TGAGGTAGTAGGTTGTATGGT 1 hsa-let-7c 
  TGAGGTAGTAGGTTGTATGGTT 12 hsa-let-7c 
let-7d  AGAGGTAGTAGGTTGCATAGTT 1072 hsa-let-7d 
 AAGAGGTAGTAGGTTGCATAGTT 3 hsa-let-7d 
 
 AGAGGTAGTAGGTTGCATAG 30 hsa-let-7d 
 
 AGAGGTAGTAGG 3 hsa-let-7d 
 
 AGAGGTAGTAGGTTGCATAGT 99 hsa-let-7d 
 AAGAGGTAGTAGGTTGCATAG 1 hsa-let-7d 
 
 AGAGGTAGTAGGTTGCATA 1 hsa-let-7d 
 
  GAGGTAGTAGGTTGCATAGT 5 hsa-let-7d 
 
  GAGGTAGTAGGTTGCATAGTT 34 hsa-let-7d 
 
 AGAGGTAGTAGGTTGCATAGTTT 72 hsa-let-7d 
 
  GAGGTAGTAGGTTGCATAGTTT 1 hsa-let-7d 
  
 AGAGGTAGTAGGTTGCATAGTTTT 2 hsa-let-7d 
let-7d* TATACGACCTGCTGCCTTTCT 1 hsa-let-7d 
let-7e TGAGGTAGGAGGTTGTATAGT 58 hsa-let-7e 
 TGAGGTAGGAGG 3 hsa-let-7e 
 TGAGGTAGGAG 1 hsa-let-7e 
 TGAGGTAGGAGGTTGT 2 hsa-let-7e 
 TGAGGTAGGAGGT 2 hsa-let-7e 
 TGAGGTAGGAGGTTGTATAGTT 72 hsa-let-7e 
 TGAGGTAGGAGGTTGTATAG 10 hsa-let-7e 
  TGAGGTAGGAGGTTGTATAGTTG 3 hsa-let-7e 
let-7f 
 TGAGGTAGTAGATTGTATAGTTT 2 hsa-let-7f-2 
 ATGAGGTAGTAGATTGTATAGT 4 hsa-let-7f-2 
 ATGAGGTAGTAGATTGTATAGTT 2 hsa-let-7f-2 
 
 TGAGGTAGTAGA 19 hsa-let-7f-1, hsa-let-7f-2 
 
 TGAGGTAGTAGAT 1 hsa-let-7f-1, hsa-let-7f-2 
 
 TGAGGTAGTAGATT 1 hsa-let-7f-1, hsa-let-7f-2 
 
 TGAGGTAGTAGATTGTATAGT 101 hsa-let-7f-1, hsa-let-7f-2 
 
 TGAGGTAGTAGATTGTATAG 14 hsa-let-7f-1, hsa-let-7f-2 
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 TGAGGTAGTAGATTGTATA 10 hsa-let-7f-1, hsa-let-7f-2 
  TGAGGTAGTAGATTGTATAGTT 131 hsa-let-7f-1, hsa-let-7f-2 
  
 TGAGGTAGTAGATTGTAT 2 hsa-let-7f-1, hsa-let-7f-2 
let-7g TGAGGTAGTAGTTTGTAC 4 hsa-let-7g 
 TGAGGTAGTAGTTTGTACAGTTT 3 hsa-let-7g 
 TGAGGTAGTAGTTTGTACAGT 65 hsa-let-7g 
 TGAGGTAGTAGTTTGTACAG 8 hsa-let-7g 
  TGAGGTAGTAGTTTGTACAGTT 91 hsa-let-7g 
let-7i TGAGGTAGTAGTTTGTGCTGTT 26 hsa-let-7i 
 TGAGGTAGTAGTTTGTGCT 2 hsa-let-7i 
 TGAGGTAGTAGTTTGTGCTGT 7 hsa-let-7i 
  TGAGGTAGTAGTTTGTGC 5 hsa-let-7i 
let-7i* CTGCGCAAGCTACTGCCTTGCT 1 hsa-let-7i 
miR-100 AAACCCGTAGATCCGAACTTGTG 1 hsa-mir-100 
 AAACCCGTAGATCCGAACT 1 hsa-mir-100 
 
  ACCCGTAGATCCGAACTTGTG 2 hsa-mir-100 
 
 AACCCGTAGATCCGAACTT 3 hsa-mir-100 
 
 AACCCGTAGATCCGAACTTG 2 hsa-mir-100 
 
 AACCCGTAGATCCGAACT 1 hsa-mir-100 
  AACCCGTAGATCCGAACTTGTG 36 hsa-mir-100 
  
 AACCCGTAGATCCGAACTTGT 15 hsa-mir-100 
miR-101 GTACAGTACTGTGATAACTGAA 1 hsa-mir-101-1, hsa-mir-101-2 
  TACAGTACTGTGATAACTGAA 2 hsa-mir-101-1, hsa-mir-101-2 
  
 TACAGTACTGTGATAACTGA 1 hsa-mir-101-1, hsa-mir-101-2 
miR-103 
 GCAGCATTGTACAGGGCTATGA 1 hsa-mir-103-1, hsa-mir-103-2 
 AGCAGCATTGTACAGGGCTATGA 24 hsa-mir-103-1, hsa-mir-103-2 
 AGCAGCATTGTACAGGGCTATG 3 hsa-mir-103-1, hsa-mir-103-2 
  AGCAGCATTGTACAGGGCTATGAA 3 hsa-mir-103-1, hsa-mir-103-2 
miR-106b TAAAGTGCTGACAGTGCAGA 4 hsa-mir-106b 
 TAAAGTGCTGACAGTGCAG 1 hsa-mir-106b 
 TAAAGTGCTGACAGTGCAGAT 8 hsa-mir-106b 
 TAAAGTGCTGACAGTGCAGATAGT 1 hsa-mir-106b 
  TAAAGTGCTGACAGTGCAGATA 4 hsa-mir-106b 
miR-107 AGCAGCATTGTACAGGGC 2 hsa-mir-107 
 AGCAGCATTGTACAGGGCTAT 1 hsa-mir-107 
 AGCAGCATTGTACAGGGCT 3 hsa-mir-107 
  AGCAGCATTGTACAGGGCTA 1 hsa-mir-107 
miR-10a 
 ACCCTGTAGATCCGAATTTG 1 hsa-mir-10a 
 
 ACCCTGTAGATCCGAATT 1 hsa-mir-10a 
 
 ACCCTGTAGATCCGAATTTGT 4 hsa-mir-10a 
 TACCCTGTAGATCCGAAT 3 hsa-mir-10a 
 TACCCTGTAGATCCGAATT 1 hsa-mir-10a 
 TACCCTGTAGATCCGAATTTGT 13 hsa-mir-10a 
 TACCCTGTAGATCCGAATTTGTG 3 hsa-mir-10a 
 
  CCCTGTAGATCCGAATTTGTG 1 hsa-mir-10a 
  
 ACCCTGTAGATCCGAATTTGTG 8 hsa-mir-10a 
miR-10a* CAAATTCGTATCTAGGGGAAT 2 hsa-mir-10a 
miR-125a-5p TCCCTGAGACCCTTTAACCTGTGA 3 hsa-mir-125a 
miR-125a-3p ACAGGTGAGGTTCTTGGGAGCC 1 hsa-mir-125a 
  ACAGGTGAGGTTCTTGGGAGC 2 hsa-mir-125a 
miR-125b-1* ACGGGTTAGGCTCTTGGGAGC 3 hsa-mir-125b-1 
 ACGGGTTAGGCTCTTGGGAGCT 7 hsa-mir-125b-1 
  ACGGGTTAGGCTCTTGGGAG 2 hsa-mir-125b-1 
miR-125b TCCCTGAGACCCTAACTTGTGAT 2 hsa-mir-125b-1 
 
 CCCTGAGACCCTAACTTGTGAT 1 hsa-mir-125b-1 
 TCCCTGAGACCCTAAC 2 hsa-mir-125b-1, hsa-mir-125b-2 
 TCCCTGAGACCCTAACTTG 1 hsa-mir-125b-1, hsa-mir-125b-2 
 TCCCTGAGACCCTAACTTGTGA 78 hsa-mir-125b-1, hsa-mir-125b-2 
 TCCCTGAGACCCTAACTTGTG 7 hsa-mir-125b-1, hsa-mir-125b-2 
  TCCCTGAGACCCTAACTTGT 6 hsa-mir-125b-1, hsa-mir-125b-2 
miR-127-3p TCGGATCCGTCTGAGCTTGGCT 6 hsa-mir-127 
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 CGGATCCGTCTGAGCTTGGCT 1 hsa-mir-127 
  TCGGATCCGTCTGAGCTTGGC 3 hsa-mir-127 
miR-130a CAGTGCAATGTTAAAAGGGC 9 hsa-mir-130a 
 CAGTGCAATGTTAAAAG 1 hsa-mir-130a 
 CAGTGCAATGTTAAAAGGG 1 hsa-mir-130a 
 CAGTGCAATGTTAAAAGGGCAT 116 hsa-mir-130a 
 CAGTGCAATGTTAAAAGGGCA 13 hsa-mir-130a 
 CAGTGCAATGTTAAAA 1 hsa-mir-130a 
  CAGTGCAATGTTAAAAGGGCATT 10 hsa-mir-130a 
miR-130b CAGTGCAATGATGAAAGGGC 7 hsa-mir-130b 
 CAGTGCAATGATGAAAGGGCA 5 hsa-mir-130b 
 CAGTGCAATGATGAAAGGG 1 hsa-mir-130b 
 
 AGTGCAATGATGAAAGGGCAT 1 hsa-mir-130b 
  CAGTGCAATGATGAAAGGGCAT 79 hsa-mir-130b 
miR-132 GTAACAGTCTACAGCCATGGTC 1 hsa-mir-132 
 
 TAACAGTCTACAGCCATGGT 1 hsa-mir-132 
   TAACAGTCTACAGCCATGGTCG 14 hsa-mir-132 
miR-134 TGTGACTGGTTGACCAGAGGG 1 hsa-mir-134 
  TGTGACTGGTTGACCAGAGGGG 2 hsa-mir-134 
miR-138 AGCTGGTGTTGTGAATCAGGCCG 1 hsa-mir-138-1, hsa-mir-138-2 
  AGCTGGTGTTGTGAATCAGGCCGTT 1 hsa-mir-138-1 
miR-140-3p TACCACAGGGTAGAACCACGGA 3 hsa-mir-140 
 TACCACAGGGTAGAACCACGGAC 2 hsa-mir-140 
 
 ACCACAGGGTAGAACCACGGAC 2 hsa-mir-140 
 
 ACCACAGGGTAGAACCACGGA 1 hsa-mir-140 
  TACCACAGGGTAGAACCACGGACA 1 hsa-mir-140 
miR-140-5p CAGTGGTTTTACCCTATGGTAG 3 hsa-mir-140 
miR-143 TGAGATGAAGCACTGTAGCTC 68 hsa-mir-143 
 TGAGATGAAGCACTGTAGCT 14 hsa-mir-143 
 TGAGATGAAGCACTGTAGC 12 hsa-mir-143 
  TGAGATGAAGC 2 hsa-mir-143 
miR-145 GTCCAGTTTTCCCAGGAAT 20 hsa-mir-145 
 GTCCAGTTTTCCCAGGAATC 4 hsa-mir-145 
 GTCCAGTTTTCCCAGGAATCCC 28 hsa-mir-145 
 GTCCAGTTTTCCCAGG 1 hsa-mir-145 
 GTCCAGTTTTCCCAGGAATCCCT 24 hsa-mir-145 
 GTCCAGTTTTCCC 3 hsa-mir-145 
 GTCCAGTTTTCCCAGGAA 13 hsa-mir-145 
 GTCCAGTTTTCCCAGGAATCCCTT 12 hsa-mir-145 
 GTCCAGTTTTCCCAGGA 2 hsa-mir-145 
 GTCCAGTTTTCCCAGGAATCC 5 hsa-mir-145 
  GTCCAGTTTTCCCAGGAATCCCTTA 1 hsa-mir-145 
miR-146a TGAGAACTGAATTCCATGGGTTG 1 hsa-mir-146a 
  TGAGAACTGAATTCCATGGGTT 7 hsa-mir-146a 
miR-151-3p TACTAGACTGAAGCTCCTTGAG 1 hsa-mir-151 
 
  CTAGACTGAAGCTCCTTGAGGA 18 hsa-mir-151 
    CTAGACTGAAGCTCCTTGAGG 6 hsa-mir-151 
miR-151-5p CTCGAGGAGCTCACAGTCTAG 1 hsa-mir-151 
 
 TCGAGGAGCTCACAGT 2 hsa-mir-151 
  TCGAGGAGCTCACAGTCTAGT 1304 hsa-mir-151 
 
 TCGAGGAGCTCACAGTCT 3 hsa-mir-151 
 
 TCGAGGAGCTCACAG 2 hsa-mir-151 
 CTCGAGGAGCTCACAGTCTAGT 25 hsa-mir-151 
 
 TCGAGGAGCTCACAGTCTA 3 hsa-mir-151 
 CTCGAGGAGCTCACAGTCT 1 hsa-mir-151 
 
 TCGAGGAGCTCACAGTCTAGTA 1135 hsa-mir-151 
 CTCGAGGAGCTCACAGTCTAGTA 19 hsa-mir-151 
 
 TCGAGGAGCTCACAGTCTAG 91 hsa-mir-151 
 
  CGAGGAGCTCACAGTCTAGTATGT 1 hsa-mir-151 
 
  CGAGGAGCTCACAGTCTAGTATG 1 hsa-mir-151 
 
  CGAGGAGCTCACAGTCTAGTAT 1 hsa-mir-151 
 195 
 
 TCGAGGAGCTCACAGTCTAGTATG 12 hsa-mir-151 
 CTCGAGGAGCTCACAGTCTAGTAT 6 hsa-mir-151 
  
 TCGAGGAGCTCACAGTCTAGTAT 79 hsa-mir-151 
miR-152 TCAGTGCATGAC 1 hsa-mir-152 
 TCAGTGCATGACAGAACTTGGG 8 hsa-mir-152 
 TCAGTGCATGACAGAACTTGG 21 hsa-mir-152 
  
 CAGTGCATGACAGAACTTGGG 1 hsa-mir-152 
miR-154* AATCATACACGGTTGACCTAT 1 hsa-mir-154 
miR-154 TAGGTTATCCGTGTTGCCTTCG 1 hsa-mir-154 
miR-155 TTAATGCTAATCGTGATAGGGGTTT 1 hsa-mir-155 
 TTAATGCTAATCGTGATAGGGGTT 1 hsa-mir-155 
  TTAATGCTAATCGTGATAGGGGT 1 hsa-mir-155 
miR-15a TAGCAGCACATAATGGTTTGTG 24 hsa-mir-15a 
  TAGCAGCACATAATGGTTTGT 4 hsa-mir-15a 
miR-15b TAGCAGCACATCATGGT 1 hsa-mir-15b 
 TAGCAGCACATCATGGTT 2 hsa-mir-15b 
 TAGCAGCACATCATGGTTTACA 101 hsa-mir-15b 
 TAGCAGCACATCATGGTTTAC 31 hsa-mir-15b 
 TAGCAGCACATCATGGTTTA 2 hsa-mir-15b 
  TAGCAGCACATCATGGTTTACAT 4 hsa-mir-15b 
miR-16-2* ACCAATATTACTGTGCTGCTTT 1 hsa-mir-16-2 
  CCAATATTACTGTGCTGCTTTA 2 hsa-mir-16-2 
 ACCAATATTACTGTGCTGCTTTA 4 hsa-mir-16-2 
 
 CCAATATTACTGTGCTGCTTT 1 hsa-mir-16-2 
  ACCAATATTACTGTGCTG 1 hsa-mir-16-2 
miR-16 TAGCAGCACGTAAATATTG 1 hsa-mir-16-1, hsa-mir-16-2 
 TAGCAGCACGTAAATATT 1 hsa-mir-16-1, hsa-mir-16-2 
 TAGCAGCACGTAAA 1 hsa-mir-16-1, hsa-mir-16-2 
 TAGCAGCACGTA 1 hsa-mir-16-1, hsa-mir-16-2 
 TAGCAGCACGT 3 hsa-mir-16-1, hsa-mir-16-2 
 TAGCAGCACGTAAATATTGGC 25 hsa-mir-16-1, hsa-mir-16-2 
 TAGCAGCACGTAAATATTGGCG 47 hsa-mir-16-1, hsa-mir-16-2 
 
 AGCAGCACGTAAATATTGGCGT 1 hsa-mir-16-1, hsa-mir-16-2 
  TAGCAGCACGTAAATATTGGCGT 32 hsa-mir-16-1, hsa-mir-16-2 
miR-17 
 CAAAGTGCTTACAGTGCAGGTAGT 3 hsa-mir-17 
  CAAAGTGCTTACAGTGCAGGTAG 111 hsa-mir-17 
 
 CAAAGTGCTTACAGTGCAGGT 1 hsa-mir-17 
 
 CAAAGTGCTTACAGTGCAGGTA 8 hsa-mir-17 
 TCAAAGTGCTTACAGTGCAGGT 3 hsa-mir-17 
  TCAAAGTGCTTACAGTGCAGGTA 1 hsa-mir-17 
miR-181a AACATTCAACGCTGTCGGTGAGT 1 hsa-mir-181a-1, hsa-mir-181a-2 
 AACATTCAACGCTGTCGGTGAGTTT 1 hsa-mir-181a-1, hsa-mir-181a-2 
  AACATTCAACGCTGTCGGTGAG 1 hsa-mir-181a-1, hsa-mir-181a-2 
miR-181b AACATTCATTGCTGTCGGTGGGTTT 1 hsa-mir-181b-2 
 AACATTCATTGCTGTCGGTGGG 2 hsa-mir-181b-1, hsa-mir-181b-2 
 AACATTCATTGCTGTCGGTGGGTT 6 hsa-mir-181b-1, hsa-mir-181b-2 
  AACATTCATTGCTGTCGGTGGGT 3 hsa-mir-181b-1, hsa-mir-181b-2 
miR-186 CAAAGAATTCTCCTTTTGGGC 3 hsa-mir-186 
  CAAAGAATTCTCCTTTTGGGCTT 1 hsa-mir-186 
miR-186* GCCCAAAGGTGAATTTTTTGGG 1 hsa-mir-186 
miR-18a TAAGGTGCATCTAGTGCAGAT 4 hsa-mir-18a 
  TAAGGTGCATCTAGTGCAGATAG 11 hsa-mir-18a 
miR-191 CAACGGAATCCCAAAAGCAGCT 117 hsa-mir-191 
 CAACGGAATCCCAAAAGCAGC 95 hsa-mir-191 
 CAACGGAATCCCAAAAGCA 1 hsa-mir-191 
 CAACGGAATCCCAAAAGC 3 hsa-mir-191 
 
 AACGGAATCCCAAAAGCAGC 1 hsa-mir-191 
 CAACGGAATCCCAAAAGCAGCTGT 115 hsa-mir-191 
 CAACGGAATCC 1 hsa-mir-191 
 
 AACGGAATCCCAAAAGCAGCTGT 1 hsa-mir-191 
 
 AACGGAATCCCAAAAGCAGCTG 11 hsa-mir-191 
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 CAACGGAATCCCAAAAGCAG 17 hsa-mir-191 
  CAACGGAATCCCAAAAGCAGCTG 275 hsa-mir-191 
miR-193a-5p TGGGTCTTTGCGGGCGAGATGA 2 hsa-mir-193a 
miR-193a-3p  AACTGGCCTACAAAGTCCCAGT 98 hsa-mir-193a 
 CAACTGGCCTACAAAGTCCCAGT 1 hsa-mir-193a 
 
  ACTGGCCTACAAAGTCCCAGT 1 hsa-mir-193a 
 
 AACTGGCCTACAAAGTCCCAG 4 hsa-mir-193a 
  
 AACTGGCCTACAAAGTCCCAGTT 3 hsa-mir-193a 
miR-194 TGTAACAGCAACTCCATGTGGAA 2 hsa-mir-194-2 
  TGTAACAGCAACTCCATGTGGA 1 hsa-mir-194-1, hsa-mir-194-2 
miR-199a-5p CCCAGTGTTCAGACTACCTGTTC 10 hsa-mir-199a-1, hsa-mir-199a-2 
 CCCAGTGTTCAGACTACCTGTT 2 hsa-mir-199a-1, hsa-mir-199a-2 
  CCCAGTGTTCAGAC 1 hsa-mir-199a-1, hsa-mir-199a-2 
miR-199b-5p CCCAGTGTTTAGACTATCTGTTC 3 hsa-mir-199b 
miR-199b-3p 
  CAGTAGTCTGCACATTGGTTA 1 hsa-mir-199b 
 
  CAGTAGTCTGCACATTG 1 hsa-mir-199b 
 
 ACAGTAGTCTGCACATTGGTT 3 hsa-mir-199b 
 
  CAGTAGTCTGCACATTGGT 1 hsa-mir-199b 
  ACAGTAGTCTGCACATTGGTTA 11 hsa-mir-199b 
 TACAGTAGTCTGCACATTGGTT 2 hsa-mir-199b 
  TACAGTAGTCTGCACATTGGT 2 hsa-mir-199b 
miR-19b TGTGCAAATCCATGCAAAACTGA 14 hsa-mir-19b-1, hsa-mir-19b-2 
 TGTGCAAATCCATGCAAAACTG 1 hsa-mir-19b-1, hsa-mir-19b-2 
  
 GTGCAAATCCATGCAAAACTGA 1 hsa-mir-19b-1, hsa-mir-19b-2 
miR-20a TAAAGTGCTTATAGTGCAGGTAG 2 hsa-mir-20a 
  TAAAGTGCTTATAGTGCAGG 1 hsa-mir-20a 
miR-20a* ACTGCATTATGAGCACTTAAAGT 1 hsa-mir-20a 
miR-21 TAGCTTATCAGAC 1 hsa-mir-21 
 TAGCTTATCAGA 1 hsa-mir-21 
 
 AGCTTATCAGACTGATGTTGA 1 hsa-mir-21 
 TAGCTTATCAGACTGATGTTG 22 hsa-mir-21 
 TAGCTTATCAGACTGATGT 9 hsa-mir-21 
 TAGCTTATCAGACTGATG 1 hsa-mir-21 
 TAGCTTATCAGACTGATGTTGACT 7 hsa-mir-21 
 TAGCTTATCAGACTGA 1 hsa-mir-21 
 TAGCTTATCAGACTGATGTTGA 337 hsa-mir-21 
 TAGCTTATCAGACTGATGTTGAC 496 hsa-mir-21 
  TAGCTTATCAGACTGATGTT 4 hsa-mir-21 
miR-21* CAACACCAGTCGATGGGCTGTC 3 hsa-mir-21 
miR-214 TACAGCAGGCACAGACAGGC 1 hsa-mir-214 
 
 ACAGCAGGCACAGACAGGCA 1 hsa-mir-214 
 
 ACAGCAGGCACAGACAGGCAG 8 hsa-mir-214 
 TACAGCAGGCACAGACAGGCAG 3 hsa-mir-214 
 
  CAGCAGGCACAGACAGGCAG 1 hsa-mir-214 
 TACAGCAGGCACAGACAGGCA 1 hsa-mir-214 
 TACAGCAGGCACAGACAGGCAGT 3 hsa-mir-214 
   ACAGCAGGCACAGACAGGCAGT 13 hsa-mir-214 
miR-22* AGTTCTTCAGTGGCAAGCTTTA 4 hsa-mir-22 
  AGTTCTTCAGTGGCAAGCTTT 2 hsa-mir-22 
miR-22 
  AGCTGCCAGTTGAAGAACTGT 5 hsa-mir-22 
 
 AAGCTGCCAGTTGAAGAA 1 hsa-mir-22 
 
 AAGCTGCCAGTTGAAGAACTG 16 hsa-mir-22 
 
 AAGCTGCCAGTTGAAGAACT 3 hsa-mir-22 
 AAAGCTGCCAGTTGAAGAACTGT 1 hsa-mir-22 
  AAGCTGCCAGTTGAAGAACTGT 400 hsa-mir-22 
 
 AAGCTGCCAGTTGAAGAAC 2 hsa-mir-22 
  
 AAGCTGCCAGTTGAAGAACTGTT 1 hsa-mir-22 
miR-221* ACCTGGCATACAATGTAGATTT 1 hsa-mir-221 
miR-221 
 GCTACATTGTCTGCTGGGTTT 1 hsa-mir-221 
 
 GCTACATTGTCTGCTGGGT 1 hsa-mir-221 
 AGCTACATTGTCTGCTGG 1 hsa-mir-221 
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 AGCTACATTGTCTGCTGGGTTTC 16 hsa-mir-221 
 
 GCTACATTGTCTGCTGGGTTTC 1 hsa-mir-221 
 AGCTACATTGTCTGCTGGGTT 1 hsa-mir-221 
 AGCTACATTGTCTGCTG 1 hsa-mir-221 
 AGCTACATTGTCTGCTGGGT 6 hsa-mir-221 
 AGCTACATTGTCTGCTGGGTTT 6 hsa-mir-221 
  AGCTACATTGTCTGCTGGGTTTCA 2 hsa-mir-221 
miR-222 
  CTACATCTGGCTACTGGGTCT 1 hsa-mir-222 
 
   TACATCTGGCTACTGGGTCTC 1 hsa-mir-222 
 
 GCTACATCTGGCTACTGGGTCTC 3 hsa-mir-222 
 AGCTACATCTGGCTACTGGG 1 hsa-mir-222 
 AGCTACATCTGGCTACTGGGT 5 hsa-mir-222 
 AGCTACATCTGGCTACTGG 1 hsa-mir-222 
 AGCTACATCTGGCTACTGGGTCTCT 3 hsa-mir-222 
 AGCTACATCTGGCTACTGGGTC 5 hsa-mir-222 
 
 GCTACATCTGGCTACTGGGTCTCT 1 hsa-mir-222 
 AGCTACATCTGGCTACTGGGTCT 11 hsa-mir-222 
  AGCTACATCTGGCTACTGGGTCTC 18 hsa-mir-222 
miR-222* GGCTCAGTAGCCAGTGTAGATCC 1 hsa-mir-222 
miR-23a 
  AATCACATTGCCAGGGATTTCCA 6 hsa-mir-23a 
 
   ATCACATTGCCAGGGATTTC 88 hsa-mir-23a 
 CAAATCACATTGCCAGGGATTTC 1 hsa-mir-23a 
 
    TCACATTGCCAGGGATTTCCA 64 hsa-mir-23a 
 
    TCACATTGCCAGGGATTTCC 33 hsa-mir-23a 
    ATCACATTGCCAGGGATTTCC 601 hsa-mir-23a 
 
    TCACATTGCCAGGGATTTC 12 hsa-mir-23a 
 
   ATCACATTGCCAGGGATTTCCA 712 hsa-mir-23a 
 
   ATCACATTGCCAGGGATTT 7 hsa-mir-23a 
 
     CACATTGCCAGGGATTTCCAA 1 hsa-mir-23a 
 
    TCACATTGCCAGGGATTTCCAA 28 hsa-mir-23a 
 
   ATCACATTGCCAGGGATTTCCAA 278 hsa-mir-23a 
 
    TCACATTGCCAGGGATTTCCAAC 105 hsa-mir-23a 
  
   ATCACATTGCCAGGGATTTCCAAC 31 hsa-mir-23a 
miR-23b AATCACATTGCCAGGGATTACCAC 1 hsa-mir-23b 
 
 ATCACATTGCCAGGGATTACCA 6 hsa-mir-23b 
 
 ATCACATTGCCAGGGATTACCAC 50 hsa-mir-23b 
 
  TCACATTGCCAGGGATTACCAC 10 hsa-mir-23b 
 
 ATCACATTGCCAGGGATTAC 3 hsa-mir-23b 
 
  TCACATTGCCAGGGATTAC 1 hsa-mir-23b 
   ATCACATTGCCAGGGATTACC 4 hsa-mir-23b 
miR-23b* TGGGTTCCTGGCATGCTGATTT 1 hsa-mir-23b 
miR-24 TGGCTCAGTTCAGCAGGAACAG 86 hsa-mir-24-1, hsa-mir-24-2 
 TGGCTCAGTTCAGCAGGAACA 5 hsa-mir-24-1, hsa-mir-24-2 
 TGGCTCAGTTCAGCAGGAAC 24 hsa-mir-24-1, hsa-mir-24-2 
 TGGCTCAGTTCAGCAGGAA 1 hsa-mir-24-1, hsa-mir-24-2 
  TGGCTCAGTTCAGCAGGA 2 hsa-mir-24-1, hsa-mir-24-2 
miR-25 CATTGCACTTGTC 1 hsa-mir-25 
  CATTGCACTTGTCTCGGTCTGA 2 hsa-mir-25 
miR-26a ATTCAAGTAATCCAGGATAGGCT 1 hsa-mir-26a-2 
 
 TTCAAGTAATCCAGGAT 1 hsa-mir-26a-1, hsa-mir-26a-2 
 
 TTCAAGTAATCCAGGATAGG 14 hsa-mir-26a-1, hsa-mir-26a-2 
 
 TTCAAGTAATCCAGGA 1 hsa-mir-26a-1, hsa-mir-26a-2 
 
 TTCAAGTAATCCAGGATAG 5 hsa-mir-26a-1, hsa-mir-26a-2 
 
 TTCAAGTAATCCAGGATA 3 hsa-mir-26a-1, hsa-mir-26a-2 
  TTCAAGTAATCCAGGATAGGCT 619 hsa-mir-26a-1, hsa-mir-26a-2 
 
  TCAAGTAATCCAGGATAGGCT 2 hsa-mir-26a-1, hsa-mir-26a-2 
  
 TTCAAGTAATCCAGGATAGGC 94 hsa-mir-26a-1, hsa-mir-26a-2 
miR-26b TTCAAGTAATTCAGGATAG 2 hsa-mir-26b 
 TTCAAGTAATTCAGGATAGG 1 hsa-mir-26b 
  TTCAAGTAATTCAGGATAGGTT 3 hsa-mir-26b 
miR-27a TTCACAGTGGCTAAGTTCCG 2 hsa-mir-27a 
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  TTCACAGTGGCTAAGTTCCGC 28 hsa-mir-27a 
miR-27b TTCACAGTGGCTAAGTTCTGC 1 hsa-mir-27b 
  TTCACAGTGGCTAAGTTCTG 2 hsa-mir-27b 
miR-27b* AGAGCTTAGCTGATTGGTGAACA 1 hsa-mir-27b 
miR-28-5p CAAGGAGCTCACAGTCTATTGA 1 hsa-mir-28 
 
 AAGGAGCTCACAGTCTATTG 2 hsa-mir-28 
  AAGGAGCTCACAGTCTATTGAG 19 hsa-mir-28 
 
  AGGAGCTCACAGTCTATTGAG 1 hsa-mir-28 
  
 AAGGAGCTCACAGTCTATTGA 18 hsa-mir-28 
miR-28-3p 
  CTAGATTGTGAGCTCCTGGAG 2 hsa-mir-28 
 CACTAGATTGTGAGCTCCTGG 2 hsa-mir-28 
  CACTAGATTGTGAGCTCCTGGA 28 hsa-mir-28 
miR-299-3p TATGTGGGATGGTAAACCGCT 2 hsa-mir-299 
  TATGTGGGATGGTAAACCGCTT 1 hsa-mir-299 
miR-29a* ACTGATTTCTTTTGGTGTTCAGA 1 hsa-mir-29a 
  ACTGATTTCTTTTGGTGTTCAG 3 hsa-mir-29a 
miR-29a 
 TAGCACCATCTGAAA 1 hsa-mir-29a 
 
 TAGCACCATCTGAAATCGGTTAT 3 hsa-mir-29a 
 
 TAGCACCATCTGAAATCGGT 18 hsa-mir-29a 
  TAGCACCATCTGAAATCGGTTA 116 hsa-mir-29a 
 CTAGCACCATCTGAAATCGGTTA 3 hsa-mir-29a 
 
 TAGCACCATCTGAAATCG 1 hsa-mir-29a 
 
 TAGCACCATCTGAAATCGGTT 24 hsa-mir-29a 
 CTAGCACCATCTGAAATCGGTT 2 hsa-mir-29a 
 
 TAGCACCATCTGAA 5 hsa-mir-29a 
  
 TAGCACCATCTGAAATCGG 6 hsa-mir-29a 
miR-29b TAGCACCATTTGAAATCAGTGTTT 3 hsa-mir-29b-2 
 TAGCACCATTTGAAATCAGTG 1 hsa-mir-29b-1, hsa-mir-29b-2 
 TAGCACCATTTGAAATCAG 1 hsa-mir-29b-1, hsa-mir-29b-2 
 TAGCACCATTTGAAATCAGTGTT 18 hsa-mir-29b-1, hsa-mir-29b-2 
 TAGCACCATTTGAAATCAGT 4 hsa-mir-29b-1, hsa-mir-29b-2 
  TAGCACCATTTGAAATCAGTGT 5 hsa-mir-29b-1, hsa-mir-29b-2 
miR-30a* CTTTCAGTCGGATGTTTGCAGC 16 hsa-mir-30a 
 CTTTCAGTCGGATGTTTGCAG 3 hsa-mir-30a 
  CTTTCAGTCGGATGTTTGCAGCT 1 hsa-mir-30a 
miR-30a TGTAAACATCCTCGACTGGAA 1 hsa-mir-30a 
 TGTAAACATCCTCGACTGGAAGC 22 hsa-mir-30a 
  TGTAAACATCCTCGACTGGAAGCT 4 hsa-mir-30a 
miR-30b TGTAAACATCCTACACTCAGC 1 hsa-mir-30b 
miR-30b* CTGGGAGGTGGATGTTTACTTC 1 hsa-mir-30b 
  CTGGGAGGTGGATGTTTAC 1 hsa-mir-30b 
miR-30c TGTAAACATCCTACACTCTCAGC 7 hsa-mir-30c-1, hsa-mir-30c-2 
  TGTAAACATCCTACACTCTCAGCT 2 hsa-mir-30c-1, hsa-mir-30c-2 
miR-30d TGTAAACATCCCCGACTGGAAG 9 hsa-mir-30d 
 TGTAAACATCCCCGACTGGAAGC 6 hsa-mir-30d 
  TGTAAACATCCCCGACTGGAAGCT 9 hsa-mir-30d 
miR-30e TGTAAACATCCTTGACTGGAAGCT 3 hsa-mir-30e 
  TGTAAACATCCTTGACTGGAAGC 2 hsa-mir-30e 
miR-30e* CTTTCAGTCGGATGTTTACAG 4 hsa-mir-30e 
 CTTTCAGTCGGATGTTTACAGC 1 hsa-mir-30e 
  CTTTCAGTCGGATGTTTACA 3 hsa-mir-30e 
miR-31 AGGCAAGATGCTGGCATAGCTG 29 hsa-mir-31 
 
 GGCAAGATGCTGGCATAGC 1 hsa-mir-31 
 AGGCAAGATGCTGGCATAGC 5 hsa-mir-31 
 
 GGCAAGATGCTGGCATAGCT 1 hsa-mir-31 
 
 GGCAAGATGCTGGCATAGCTG 3 hsa-mir-31 
 AGGCAAGATGCTGGCATAGCT 19 hsa-mir-31 
 AGGCAAGATGCTGGCATAGCTGT 30 hsa-mir-31 
  
 GGCAAGATGCTGGC 1 hsa-mir-31 
miR-320a 
  AAGCTGGGTTGAGAGGGCGAAA 1 hsa-mir-320a 
 AAAAGCTGGGTTGAGAGGGCGAA 1 hsa-mir-320a 
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 AAAGCTGGGTTGAGAGGGCGA 1 hsa-mir-320a 
 AAAAGCTGGGTTGAGAGGGCGAAA 1 hsa-mir-320a 
  AAAAGCTGGGTTGAGAGGGCGA 3 hsa-mir-320a 
miR-324-5p CGCATCCCCTAGGGCATTGGTGT 2 hsa-mir-324 
  CGCATCCCCTAGGGCATTGGTG 1 hsa-mir-324 
miR-329 AACACACCTGGTTAACCTCTT 6 hsa-mir-329-1, hsa-mir-329-2 
  
 ACACACCTGGTTAACCTCTT 2 hsa-mir-329-1, hsa-mir-329-2 
miR-335 TCAAGAGCAATAACGAAAAATGT 3 hsa-mir-335 
 TCAAGAGCAATAACGAAA 2 hsa-mir-335 
 TCAAGAGCAATAACGAAAAATG 1 hsa-mir-335 
  TCAAGAGCAATAACGAAAAAT 2 hsa-mir-335 
miR-335* TTTTTCATTATTGCTCCTGACC 8 hsa-mir-335 
  TTTTTCATTATTGCTCCTGAC 2 hsa-mir-335 
miR-337-3p 
 TCCTATATGATGCCTTTCTTCA 1 hsa-mir-337 
 CTCCTATATGATGCCTTTCTTC 30 hsa-mir-337 
 CTCCTATATGATGCCTTTCTT 7 hsa-mir-337 
 CTCCTATATGATGCCTTTCT 1 hsa-mir-337 
 
 TCCTATATGATGCCTTTCT 1 hsa-mir-337 
 
 TCCTATATGATGCCTTTCTTC 63 hsa-mir-337 
  
 TCCTATATGATGCCTTTCTT 6 hsa-mir-337 
miR-339-5p TCCCTGTCCTCCAGGAGCTCA 1 hsa-mir-339 
 TCCCTGTCCTCCAGGAGCTCAC 1 hsa-mir-339 
  TCCCTGTCCTCCAGGAGCTCACG 1 hsa-mir-339 
miR-345 GCTGACTCCTAGTCCAGGGCTC 4 hsa-mir-345 
 GCTGACTCCTAGTCCAGGGC 1 hsa-mir-345 
  GCTGACTCCTAGTCCAGGGCT 1 hsa-mir-345 
miR-361-5p TTATCAGAATCTCCAGGGGTA 1 hsa-mir-361 
 TTATCAGAATCTCCAGGGGTAC 8 hsa-mir-361 
  TTATCAGAATCTCCAGGGGTACT 1 hsa-mir-361 
miR-365 TAATGCCCCTAAAAATCC 1 hsa-mir-365-1, hsa-mir-365-2 
 TAATGCCCCTAAAAATCCT 1 hsa-mir-365-1, hsa-mir-365-2 
  TAATGCCCCTAAAAATCCTTA 1 hsa-mir-365-1, hsa-mir-365-2 
miR-376c 
  AACATAGAGGAAATTCCACGTT 19 hsa-mir-376c 
 
   ACATAGAGGAAATTCCACGTT 1 hsa-mir-376c 
 
  AACATAGAGGAAATTCCAC 3 hsa-mir-376c 
 
   ACATAGAGGAAATTCCAC 1 hsa-mir-376c 
 
  AACATAGAGGAAATTCC 1 hsa-mir-376c 
 
 AAACATAGAGGAAATTCCACG 2 hsa-mir-376c 
 
  AACATAGAGGAAATTCCACGTTT 2 hsa-mir-376c 
 
   ACATAGAGGAAATTCCACGT 25 hsa-mir-376c 
 TAAACATAGAGGAAATTCCACG 1 hsa-mir-376c 
 
 AAACATAGAGGAAATTCCACGT 3 hsa-mir-376c 
   AACATAGAGGAAATTCCACGT 384 hsa-mir-376c 
 
  AACATAGAGGAAATTCCACG 5 hsa-mir-376c 
 
  AACATAGAGGAAAT 1 hsa-mir-376c 
 
  AACATAGAGGA 2 hsa-mir-376c 
  
  AACATAGAGGAAA 4 hsa-mir-376c 
miR-369-3p AATAATACATGGTTGATCTT 6 hsa-mir-369 
 AATAATACATGGTTGATCTTTT 4 hsa-mir-369 
 AATAATACATGGTTGATCTTT 18 hsa-mir-369 
 AATAATACATGGTTGATC 1 hsa-mir-369 
  
 ATAATACATGGTTGATCTTT 1 hsa-mir-369 
miR-374a TTATAATACAACCTGATAAGTG 1 hsa-mir-374a 
  TTATAATACAACCTGATAAGT 2 hsa-mir-374a 
miR-376a 
 ATCATAGAGGAAAATCCAC 5 hsa-mir-376a-1, hsa-mir-376a-2 
 AATCATAGAGGAAAATCCACGT 17 hsa-mir-376a-1, hsa-mir-376a-2 
 
 ATCATAGAGGAAAATCCACGTT 4 hsa-mir-376a-1, hsa-mir-376a-2 
 
  TCATAGAGGAAAATCCACGT 7 hsa-mir-376a-1, hsa-mir-376a-2 
 
 ATCATAGAGGAAAATCCACG 4 hsa-mir-376a-1, hsa-mir-376a-2 
   ATCATAGAGGAAAATCCACGT 207 hsa-mir-376a-1, hsa-mir-376a-2 
miR-376b ATCATAGAGGAAAATCCAT 2 hsa-mir-376b 
 200 
 
 TCATAGAGGAAAATCCATGTTT 5 hsa-mir-376b 
 ATCATAGAGGAAAATCCATGTTT 8 hsa-mir-376b 
 ATCATAGAGGAAAATCCATGTT 27 hsa-mir-376b 
 ATCATAGAGGAAAATCCATG 1 hsa-mir-376b 
 
 TCATAGAGGAAAATCCATGT 6 hsa-mir-376b 
 ATCATAGAGGAAAATCCATGTTTT 1 hsa-mir-376b 
 ATCATAGAGGAAAATCCATGT 116 hsa-mir-376b 
  
 TCATAGAGGAAAATCCATGTT 1 hsa-mir-376b 
miR-377* AGAGGTTGCCCTTGGTGAAT 2 hsa-mir-377 
 AGAGGTTGCCCTTGGTGAATTCG 1 hsa-mir-377 
 AGAGGTTGCCCTTGGTGAATT 1 hsa-mir-377 
  AGAGGTTGCCCTTGGTGAATTC 6 hsa-mir-377 
miR-378 ACTGGACTTGGAGTCAGAAGGC 2 hsa-mir-378 
  ACTGGACTTGGAGTCAGAAGG 14 hsa-mir-378 
miR-379 ATGGTAGACTATGGAACGTAGG 1 hsa-mir-379 
  TGGTAGACTATGGAACGTAGG 4 hsa-mir-379 
  
 TGGTAGACTATGGAACGTAG 1 hsa-mir-379 
miR-379* 
 ATGTAACATGGTCCACTAACT 2 hsa-mir-379 
 TATGTAACATGGTCCACTAA 2 hsa-mir-379 
  TATGTAACATGGTCCACTAAC 12 hsa-mir-379 
miR-382 GAAGTTGTTCGTGGTGGATTC 7 hsa-mir-382 
 
  AGTTGTTCGTGGTGGATTC 2 hsa-mir-382 
 
  AGTTGTTCGTGGTGGATTCGCT 1 hsa-mir-382 
 
 AAGTTGTTCGTGGTGGAT 1 hsa-mir-382 
 GAAGTTGTTCGTGGTGGATTCG 15 hsa-mir-382 
 
 AAGTTGTTCGTGGTGGATTC 1 hsa-mir-382 
 GAAGTTGTTCGTGGTGGAT 4 hsa-mir-382 
  GAAGTTGTTCGTGGTGGATT 5 hsa-mir-382 
miR-409-3p CGAATGTTGCTCGGTGAACCCCT 2 hsa-mir-409 
  GAATGTTGCTCGGTGAACCCCT 2 hsa-mir-409 
 CGAATGTTGCTCGGTGAACCCC 1 hsa-mir-409 
  CGAATGTTGCTCGGTGAACCC 1 hsa-mir-409 
miR-409-5p GGTTACCCGAGCAAC 1 hsa-mir-409 
miR-411 TAGTAGACCGTATAGCGTACG 1 hsa-mir-411 
miR-411* TATGTAACACGGTCCACTAAC 14 hsa-mir-411 
  TATGTAACACGGTCCACTAA 12 hsa-mir-411 
miR-423-3p AGCTCGGTCTGAGGCCCCTCAGT 5 hsa-mir-423 
miR-423-5p TGAGGGGCAGAGAGCGAGAC 2 hsa-mir-423 
 TGAGGGGCAGAGAGCGAGA 1 hsa-mir-423 
 TGAGGGGCAGAGAGCGAGACTT 1 hsa-mir-423 
 TGAGGGGCAGAGAGCGAGACTTTT 1 hsa-mir-423 
 TGAGGGGCAGAGA 1 hsa-mir-423 
 TGAGGGGCAGAGAGCGAGACTTT 2 hsa-mir-423 
  TGAGGGGCAGAGAGCGAGACT 2 hsa-mir-423 
miR-424* CAAAACGTGAGGCGCTGCTATA 2 hsa-mir-424 
  CAAAACGTGAGGCGCTGCTAT 1 hsa-mir-424 
miR-424 CAGCAGCAATTCATGTTTTGAA 51 hsa-mir-424 
 CAGCAGCAATTCATGTTTTGA 20 hsa-mir-424 
  CAGCAGCAATTCATGTTTTG 1 hsa-mir-424 
miR-425 AATGACACGATCACTCCCGTTGAGT 6 hsa-mir-425 
 
 ATGACACGATCACTCCCGTTGAGT 1 hsa-mir-425 
  AATGACACGATCACTCCCGTTGAG 1 hsa-mir-425 
miR-425* 
  TCGGGAATGTCGTGTCCGCCC 1 hsa-mir-425 
 
  TCGGGAATGTCGTGTCCGCC 1 hsa-mir-425 
  CATCGGGAATGTCGTGTCCGCC 1 hsa-mir-425 
miR-432 TCTTGGAGTAGGTCATTGGGTG 2 hsa-mir-432 
 
  TTGGAGTAGGTCATTGGGTGG 1 hsa-mir-432 
  TCTTGGAGTAGGTCATTGGGTGG 9 hsa-mir-432 
miR-433 ATCATGATGGGCTCCTCGGTG 1 hsa-mir-433 
 ATCATGATGGGCTCCTCGGTGT 3 hsa-mir-433 
  ATCATGATGGGCTCCTCGGT 1 hsa-mir-433 
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miR-455-3p 
  GCAGTCCATGGGCATATACA 2 hsa-mir-455 
 ATGCAGTCCATGGGCATATACAC 1 hsa-mir-455 
 ATGCAGTCCATGGGCATAT 3 hsa-mir-455 
 
 TGCAGTCCATGGGCATATACAC 1 hsa-mir-455 
   GCAGTCCATGGGCATATACAC 4 hsa-mir-455 
 
  GCAGTCCATGGGCATATACACT 1 hsa-mir-455 
  ATGCAGTCCATGGGCATATAC 1 hsa-mir-455 
miR-483-5p 
 AGACGGGAGGAAAGAAGGGAGT 1 hsa-mir-483 
  AAGACGGGAGGAAAGAAGGGAG 1 hsa-mir-483 
miR-484 TCAGGCTCAGTCCCCTCCCGA 2 hsa-mir-484 
  TCAGGCTCAGTCCCCTCCCGAT 4 hsa-mir-484 
miR-485-5p AGAGGCTGGCCGTGATGAATTCG 2 hsa-mir-485 
  AGAGGCTGGCCGTGATGAATT 2 hsa-mir-485 
miR-487b 
 ATCGTACAGGGTCATCCACTTT 1 hsa-mir-487b 
  AATCGTACAGGGTCATCCACTT 2 hsa-mir-487b 
miR-490-5p CCATGGATCTCCAGGTGGGTCA 1 hsa-mir-490 
 CCATGGATCTCCAGGTGGGT 3 hsa-mir-490 
  CCATGGATCTCCAGGTGGG 1 hsa-mir-490 
miR-491-5p 
  TGGGGAACCCTTCCATGAGGA 1 hsa-mir-491 
 AGTGGGGAACCCTTCCATGAGGA 26 hsa-mir-491 
 
  TGGGGAACCCTTCCATGAGGAGT 1 hsa-mir-491 
 AGTGGGGAACCCTTCCATGA 1 hsa-mir-491 
 AGTGGGGAACCCTTCCATGAGG 2 hsa-mir-491 
  AGTGGGGAACCCTTCCATG 1 hsa-mir-491 
miR-493* TTGTACATGGTAGGCTTTC 3 hsa-mir-493 
 TTGTACATGGTAGGCTTTCA 5 hsa-mir-493 
 TTGTACATGGTAGGCTTTCAT 20 hsa-mir-493 
  TTGTACATGGTAGGCTTTCATT 91 hsa-mir-493 
miR-494 TGAAACATACACGGGAAACCTCT 4 hsa-mir-494 
 TGAAACATACACGGGAAAC 2 hsa-mir-494 
  TGAAACATACACGGGAAACC 1 hsa-mir-494 
miR-495 
 AACAAACATGGTGCACTTCTTT 13 hsa-mir-495 
 
  ACAAACATGGTGCACTTCTTTTT 1 hsa-mir-495 
 
 AACAAACATGGTGCACTTCTTTTT 1 hsa-mir-495 
 
 AACAAACATGGTGCACTTCTTTT 3 hsa-mir-495 
 
  ACAAACATGGTGCACTTCTTTT 1 hsa-mir-495 
 AAACAAACATGGTGCACTTCTTTT 16 hsa-mir-495 
 AAACAAACATGGTGCACTTCTTT 71 hsa-mir-495 
 AAACAAACATGGTGCACTT 4 hsa-mir-495 
 
 AACAAACATGGTGCACTTC 1 hsa-mir-495 
 
 AACAAACATGGTGCACTTCT 1 hsa-mir-495 
 AAACAAACATGGTGCACTTCTT 90 hsa-mir-495 
 
 AACAAACATGGTGCACTTCTT 21 hsa-mir-495 
 AAACAAACATGGTGCACTTCT 13 hsa-mir-495 
  AAACAAACATGGTGCACTTC 2 hsa-mir-495 
miR-501-3p ATGCACCCGGGCAAGGATTCT 1 hsa-mir-501 
miR-501-5p AATCCTTTGTCCCTGGGTGAGAGT 1 hsa-mir-501 
miR-503 TAGCAGCGGGAACAGTTCT 1 hsa-mir-503 
 TAGCAGCGGGAACAGTTCTGCAGT 1 hsa-mir-503 
 TAGCAGCGGGAACAGTTCTGCAG 3 hsa-mir-503 
  TAGCAGCGGGAACAGTTCTGCA 5 hsa-mir-503 
miR-539 
  AGAAATTATCCTTGGTGTGTTC 1 hsa-mir-539 
 GGAGAAATTATCCTTGGTGTGT 1 hsa-mir-539 
  GGAGAAATTATCCTTGGTGTGTT 1 hsa-mir-539 
miR-542-3p TGTGACAGATTGATAACTGAAA 3 hsa-mir-542 
  TGTGACAGATTGATAACTGAAAG 1 hsa-mir-542 
miR-652 AATGGCGCCACTAGGGTTGTGC 1 hsa-mir-652 
  
 ATGGCGCCACTAGGGTTGTG 1 hsa-mir-652 
miR-654-5p TGGTGGGCCGCAGAACATGTGCT 1 hsa-mir-654 
 TGGTGGGCCGCAGAACATGT 1 hsa-mir-654 
  TGGTGGGCCGCAGAACATGTGC 3 hsa-mir-654 
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miR-654-3p 
  TATGTCTGCTGACCATCACC 2 hsa-mir-654 
 CATATGTCTGCTGACCATCACC 1 hsa-mir-654 
  
  TATGTCTGCTGACCATCAC 1 hsa-mir-654 
miR-708 AAGGAGCTTACAATCTAGCTGGG 2 hsa-mir-708 
miR-744 TGCGGGGCTAGGGCTAACAGCA 2 hsa-mir-744 
  TGCGGGGCTAGGGCTAACAGC 1 hsa-mir-744 
miR-769-3p TGGGATCTCCGGGGTCTTGGTT 1 hsa-mir-769 
miR-785 TTTGTGACCTGGTCCACTAAC 6 hsa-mir-785 
  TTTGTGACCTGGTCCACTAACC 1 hsa-mir-785 
miR-886-3p CGCGGGTGCTTACTGACCCTT 4 hsa-mir-886 
  CGCGGGTGCTTACTGACCCTTT 1 hsa-mir-886 
miR-92a TATTGCACTTGTCCCGGCC 1 hsa-mir-92a-1, hsa-mir-92a-2 
 
 ATTGCACTTGTCCCGGCCTGT 1 hsa-mir-92a-1, hsa-mir-92a-2 
  TATTGCACTTGTCCCGGCCTGT 5 hsa-mir-92a-1, hsa-mir-92a-2 
miR-93 CAAAGTGCTGTTCGTGCAGGT 1 hsa-mir-93 
 CAAAGTGCTGTTCGTGCAG 1 hsa-mir-93 
  CAAAGTGCTGTTCGTGCAGGTAG 4 hsa-mir-93 
miR-98 TGAGGTAGTAAG 2 hsa-mir-98 
 TGAGGTAGTAA 2 hsa-mir-98 
 TGAGGTAGTAAGTTGTATTGT 11 hsa-mir-98 
 TGAGGTAGTAAGTTGTATTGTT 10 hsa-mir-98 
  TGAGGTAGTAAGTTGTATTG 1 hsa-mir-98 
miR-1180 TTTCCGGCTCGCGTGGGTGTGT 11 hsa-mir-1180 
  TTTCCGGCTCGCGTGGGTGTGTAG 1 hsa-mir-1180 
miR-1185 AGAGGATACCCTTTGTATGTTCA 2 hsa-mir-1185-1, hsa-mir-1185-2 
  AGAGGATACCCTTTGTATGTTC 7 hsa-mir-1185-1, hsa-mir-1185-2 
miR-1255b CGGATGAGCAAAGAAAGTGGTT 1 hsa-mir-1255b-1, hsa-mir-1255b-2 
miR-1274b GTCCCTGTTCGGGCGCCA 2 hsa-mir-1274b 
miR-1285 TCTGGGCAACAAAGTGAGA 1 hsa-mir-1285-1, hsa-mir-1285-2 
miR-1296 TTAGGGCCCTGGCTCCATC 1 hsa-mir-1296 
  TTAGGGCCCTGGCTCCATCT 1 hsa-mir-1296 
miR-1301 TGCAGCTGCCTGGGAGTGAC 1 hsa-mir-1301 
miR-1305 TTTCAACTCTAATGGGAGAGAC 1 hsa-mir-1305 
miR-1308 GCATGGGTGGTTCAGTGG 2 hsa-mir-1308 
  GCATGGGTGGTTCAGT 3 hsa-mir-1308 
miR-1826 ATTGATCATCGACACTTCGAAC 1 hsa-mir-1826 
miR-1974 ATTGGTCGTGGTTGTAGTCCGTGCG 1 hsa-mir-1974 
miR-2110 TTGGGGAAACGGCCGCTGAGTGAG 1 hsa-mir-2110 
 
   
 
   
Novels 
   
  
      
miR-382* AATCATTCACGGACAACACTT 1 hsa-mir-382 
  AATCATTCACGGACAACACTTT 1 hsa-mir-382 
  AATCATTCACGGACAACACTTTT 1 hsa-mir-382 
miR-494* AGGTTGTCCGTGTTGTCTTCTC 2 hsa-mir-494 
miR-889* AATGGCTGTCCGTAGTATGG 1 hsa-mir-889 
miR-1271* AGTGCCTGCTATGTGCCAGGCAA 2 hsa-mir-1271 
miR-1304* CTCACTGTAGCATCGAACCCCT 1 hsa-mir-1304 
miR-1826* CTGTCTGAGCGTCGCTA 1 hsa-mir-1826 
miR-1197* CGGTTGACCATGGTGTGTACG 1 hsa-mir-1197 
Novel-1 GCTAAGGAAGTCCTGTGCTCAGTTTT 25 Chr:17(+) 8030991 - 8031016      
  GCTAAGGAAGTCCTGTGCTCAGTTT 22 
  
Novel-2 GGAGGAACCTTGGAGCTTCGGT 1 Chr:22(-) 29886049 - 29886069     
  GGAGGAACCTTGGAGCTTCGG 1   
  GGAGGAACCTTGGAGCTTCGGCT 6   
  GGAGGAACCTTGGAGCTTCGGC 1   
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ADAR editing of microRNAs. Sequences in blue denote the annotated 
mature form. Potential ADAR editing of bases is shown in red, 
additional modifications are shown in orange. 
 
 
hsa-mir-376a-1,  AATCATAGAGGAAAATCCACGTTT 207 
hsa-mir-376a-2 
 ATCATGGAGGAAAATCCACG 1 
 AATCATGGAGGAAAATCCACGT 1 
 
 ATCATGGAGGAAAATCCACGT 185 
 
 ATCATGGAGGAAAATCCACGTT 1 
 
  TCATGGAGGAAAATCCACGT 5 
 
 ATCATGGAAGAAAATCCACGT 1 
 
 ATCATGGAGGAAAATCCACGC 1 
 
 ATCATGGAGGAAAATCCACGTA 3 
 
 GTCATGGAGGAAAATCCACGT 1 
 
 ATCATGGAGGAAAATCCACGTAG 2 
 
 ATCATGGAGGAAAATCCACGTAT 1 
 ATTCATGGAGGAAAATCCACGT 1 
 
  
hsa-mir-376c AACATAGAGGAAATTCCACGTT 384 
 AACATAGAGGAAGTTCCACGT 1 
 AACATAGAGGAGATTCCACGT 1 
 
 ACATAGAGGAAGTTCCACGT 1 
 AACATAAAGGAAATTCCACGT 2 
 AACATAGAAGAAATTCCACGT 2 
 AACATAGGGGAAATTCCACGT 2 
 AACATGGAGGAAATTCCACGT 28 
 AACATGGAGGAAATTCCACGTT 2 
 
 ACATGGAGGAAATTCCACGT 4 
 AGCATAGAGGAAATTCCACGT 2 
 AACATAGAGGAAATTCCACAT 2 
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Supplementary Table S2. Human mesenchymal stem cell mRNA 
microarray. The top mRNAs detected by microarray are listed below, representing 
1% of the total mRNAs that are spotted on the array.  
 
 
mRNA hMSC 1 hMSC 2 
 
mRNA hMSC 1 hMSC 2 
LOC642210 63796.70 61989.30  LOC389435 39883.50 39854.70 
LOC401206 58342.40 58306.60  RPL19 39331.60 34189.40 
FTL 58112.60 55076.60  TUBA1B 39326.20 34112.60 
LOC341457 56796.40 53653.20  HS.508682 39244.90 31517.70 
EEF1A1 56198.00 57240.80  LOC731365 38864.00 27798.30 
LOC729466 55313.60 36430.20  NPC2 38280.20 26152.80 
RPL27 53570.50 42324.40  RPL18 38277.80 36278.10 
MYL6 53094.80 48597.90  H2AFZ 38216.50 28189.10 
OAZ1 51675.20 49163.80  DNCL1 37958.30 31294.60 
MT2A 50277.00 43871.80  RPL10A 37859.50 29296.30 
LOC441876 50021.80 38208.10  RPLP2 37684.10 30248.20 
LOC731096 49629.40 41731.70  MT1A 37683.80 30879.50 
ACTA2 49299.60 47799.00  RPS16 37561.10 34321.60 
MRCL3 49030.20 43174.10  RPL18A 37463.90 34940.80 
TUBA1C 48961.30 46640.10  PRDX6 36621.60 29016.50 
RPL24 48951.00 39201.50  LOC652071 36416.70 33435.40 
LOC388474 48913.10 46940.10  TOMM7 36411.70 25539.20 
RPS25 48897.90 55027.10  LOC652624 36135.80 29422.50 
EIF4A1 48798.90 43539.90  LOC645683 35995.10 31479.10 
TPT1 47790.40 44235.90  VIM 35918.00 33571.80 
LOC646195 47536.00 46992.40  RPL30 35352.70 27100.80 
TMEM158 47510.30 32684.00  LOC387867 35164.70 29089.10 
ACTG1 47141.90 44207.90  LDHA 35122.10 27269.10 
ACTB 47010.90 46124.80  ATP5B 35115.50 31160.40 
LGALS1 46377.30 48217.40  RPS2 35054.90 32898.30 
HINT1 46049.30 32184.60  PFN1 34777.10 29323.50 
RPS12 45849.30 44467.30  RPS5 34686.30 30997.40 
RPL38 45763.50 43315.70  RPL27A 34685.90 30817.70 
RPL39 45346.60 43028.50  COL6A3 34502.50 25826.40 
RN7SL1 45332.40 41089.90  EEF1G 34369.50 31514.20 
TIMP1 44782.00 45858.60  S100A10 34311.40 29057.10 
LOC645899 44710.50 29091.30  SRP14 34134.50 25633.50 
LOC400963 44397.30 45806.90  MRLC2 34021.50 31367.20 
ATP5EP2 44341.80 34873.20  IFITM3 33960.80 21200.60 
UBB 43819.50 36425.80  LOC650276 33891.90 27402.30 
LOC440589 43755.40 44965.10  LOC441246 33862.70 30391.10 
RPL35A 43669.20 36331.70  H3F3A 33588.50 25760.40 
ACTG2 43408.30 43089.90  LOC649548 33526.10 25348.00 
RPS10 43359.60 49932.80  ANXA1 33457.40 21983.10 
LOC388720 42978.70 46117.00  COX4I1 33275.50 27859.20 
COL1A1 42676.10 34242.20  CALM2 33147.80 28910.30 
COX7C 41832.70 31024.90  BASP1 33097.20 25026.80 
IGFBP5 41637.10 40536.90  TRAM1 33086.00 28580.30 
RPS3 41607.60 37648.20  TXN 33045.60 28081.30 
RPS11 41195.40 36531.40  COL1A2 32958.80 26661.10 
CD81 41018.50 40341.30  RPL26 32802.40 22445.70 
FARSLB 40940.90 36440.40  UBC 32759.00 31791.40 
LOC441034 40492.50 37365.00  TMSB10 32501.80 29645.80 
LOC647361 40446.20 35757.80  RPS6 32450.80 29818.00 
ENO1 40422.10 34189.40  AP2S1 32386.00 25093.50 
LOC440733 40349.50 31350.00  RPL12 32379.10 27526.40 
LOC284821 40163.80 37925.40  LOC401019 32346.90 27549.60 
 
 
 205 
mRNA hMSC 1 hMSC 2 
 
mRNA hMSC 1 hMSC 2 
IFITM2 32174.80 28578.60  LOC645895 26333.90 21039.90 
LOC654194 32154.20 23750.80  UBA52 26325.20 24894.40 
RPS19 32091.40 25772.20  SERF2 26193.40 17737.90 
IGFBP7 31928.50 25748.80  LOC646200 26154.40 19354.70 
GNB2L1 31923.20 29496.40  LOC643284 26150.00 22541.80 
ATP5A1 31873.60 28335.90  NDUFB8 26031.30 21160.80 
RPS14 31593.20 23667.50  FAU 25791.60 17882.20 
RPL11 31227.60 26740.90  HIST1H4C 25726.60 19043.10 
LOC400721 30940.10 26476.60  GPX4 25543.00 17509.30 
LOC644863 30931.50 25406.40  RPSA 25495.60 26321.50 
RPS27 30692.60 27106.00  LOC645436 25299.00 21765.40 
PITX1 30676.30 27358.30  LASP1 25287.30 24221.70 
MDH2 30458.00 23025.60  LOC646766 25189.30 17153.00 
SNRPG 30433.70 20326.10  LOC651436 25181.80 21790.80 
LOC388654 30279.60 22803.90  LOC649150 24972.60 26142.60 
LOC646483 30207.30 25918.70  MYH9 24934.90 17514.70 
LOC399900 30089.10 25238.90  DAD1 24904.60 17933.70 
RPL3 30031.70 24617.40  PSMB1 24822.40 19441.00 
SEC61G 29935.80 19269.80  JTB 24766.10 19060.00 
COX6B1 29931.00 20458.40  LOC647000 24748.50 20910.40 
NDUFA4 29714.20 19586.80  RPS27A 24739.10 21152.20 
TUBA1A 29714.20 25197.50  LOC729603 24691.30 21530.50 
COX7A2 29680.80 23330.60  HSPA8 24604.50 20701.30 
UQCRQ 29602.20 20913.20  COX8A 24568.80 18256.30 
ANXA5 29581.80 29657.30  HSP90B1 24413.10 22527.70 
PRDX1 29459.30 23393.70  NOLA3 24355.90 18542.70 
NDUFS5 29283.40 23490.40  ANP32B 24238.00 20205.60 
LOC650646 29161.10 24976.40  RPS9 24217.70 18962.70 
CHCHD2 29033.00 22396.90  BTF3 24114.90 17841.90 
MFGE8 28953.60 28580.70  CCNI 23943.70 22669.20 
LOC644039 28755.00 23951.40  EMP3 23858.10 18906.60 
RPS29 28745.20 26481.90  TMSB4X 23826.10 23471.20 
LOC653232 28568.40 26674.80  SOD1 23812.60 19186.00 
LOC441087 28504.80 25464.60  CTHRC1 23765.50 17143.80 
CCND1 28469.10 25061.60  LOC388524 23673.90 23228.80 
RPL36AL 28392.10 21351.80  RPS13 23590.90 17403.20 
RPL35 28328.00 21223.40  EEF2 23518.60 19611.80 
RPS20 28303.10 20871.80  CAP1 23223.90 15828.40 
RPS17 28245.50 26134.90  LOC441775 23126.50 21079.80 
EIF3E 28203.40 24394.90  REXO2 23118.50 16555.00 
ATP5H 28141.00 19754.80  FTHL7 23077.80 22468.10 
GAPDH 28109.30 23311.20  NEDD8 22898.30 19076.40 
RPL17 27969.40 22216.10  39700 22865.30 18241.70 
RPL21 27623.50 20204.70  CFL1 22663.90 19744.60 
RPL6 27617.70 26935.10  RPL41 22623.70 21692.00 
MTCH1 27484.60 21847.10  CLIC1 22439.30 16851.80 
DYNLL1 27438.20 19521.40  JUND 22387.10 16473.80 
TGFBI 27401.30 23829.50  LOC642250 22182.10 18387.40 
LOC648000 27387.20 20663.50  RPL8 22131.30 19362.70 
CTGF 27149.00 23402.80  F2R 21915.10 22822.70 
TBCA 27146.30 21420.30  LOC646531 21894.80 18092.00 
NACA 27142.10 22482.60  RPS18 21827.30 15592.80 
S100A6 26956.70 21856.10  RPS15A 21780.70 17623.20 
C17ORF45 26807.80 21983.50  RND3 21762.50 17951.50 
SFRP1 26778.50 24293.10  RPS26L 21731.60 14370.60 
YWHAQ 26712.30 23931.30  C14ORF156 21703.10 17128.50 
ADM 26667.80 24080.30  EIF4A2 21666.70 15232.80 
TPM2 26522.20 26625.80  CDC37 21632.10 21049.60 
NDUFA1 26482.50 21823.30  LOC653314 21447.70 16405.40 
LOC91561 26456.00 23921.70  CNN3 21421.10 16855.80 
PSMB6 21379.20 16076.40  GSTO1 18941.80 15182.70 
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mRNA hMSC 1 hMSC 2 
 
mRNA hMSC 1 hMSC 2 
SLC25A5 21297.00 18717.30  ROCK2 18933.20 16670.00 
C20ORF52 21291.80 13043.00  CSTB 18907.00 14129.50 
SEC61B 21289.00 14743.50  LOC391656 18881.30 11534.90 
GSTP1 21184.90 18494.70  COL4A1 18840.30 13966.80 
LOC649049 21105.50 16627.30  VDAC1 18820.50 14624.40 
RPS4X 21051.80 17493.40  TXNDC17 18773.50 13667.60 
LRAP 20823.10 18055.60  PEA15 18731.40 16370.00 
C11ORF10 20762.40 14998.10  CKAP4 18729.20 15449.30 
RPS27L 20760.40 15329.90  P4HB 18709.30 15108.80 
CLDN11 20757.20 16059.10  COX5A 18670.30 12105.80 
YWHAH 20714.70 17801.30  LOC647340 18627.50 13785.90 
RPLP1 20590.60 15475.40  UCHL1 18458.90 14951.70 
LOC642817 20556.40 19638.40  LAIR1 18423.20 20656.70 
TMED3 20528.70 18675.60  LOC402251 18416.80 15539.30 
PPA1 20449.80 17423.00  B2M 18369.50 16292.90 
COL5A2 20447.40 19096.00  PSMB7 18366.60 17357.80 
SNRPD2 20420.70 15678.70  THBS1 18349.10 12554.50 
LOC285053 20380.60 15409.60  SFRS9 18311.30 15539.80 
ORC6L 20375.10 18072.40  BGN 18226.90 16252.40 
ARPC3 20354.70 17376.20  TM4SF1 18213.90 16438.60 
LOC285176 20345.90 21529.80  NAG18 18209.10 16199.00 
ATP6V0E1 20336.80 16044.40  TMEM14C 18110.30 15314.00 
C13ORF15 20283.10 16145.40  SERPINE2 18059.60 16097.60 
RPL4 20274.00 17197.30  MDH1 17991.70 14147.60 
LOC646630 20252.40 13330.20  DCN 17990.30 13662.00 
LOC644029 20243.90 18424.40  HLA-A 17981.20 14725.50 
CAMK2N1 20242.40 16270.80  M6PRBP1 17942.90 15979.40 
C19ORF31 20218.20 18638.40  COL3A1 17830.90 12658.80 
KPNB1 20218.00 15070.20  MGC16703 17759.70 15727.10 
ARID5B 20217.30 17486.90  ATP5O 17719.30 14140.90 
TPI1 20186.50 15766.50  LSM1 17716.10 15474.40 
LOC390354 20176.10 15184.50  LOC645317 17515.00 13842.80 
LOC134997 20157.20 15402.80  HMGN1 17487.60 14904.60 
NUCB1 20155.60 16198.20  ARF4 17463.90 15314.60 
PALLD 20115.00 14439.10  PFDN5 17394.00 12887.70 
MIF 20040.30 12884.60  C20ORF24 17250.30 13732.60 
HSPB1 19979.80 17713.20  DNAJA1 17241.50 15421.10 
FSCN1 19934.30 19042.10  PSMB3 17234.60 11054.10 
PRDX5 19844.60 15419.80  LOC402057 17198.80 12658.30 
LOC440567 19796.50 13973.10  LOC643433 17192.30 13664.90 
MRPS6 19789.60 14660.70  IL18 17152.70 14471.00 
LOC649821 19772.30 13674.50  COX5B 17139.70 12129.00 
AMY1C 19765.50 15711.30  LOC387882 17124.00 13764.80 
HEXB 19686.10 19378.80  PCBP2 17100.90 13306.60 
LOC649447 19543.40 12532.30  LOC647856 17077.10 13792.10 
LOC387841 19532.20 16168.50  DNAJC8 17039.20 15683.60 
TUBB 19508.70 19559.60  MGST3 16948.60 11542.80 
ANXA2 19471.20 17240.60  NDUFA11 16909.90 10796.50 
TAGLN 19441.20 19870.20  SSR4 16890.90 11429.80 
GNB1 19423.50 15713.10  LOC645385 16871.00 15544.80 
MSH3 19320.20 16122.30  PHLDA1 16861.70 12103.00 
UQCRFS1 19304.90 14187.80  COX6C 16829.90 13314.20 
TMEM59 19300.50 16691.60  CAV1 16777.60 15229.10 
ZFAND5 19300.10 16586.50  RAI14 16768.50 13634.00 
SPCS1 19147.40 13982.60  LOC440926 16768.40 12838.50 
DDX5 19115.30 15292.20  SEC11A 16725.90 13805.80 
PRDX4 19096.10 13956.90  PSMA6 16724.40 13696.70 
GAS6 19005.10 13837.10  SCD 16669.30 12586.90 
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Supplementary Table S3. RNAs isolated from Ago2 immunoprecipitation 
from human mesenchymal stem cells. A list of all mRNAs isolated from Ago2 
immunoprecipitation and detected by microarray analysis is listed below. An average 
signal of 150.00 (arbitrary units) was taken as the threshold above background and 
mRNAs detected below this signal are not included.  
 
 
TargetID 
 
Target description 
 
Ago2 IP ave. 
signal 
LAIR1 Leukocyte-associated immunoglobulin-like receptor 1 3986.1 
F2R Coagulation factor II (thrombin) receptor (F2R) 1894.1 
IMAA SLC7A5 pseudogene (IMAA) 1499.2 
C19ORF31 Chromosome 19 open reading frame 31 1326.4 
FARSLB 
Brain cDNA clone: QmoA-12104, similar to human phenylalanine-tRNA 
synthetase-like, beta subunit(FARSLB), mRNA, RefSeq: NM_005687.2 1127.3 
NAG18 NAG18 mRNA 935.9 
CLUAP1 Clusterin associated protein 1 918.2 
RN7SL1 RN7SL1 RNA, 7SL, cytoplasmic 1 808.6 
BCYRN1 
Brain cDNA clone: QflA-18095, similar to human brain cytoplasmic RNA 1, 
Bc1 analog (mouse) (BCYRN1) onchromosome 2, RefSeq: NR_001568.1 681.6 
AKR1D1 
Aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-beta-
reductase) 652.3 
KIAA0101 KIAA0101 (KIAA0101) 560.9 
LOC441087 LOC441087 hypothetical gene supported by AK125735 [ Homo sapiens ] 542.6 
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 526.3 
HS.573763 Transcribed locus 516.8 
ORC6L Origin recognition complex, subunit 6 like (yeast) 497.3 
LRAP Endoplasmic reticulum aminopeptidase 2 472 
LOC400721 Transcribed locus 456.6 
MSH3 MutS homolog 3 (E. coli) 445 
LOC645895 V-myb myeloblastosis viral oncogene homolog (avian)-like 1 420.9 
LILRB3 
Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM 
domains), member 3 396.6 
CCR6 Chemokine (C-C motif) receptor 6 390.3 
HS.579631 Small ILF3/NF90-associated RNA A1 (SNAR-A2) 379.2 
LOC729603 Calcium binding protein P22 pseudogene 378.1 
PDCD7 Programmed cell death 7 374.7 
XPNPEP3 X-prolyl aminopeptidase (aminopeptidase P) 3, putative 365.4 
GGA1 Golgi associated, gamma adaptin ear containing, ARF binding protein 1 363.3 
MGC16703 Tubulin, alpha pseudogene 324.7 
RPL7L1 Ribosomal protein L7-like 1 302.5 
ZMAT3 Zinc finger, matrin type 3 301.2 
LOC399900 Hypothetical gene supported by AK093779 294.7 
LOC643509 LOC643509 similar to Dihydrofolate reductase 286.2 
C14ORF24 family with sequence similarity 177, member A1 [Homo sapiens] 277.3 
SHCBP1 SHC SH2-domain binding protein 1 271.6 
ITIH5 Inter-alpha (globulin) inhibitor H5 267.1 
HS.539765 Transcribed locus 254.9 
FKTN Fukutin 249.5 
RPL18A Ribosomal protein L18a 226.3 
LOC388474 Similar to ribosomal protein L7a 225.9 
COX6C Cytochrome c oxidase subunit VIc 225.6 
MGC29891 GA binding protein transcription factor, beta subunit 2 225.6 
SLC44A4 Solute carrier family 44, member 4 223.5 
IL18 Interleukin 18 (interferon-gamma-inducing factor) 219.3 
PNPT1 Polyribonucleotide nucleotidyltransferase 1 217.9 
HS.560726 Transcribed locus 212.5 
GFRA2 GDNF family receptor alpha 2 208.1 
HS.538554 Transcribed locus 201.2 
SALL3 Sal-like 3 (Drosophila) 200.7 
LOC643031 similar to NADH dehydrogenase subunit 5 [Homo sapiens] 199.6 
BGN Biglycan 196 
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TargetID 
 
Target description 
 
Ago2 IP ave. 
signal 
GJC1 Gap junction protein, gamma 1, 45kDa 193.8 
DUSP19 Dual specificity phosphatase 19 190.1 
LOC654155 Transcribed locus 190.1 
DIS3L2 DIS3 mitotic control homolog (S. cerevisiae)-like 2 189.2 
LILRB1 
Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM 
domains), member 1 186.5 
C3ORF34 Chromosome 3 open reading frame 34 186.4 
LOC649661 Transcribed locus 185.1 
HS.508682 Transcribed locus 184.1 
C21ORF24 Non-protein coding RNA 114 183.5 
SKI V-ski sarcoma viral oncogene homolog (avian) 181 
PDE4C 
Phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce 
homolog, Drosophila) 180.7 
RBBP4 Retinoblastoma binding protein 4 180.7 
SLC16A12 Solute carrier family 16, member 12 (monocarboxylic acid transporter 12) 179.7 
HS.516420 Chromosome 1 open reading frame 46 177.6 
CREB1 CAMP responsive element binding protein 1 176.9 
HS.580452 Transcribed locus 175.4 
HS.442696 Hypothetical protein LOC100132959 175.3 
LOC642947 Hypothetical protein LOC642947 174.3 
C8ORF37 Chromosome 8 open reading frame 37 173.2 
AKR7A2 Aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) 172.4 
HS.374221 CDNA clone IMAGE:5787947 171.4 
LOC645683 Ribosomal protein L13a pseudogene 171.3 
RPLP2 Ribosomal protein, large, P2 170 
PSMD12 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 169.8 
SUV39H2 Suppressor of variegation 3-9 homolog 2 (Drosophila) 169.6 
HS.336511 Transcribed locus 168.5 
HS.439692 Transcribed locus 167.8 
EFNA4 Ephrin-A4 167.5 
RNASE10 Ribonuclease, RNase A family, 10 (non-active) 167.5 
C9ORF80 Chromosome 9 open reading frame 80 167.2 
KCNH6 Potassium voltage-gated channel, subfamily H (eag-related), member 6 166 
PLK1 Polo-like kinase 1 (Drosophila) 165.7 
TMEM49 Transmembrane protein 49 165.6 
HS.442504 Transcribed locus 164.8 
ZNF549 Zinc finger protein 549 163.8 
VIPR1 Vasoactive intestinal peptide receptor 1 163.5 
ZNF486 Zinc finger protein 486 163.3 
BAT2D1 BAT2 domain containing 1 162.3 
HS.537603 Transcribed locus 162 
C10ORF91 Chromosome 10 open reading frame 91 161.1 
HS.123511 Transcribed locus 160.7 
CDKN2AIPNL CDKN2A interacting protein N-terminal like 160.6 
CTSD Cathepsin D 159.1 
HS.565250 Transcribed locus 158.9 
HS.211930 
Transcribed locus, strongly similar to XP_531205.1 PREDICTED: 
hypothetical protein [Pan troglodytes] 158.6 
HS.566890 Transcribed locus 157.8 
HS.98466 Transcribed locus 157.4 
COL8A2 Collagen, type VIII, alpha 2 157 
ZNF430 Zinc finger protein 430 156.6 
HS.576373 Transcribed locus 156.4 
AIRE Autoimmune regulator 156.2 
IRF3 Interferon regulatory factor 3 155.5 
TMEM177 Transmembrane protein 177 155.4 
HS.426929 Transcribed locus 155.1 
HS.471011 Transcribed locus 154.6 
HS.557481 Transcribed locus 154.3 
LOC642017 Transcribed locus 154.2 
HS.563639 Transcribed locus 153.7 
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TargetID 
 
Target description 
 
Ago2 IP ave. 
signal 
HNRPR Heterogeneous nuclear ribonucleoprotein R 153.6 
HS.245405 Transcribed locus 153.5 
HS.529324 Transcribed locus 153.4 
UBXD3 UBX domain containing 3 153.2 
STX10 Syntaxin 10 153.1 
LOC653635 Transcribed locus 153 
HS.97408 Hypothetical protein LOC338864 153 
LOC643932 similar to ribosomal protein S3A [Homo sapiens] 152.2 
LOC402066 Transcribed locus 152.1 
SEPW1 Selenoprotein W, 1 151.8 
HS.582701 Transcribed locus 151.5 
HS.207604 Transcribed locus 150.2 
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Supplementary Table S4. Human embryonic stem cell miRNAs and their 
host mRNAs. List of all microRNAs cloned from human embryonic stem cells with a 
sequencing frequency ≥5. Host mRNA (Host) ID and average expression levels (ave. 
signal) as detected by microarray are given where relevant, na = not applicable, U = 
unclassified EST ( -1, -2 matches the microRNA nomenclature e.g. miR-103-1, miR-
103-2 etc.).  
 
 
miRNA ES1   Host -1 ave. signal Host -2 ave. signal 
302a* 2370 
  U     
130a 1006 
  na     
182 905 
  na     
423-5p 717 
  CCDC55 352.30    
151-3p 663 
  PTK2 3410.40    
103 539 
  PANK3 416.50 PANK2 1826.90 
378 488 
  PPARGC1B 183.50    
340 474 
  RNF130 1660.90    
21 445 
  na     
320a 413 
  na     
101 397 
  na  RCL1 652.40 
183 350 
  na     
130b 321 
  PPIL2 118.50    
335 176 
  MEST 619.50    
191 156 
  DALRD3 249.10    
30e* 151 
  NFYC 704.60    
148a 142 
  na     
221* 117 
  na     
302b 115 
  U     
30a* 109 
  C6ORF155 98.90    
302a 105 
  U     
25 104 
  MCM7 2891.90    
93 89 
  MCM7 2891.90    
31 83 
  U     
302d 75 
  U     
106b 71 
  MCM7 2891.90    
302c 68 
  U     
17 66 
  C13ORF25 264.00    
140-3p 79 
  WWP2 618.70    
1323 58 
  na     
503 48 
  MGC16121 190.40    
28-3p 47 
  LPP 4342.80    
99b 47 
  na     
302d* 46 
  U     
367 45 
  U     
30a 44 
  C6ORF155 98.90    
1308 43 
  na     
532 42 
  CLCN5 138.00    
26a 38 
  CTDSPL 1321.90 CTDSP2 1969.00 
185 35 
  C22ORF25 221.90    
20b 33 
  na     
25* 33 
  MCM7 2891.90    
708 31 
  na     
374b 31 
  na     
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miRNA ES1   Host -1 ave. signal Host -2 ave. signal 
16 30 
  DLEU2 152.30 SMC4 874.60 
744 30 
  MAP2K4 477.20    
29a 30 
  na     
30d 30 
  na     
222 28 
  na     
1270 27 
  ZNF826 108.60    
1275 26 
  na     
124 25 
  na  na  
141 25 
  na     
92b 25 
  na     
24 24 
  C9ORF3 147.10 na  
374a 24 
  U     
548f 24 
  PCDH15 97.10 ERBB4 123.70 
221 22 
  na     
92b* 22 
  na     
219-2-3p 20 
  na     
let-7a 20 
  na  na  
92a 18 
  C13ORF25 264.00 na  
151-5p 17 
  PTK2 3410.40    
30c-2* 16 
  C6ORF155 98.90    
708* 16 
  na     
106b* 15 
  MCM7 2891.90    
193a-3p 15 
  na     
28-5p 13 
  LPP 4342.80    
128 12 
  R3HDM1 215.30 ARPP-21 103.90 
363 12 
  na     
769-5p 11 
  na     
107 10 
  PANK1 602.20    
210 10 
  na     
1260 10 
  na     
19b 10 
  C13ORF25 264.00 na  
96 9 
  na     
421 9 
  na     
200c 9 
  na     
1 8 
  C20ORF166 84.90    
192 8 
  na     
424 8 
  U     
20a 8 
  C13ORF25 264.00    
186 7 
  ZRANB2 2422.40    
941 7 
  DNAJC5 229.40 DNAJC5 229.40 
1298 7 
  HTR2C 141.20    
27b 7 
  C9ORF3 147.10    
23b 6 
 C9ORF3 147.10   
92a-1* 6 
  C13ORF25 264.00    
375 5 
  na     
1826 5 
  na     
181a 5 
  U  U  
18a 5 
  C13ORF25 264.00    
302b* 5 
  U     
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MicroRNAs with additional host mRNAs (e.g. miR-941-3, miR-941-4 etc.) are listed 
below as a continuation of the above list.  
 
miRNA ES1   Host -3 
ave. 
signal Host -4 
ave. 
signal Host -5 
ave. 
signal 
548f 24 
  na  na  DMD 166.50 
let-7a 20 
  U       
941 7 
  DNAJC5 229.40 DNAJC5 229.40   
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Supplementary Table S5. Human neuronal progenitor stem cell miRNAs 
and their host mRNAs. List of all microRNAs cloned from human neuronal 
progenitor stem cells with a sequencing frequency ≥5. Host mRNA (Host) ID and 
average expression levels (ave. signal) as detected by microarray are given where 
relevant, na = not applicable, U = unclassified EST ( -1, -2 matches the microRNA 
nomenclature e.g. miR-103-1, miR-103-2 etc.).  
 
 
miRNA NS 
  
Host -1 ave. signal Host -2 ave. signal 
let-7f 4356 
  na  HUWE1 238.20 
let-7a 3701 
  na  na  
21 3162 
  na     
423-5p 2418 
  CCDC55 385.30    
9* 1299 
  C1ORF61 34425.20 na  
92b 885 
  na     
9 870 
  C1ORF61 34425.20 na  
101 768 
  na  RCL1 413.50 
151-3p 761 
  PTK2 3408.00    
130a 689 
  na     
340 682 
  RNF130 1683.20    
29a 559 
  na     
let-7c 481 
  C21ORF34 665.50    
320a 448 
  na     
103 427 
  PANK3 168.50 PANK2 835.60 
26a 393 
  CTDSPL 478.50 CTDSP2 2810.60 
let-7b 371 
  U     
let-7e 326 
  na     
24 297 
  C9ORF3 196.90 na  
125b 297 
  na  C21ORF34 665.50 
378 280 
  PPARGC1B 149.40    
130b 268 
  PPIL2 110.70    
30e* 222 
  NFYC 456.10    
210 209 
  na     
30d 207 
  na     
let-7g 199 
  WDR82 2258.40    
100 197 
  na     
let-7d 190 
  na     
92b* 188 
  na     
16 175 
  DLEU2 131.10 SMC4 410.60 
27b 170 
  C9ORF3 196.90    
140-3p 169 
  WWP2 227.00    
181a 168 
  U  U  
25 166 
  MCM7 1275.70    
let-7i 153 
  na     
7 150 
  HNRPK 2797.30 na  
744 135 
  MAP2K4 359.70    
221* 134 
  na     
30a* 131 
  C6ORF155 88.70    
99b 124 
  na     
30a 116 
  C6ORF155 88.70    
191 114 
  DALRD3 294.70    
335 101 
  MEST 107.50    
106b 88 
  MCM7 1275.70    
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miRNA NS 
  
Host -1 ave. signal Host -2 ave. signal 
146b 88 
  na     
148a 85 
  na     
93 72 
  MCM7 1275.70    
532 68 
  CLCN5 135.20    
28-3p 58 
  LPP 2796.30    
151-5p 57 
  PTK2 3408.00    
185 54 
  C22ORF25 456.30    
23a 53 
  na     
128 49 
  R3HDM1 220.00 ARPP-21 101.30 
99a 44 
  C21ORF34 665.50    
27a 43 
  na     
222 42 
  na     
17 41 
  C13ORF25 180.90    
25* 39 
  MCM7 1275.70    
374b 38 
  na     
374a 35 
  U     
26b 34 
  CTDSP1 618.50    
92a 34 
  C13ORF25 180.90 na  
181b 32 
  U  U  
769-5p 29 
  na     
941 27 
  DNAJC5 244.20 DNAJC5 244.20 
15a 24 
  DLEU2 131.10    
124 23 
  na  na  
1274b 22 
  na     
107 21 
  PANK1 449.60    
379 21 
  na     
135b 20 
  LEMD1 1779.80    
148b 20 
  COPZ1 2367.80    
20a 20 
  C13ORF25 180.90    
23b 20 
  C9ORF3 196.90    
30c-2* 19 
  C6ORF155 88.70    
98 18 
  HUWE1 238.20    
1260 18 
  na     
1275 18 
  na     
138 17 
  na  na  
195 17 
  U     
221 17 
  na     
542-3p 16 
  na     
29c 15 
  na     
720 14 
  na     
10a 14 
  na     
30e 13 
  NFYC 456.10    
450b 12 
  na     
153 11 
  PTPRN 91.90 PTPRN2 228.60 
186 11 
  ZRANB2 1837.30    
19b 11 
  C13ORF25 180.90 na  
28-5p 9 
  LPP 2796.30    
125b-2* 8 
  C21ORF34 665.50    
22 7 
  C17ORF91 451.90    
421 7 
  na     
30b 7 
  na     
424 6 
  U     
324-5p 6 
  na     
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miRNA NS 
  
Host -1 ave. signal Host -2 ave. signal 
532-5p 6 
  CLCN5 135.20    
125a-5p 5 
  na     
342-3p 5 
  EVL 8128.60    
 
 
 
MicroRNAs with additional host mRNAs (e.g. miR-941-3, miR-941-4 etc.) are listed 
below as a continuation of the above list.  
 
miRNA NS 
  
Host -3 ave. signal Host -4 ave. signal 
let-7a 3701 
  U     
9* 1299 
  na     
9 870 
  na     
7 150 
  C19ORF30 251.10    
941 27 
  DNAJC5 244.20 DNAJC5 244.20 
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Supplementary Table S6. Novel and PIWI-interacting RNAs isolated from 
human embryonic and neuronal progenitor stem cells. The putative novel miRNA 
designated novel-cfa-1839 and all the piwi-interacting RNAs isolated from the human 
embryonic and neuronal progenitor stem cells are listed below. Total sequencing 
numbers include any length variant sequences detected. 
 
 
 
Novel miR- sequence length location ES NS 
Novel-cfa-
1839 AAGGTAGATAGAACAGGTCTTG 22 15(+)81221815:81221836     25 35 
 
 
 
 
piRNA ES NS 
hsa_piR_000045 23 140 
hsa_piR_004987 3 6 
hsa_piR_008112 2 8 
hsa_piR_008113* 2 8 
hsa_piR_012753 4 18 
hsa_piR_016658 132 60 
hsa_piR_016735 21 17 
hsa_piR_018780 180 435 
hsa_piR_018849 4 5 
hsa_piR_020497 3 9 
hsa_piR_020813 0 6 
dme_piR_021108 60 29 
dr_piR_0011727 4 4 
dr_piR_0022572 15 4 
dr_piR_0025349 6 5 
dr_piR_0029287 22 174 
dr_piR_0038184 106 9 
mmu_piR_000580 5 4 
mmu_piR_000634 6 0 
mmu_piR_022877 9 22 
mmu_piR_038322 46 8 
ona_piR_137996 7 4 
rno_piR_005359 13 2 
rno_piR_005595 7 11 
rno_piR_012452 4 4 
 
* is identical and maps to the same location as miRNA miR-let-7a-1
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Supplementary Table S7. 10-Fold up-regulated mRNAs detected by 
microarray in human embryonic and neuronal progenitor stem cells. The 
mRNAs that were up-regulated in ESCs (red) and NSCs (blue) by a minimum of 10-
fold are listed below with their relative microarray detection signals (arbitrary units). 
Two technical repeats was performed for each sample.  
 
 
mRNA ESC 1 ESC 2   mRNA NSC 1 NSC 2 
ZIC2 24323.80 20584.10   FABP7 37440.20 28064.30 
LIN28 18708.90 16735.80   C1ORF61 34425.20 24907.90 
DPPA4 21988.50 18532.80   HLA-DRA 34000.50 23127.60 
LOC642559 25550.90 21503.80   SCRG1 23231.40 15931.60 
LOC643272 16285.40 12236.60   SYT11 21249.00 16259.50 
LOC645682 13245.00 9358.70   ID3 18399.90 11837.50 
GAL 17198.70 12362.40   TTYH1 17913.10 11821.30 
CNTNAP2 12591.40 9351.20   HES5 16257.00 11282.30 
POU5F1P1 9987.60 7424.40   IGFBP5 15408.30 9868.10 
CDH1 9878.70 7679.70   PMP2 14748.60 9525.50 
C17ORF92 8008.70 5958.50   CRYAB 14402.00 9448.30 
LEFTY1 7883.60 6170.90   GFAP 13446.90 10100.30 
SPINT2 8816.90 6909.30   LOC730994 13253.10 8532.10 
SCNN1A 5807.20 4714.50   GABBR2 12076.90 9439.60 
NTS 6125.50 4773.10   HLA-DPA1 11535.10 8416.30 
OCIAD2 6934.40 5156.50   ASCL1 10541.30 7984.50 
ZSCAN10 6021.70 4855.40   LHX2 10430.90 7571.70 
TACSTD1 10365.20 8341.30   GPR56 9814.40 6865.90 
RARRES2 5795.80 5664.60   TSPO 8252.80 5003.80 
LOC652097 5699.60 4814.70   ARHGEF6 8140.50 6099.40 
HS.574590 4429.00 3249.70   DKK3 7699.00 5024.70 
TRIML2 5132.70 4063.10   SPARCL1 7012.10 5026.00 
ZIC3 4691.20 4408.10   ELMOD1 7005.30 4417.00 
H1F0 4500.10 3502.10   CD44 6997.30 5138.50 
HS.129302 5601.20 4320.60   STS-1 6887.60 5108.60 
RPRM 5735.10 4307.60   TAGLN3 6667.80 4901.70 
CYBA 4621.20 3949.30   SLC1A3 6391.10 4418.10 
C9ORF135 5448.20 4351.70   SCG2 6247.80 4208.70 
POU5F1 5915.90 4837.40   PMP22 6109.10 4184.60 
ALPL 9154.00 7186.00   TXNIP 5699.90 3501.30 
NMU 3662.50 3296.50   ALPK2 5463.70 3855.30 
NANOG 4205.50 3075.70   HS.202577 5259.50 3694.70 
ITGB1BP3 4391.70 3537.60   TRIM9 5253.30 3560.80 
HS.575696 3501.20 2231.80   RGL1 5133.00 3330.40 
NODAL 4464.00 3364.20   HLA-DQA1 5128.60 2952.20 
WDR72 3132.00 2482.80   NFIX 5092.40 3633.50 
L1TD1 4217.10 2949.70   EFEMP2 4966.40 3738.60 
COL5A2 6218.60 4992.20   LOC650494 4960.90 2925.30 
EPHA1 3190.50 3083.50   DLX1 4850.60 3414.20 
LIN28B 4311.40 4251.10   LOC646345 4783.00 3032.60 
HTATIP2 2827.30 2345.50   CA12 4757.30 3557.70 
KRT19 2609.40 1956.80   COMT 4753.70 3187.90 
SALL4 4493.30 4305.40   NCAN 4695.60 3858.50 
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SFRP2 2794.80 2340.90   CRIP2 4679.60 3287.30 
BAIAP2L1 2537.40 2267.80   RPE65 4619.90 2941.10 
ACTA1 2491.10 2065.60   HLA-DMB 4530.90 2912.70 
RAB25 2873.50 2398.10   PITX1 4326.20 3263.90 
MYC 2745.10 2271.10   MGC33846 4259.10 2698.20 
CRABP2 6637.10 5122.20   S100A16 4256.80 2543.20 
MAL2 2126.10 1833.80   POU3F2 4115.00 2851.80 
MST4 3402.80 2872.40   COL8A1 4053.20 3076.40 
HS.276860 3187.60 2163.00   GPX3 3833.90 2884.10 
FLJ22662 2799.00 2499.60   TCTN1 3809.70 2294.80 
SOX15 2985.10 2483.60   SOX9 3804.80 2978.40 
ERVK6 2524.70 1938.00   OAF 3791.50 2652.90 
ACTG2 2850.70 2153.00   ITGB8 3751.40 2522.50 
CYP2S1 2573.50 2183.50   EFNA1 3665.30 2494.50 
PIM1 3878.60 2834.50   AGT 3598.50 2323.10 
LOC649970 3858.90 3197.40   BCHE 3482.50 2406.90 
HS.148659 2274.30 1728.10   PDGFRA 3411.30 2300.00 
CGNL1 6990.30 6099.70   NDUFA4L2 3397.30 2332.50 
VAMP8 4655.00 3989.60   HLA-DRB5 3365.70 1991.80 
DNMT3B 2835.60 2088.10   C14ORF152 3304.70 2300.80 
HERC5 1995.20 1870.30   EMP1 3284.30 2336.90 
GJA1 12235.00 8434.10   NDP 3255.40 2261.00 
SLC7A3 2366.70 1919.60   GPR177 3255.20 2219.40 
VASH2 2310.90 2095.10   LGALS3BP 3226.40 1788.90 
ZFP42 2233.00 1876.00   HLA-DRB4 3184.60 1781.20 
RAB17 1868.40 1680.00   CD74 3121.70 2155.10 
CTGF 7465.20 5988.60   HS.525171 3066.10 2129.00 
LECT1 2259.40 1838.80   GPM6A 2915.10 2065.80 
MT1G 5124.80 4302.30   PDLIM3 2846.00 1941.20 
UBE2E2 4790.70 3447.80   LGALS3 2727.90 2146.20 
LRAT 2084.50 1544.40   LHFP 2714.20 2320.50 
CLDN7 1749.80 1189.90   RFTN2 2691.30 1945.30 
COL1A2 2323.40 2115.20   FRMD4A 2675.80 2079.40 
CDH3 1869.60 1587.50   RUNX3 2668.70 1859.30 
HS.290255 1680.40 1611.30   IFI16 2659.30 2153.60 
ITM2A 1803.50 1376.00   HS.535825 2636.60 1861.70 
TAGLN 7704.50 6130.00   PCSK1N 2634.30 1587.30 
ARID3A 3220.40 2806.80   HS.193784 2614.10 1819.80 
LOC440132 2163.80 1871.90   RGS4 2583.20 1844.00 
STX3 2514.20 1893.90   DOCK10 2567.50 1868.10 
MICB 1777.10 1383.60   RHBDL3 2506.00 2216.50 
PRKCDBP 1724.00 1549.50   LOC442597 2499.10 1690.20 
HS.540043 1949.10 1564.80   HS.347185 2496.00 1419.30 
RBPMS2 15597.00 12973.40   FAM134B 2474.40 1746.20 
GCHFR 1976.50 1783.70   HSPB8 2474.00 1853.20 
ALDH1A3 1689.00 1410.20   HLA-DRB1 2371.90 1298.30 
CTSL2 3225.20 2518.70   GPR162 2350.70 1850.10 
ITPR3 3712.30 3545.60   HS.208066 2318.20 1619.40 
C1ORF85 3533.40 2855.70   JAM2 2295.10 1597.60 
OLFML3 2156.30 1767.00   A2M 2287.50 1804.20 
FAM83D 2852.90 2612.70   ZBTB20 2269.00 1615.80 
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FXYD5 3162.20 2592.00   C21ORF62 2134.30 1490.00 
SCGB3A2 1654.30 1280.90   CHRNA9 2040.30 1581.00 
KCNMB4 1710.50 1292.00   C11ORF70 2038.80 1386.60 
CPVL 1819.30 1431.90   IFIT2 1955.00 1587.50 
NELL2 1947.70 1861.80   PTGDS 1954.40 1315.00 
DMKN 1583.80 1318.90   LIMCH1 1944.90 1524.20 
CYP26A1 1428.50 1257.30   C15ORF52 1916.50 1508.40 
MAFB 1883.90 1639.80   GPC1 1914.90 1315.90 
TCEAL2 1218.20 1131.80   MGC42105 1889.00 1220.20 
ECHDC3 1292.50 1122.90   SLN 1864.70 1226.50 
LOC644743 2696.30 1825.50   HS.100261 1855.60 1269.00 
KIF1A 4510.30 4299.60   SERPINF1 1806.90 1338.60 
RASL11B 3122.70 2470.80   CSPG5 1732.20 1286.20 
CRABP1 15515.20 12584.60   PLEKHB1 1691.50 1260.40 
COL1A1 1645.60 1356.60   TH 1639.60 1310.80 
HS.270778 1241.30 1075.80   SLC25A18 1600.00 1213.30 
GPR160 1350.90 1088.50   EDNRB 1596.50 1158.60 
KRT8 3142.10 2442.00   SERPINA3 1542.40 1009.60 
ADAMTS19 1658.20 1549.00   METTL7B 1538.40 1079.00 
APOC1 1926.10 1790.50   EPHA3 1503.40 1040.20 
AURKB 5056.70 4029.50   MEIS1 1439.20 1103.10 
CDS1 1180.90 938.10   DMN 1406.80 905.20 
MT1E 1540.70 1360.90   PDE8B 1404.90 1229.40 
HS.561216 1282.00 1034.50   CITED1 1361.20 921.30 
GNA14 1308.70 901.50   GRIA2 1343.20 988.50 
BBS9 2502.90 1808.70   VCAM1 1336.00 1062.60 
SHISA2 1345.60 1107.00   RAB7B 1323.30 991.20 
LEFTY2 1776.30 1533.10   KCNIP1 1291.00 871.60 
CKMT1A 1447.40 1377.70   MTTP 1196.10 696.50 
HS.363526 2203.50 1690.20   SLC47A2 1110.10 760.50 
ECHDC2 1518.10 1259.20   OSR1 1109.90 851.20 
PROCR 1571.40 1290.40   RHOJ 1108.50 735.40 
CHST4 1111.20 889.40   BAI3 1077.10 870.80 
TRIM71 1219.60 1188.40   LMO1 1052.90 681.10 
AURKA 5788.00 4734.20   C18ORF51 1023.40 789.40 
PAK1 3027.20 2684.30   SARM1 990.50 693.90 
OVOL2 1078.30 856.90      
IFITM1 24937.30 22105.00      
F2RL1 2255.50 1798.90      
TOP2A 11109.30 9348.40      
LOC644919 1272.20 1124.70      
C1ORF59 1310.30 1111.90      
CORO2A 1465.30 1282.00      
TTK 3270.10 2943.40      
KIAA1324L 1124.10 959.10      
ABHD12B 1162.10 872.60      
ARID3B 3757.30 3199.90      
PRSS8 1656.60 1215.60      
NMRAL1 1668.40 1423.60      
PHF17 1855.80 1534.00      
USP44 1122.00 992.30      
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LOC283340 1004.80 746.60      
SH3GL3 1172.20 902.90      
GSTO2 2757.20 2313.70      
UBE2C 5701.90 4789.60      
QPRT 5820.10 4972.30      
DPPA2 1100.40 933.90      
ARMCX2 3358.70 2509.00      
RAD51AP1 4102.20 3113.70      
SILV 1142.90 956.60      
HJURP 2277.40 1693.70      
CDC20 10402.00 7748.50      
KIFC1 2500.60 2069.90      
SOX3 1671.00 1323.20      
TRIM6 1231.10 1000.30      
HMMR 2011.10 1892.70      
GPC4 6516.80 5435.10      
HOOK1 1167.00 1197.50      
FGD6 1075.60 938.00      
FST 1980.50 1712.90      
CD55 1024.40 789.50      
FRAS1 1043.00 927.60      
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Supplementary Table S8. Comparison of expression levels between 
intragenic microRNA and their host mRNA in human embryonic and neuronal 
progenitor stem cells. Intragenic miRNA expression levels as determined by Solexa 
sequencing frequency are listed against their host mRNA expression levels as 
determined by microarray detection.  
 
miRNA Host mRNA   ES Array signal   NS Array signal 
17 C13ORF25   66 264.00   41 180.90 
22 C17ORF91   0 121.50   7 451.90 
25 MCM7   104 2891.90   166 1275.70 
93 MCM7   89 2891.90   72 1275.70 
98 HUWE1   0 338.20   18 238.20 
107 PANK1   10 602.20   21 449.60 
185 C22ORF25   35 221.90   54 456.30 
186 ZRANB2   7 2422.40   11 1837.30 
191 DALRD3   156 249.10   114 294.70 
335 MEST   176 619.50   101 107.50 
340 RNF130   474 1660.90   682 1683.20 
378 PPARGC1B   488 183.50   280 149.40 
503 MGC16121   48 190.40   0 223.50 
532 CLCN5   42 138.00   68 135.20 
744 MAP2K4   30 477.20   135 359.70 
1270 ZNF826   27 108.60   0 122.00 
1298 HTR2C   7 141.20   0 96.40 
106b MCM7   71 2891.90   88 1275.70 
106b* MCM7   15 2891.90   0 1275.70 
125b-2* C21ORF34   0 106.60   8 665.50 
135b LEMD1   0 225.30   20 1779.80 
140-3p WWP2   79 618.70   169 227.00 
148b COPZ1   0 2187.00   20 2367.80 
151-3p PTK2   663 3410.40   761 3408.00 
151-5p PTK2   17 3410.40   57 3408.00 
15a DLEU2   0 152.30   24 131.10 
18a C13ORF25   5 264.00   0 180.90 
20a C13ORF25   8 264.00   20 180.90 
23b C9ORF3   0 147.10   20 196.90 
25* MCM7   33 2891.90   39 1275.70 
26b CTDSP1   0 229.40   34 618.50 
27b C9ORF3   7 147.10   170 196.90 
28-3p LPP   47 4342.80   58 2796.30 
28-5p LPP   13 4342.80   9 2796.30 
30a C6ORF155   44 98.90   116 88.70 
30a* C6ORF155   109 98.90   131 88.70 
30c-2* C6ORF155   16 98.90   19 88.70 
30e NFYC   151 704.60   228 456.10 
30e* NFYC   0 704.60   7 456.10 
342-3p EVL   0 4406.30   5 8128.60 
423-5p CCDC55   717 352.30   2418 385.30 
532-5p CLCN5   0 138.00   6 135.20 
92a-1* C13ORF25   6 264.00   0 180.90 
99a C21ORF34   0 106.60   44 665.50 
let-7c C21ORF34   0 106.60   481 665.50 
let-7g WDR82   0 1548.30   199 2258.40 
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Supplementary Table S9. Comparison of microRNAs detected by 
microarray and deep sequencing. All of the miRNAs detected on microarray 
(average of 4 technical repeats) for human mesenchymal (green), embryonic (red) and 
neuronal (blue) stem cells are listed below. Expression levels were determined based 
on the average signal intensity for the microarray (arbitrary units) and the sequencing 
frequencies for the deep sequencing libraries.  
 
 
miRNA 
MSC 
Array  MSC 
ESC 
Array  ESC 
NSC 
Array  NSC 
hsa-let-7a 50677.95 2052 12654.075 20 54860.7 3701 
hsa-let-7b 14121.8 211 30.55  36068.35 371 
hsa-let-7c 5960.075 76 621.75  24371.1 481 
hsa-let-7d 15404.275 1324 -2  19191.825 190 
hsa-let-7e 39405.825 151 2545.875  34664.2 326 
hsa-let-7f 33060.45 289 134.8  32837.5 4356 
hsa-let-7g 34049.55 171 400.725  37597.725 199 
hsa-let-7i 31411.4 54 885.75  42774.325 154 
hsa-miR-1 15.725  -20.85 8 -25.5  
hsa-miR-100 44327.65 65 725.05  30359.95 197 
hsa-miR-101 12492.675 4 29083.075 397 24895.975 768 
hsa-miR-103 17493.6 31 24485.05 539 20683.7 427 
hsa-miR-105 641.5  5110.95  943.55  
hsa-miR-106a 817.225 2 7094.325  3302.175  
hsa-miR-106b 22735.275 18 33722.825 71 29593.625 88 
hsa-miR-107 6692.5 7 7646.95 10 10969.2 21 
hsa-miR-10a 6500.55 35 -28.025  286.625 14 
hsa-miR-10b 346.15  14.225  5.175  
hsa-miR-122a 305.225 1 652.55  495.05  
hsa-miR-124a -27.6  14954.85 25 4247.975 23 
hsa-miR-125a 20968.425 3 18337.975  22600.725 5 
hsa-miR-125b 49091.675 97 2728.85  47174 297 
hsa-miR-126 4748.475 1 12579.05  8973.775  
hsa-miR-126* 2029.825  9565.475  1255.575  
hsa-miR-127 16318.9 10 24.55  905.7  
hsa-miR-128a 2060.825 1 1044.575 12 3738.675 49 
hsa-miR-128b 211.4  175.075  288.5  
hsa-miR-129 14410.25  21459.375  19731.3  
hsa-miR-130a 44552.5 151 44594.25 1006 34831.35 689 
hsa-miR-130b 11208 93 17183.275 321 15373.45 268 
hsa-miR-132 5304.525 16 1267.425  13350.65  
hsa-miR-133a 606.825  414.4  503.625  
hsa-miR-133b 34740.7  36794.5  33291.575  
hsa-miR-134 14540.075 3 130.1  920.475  
hsa-miR-135a 289.775  24623.5  21866.525  
hsa-miR-135b 783.475  21339.125  26742.85 20 
hsa-miR-136 23849.125 12 37.125  2202.65  
hsa-miR-137 10337.85 1 278.35  7689.225  
hsa-miR-138 1073.75 2 594  12782.65 17 
hsa-miR-139 246.1  312.1  2721.15  
hsa-miR-140 7720.875 9 6174.925 79 12784.525 169 
hsa-miR-141 3350.45  27173.15 25 4293.35  
hsa-miR-142-3p 790.05  864.075  5.4  
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hsa-miR-142-5p 173.65  206.525  20.5  
hsa-miR-143 39826.4 96 1363.25  1467.5  
hsa-miR-144 169.05  232.75  353.95  
hsa-miR-145 29266.85 113 4820.225  6588.1  
hsa-miR-146a 528.65 8 4157.1  313.75  
hsa-miR-146b 4618.925 8 350.225  6224.175 88 
hsa-miR-147 25.975  -30.65 142 -26.3  
hsa-miR-148a 3916.725  21887.775  12587.175 85 
hsa-miR-148b 2390.575  1487.725  4005.325 20 
hsa-miR-149 4903.7 1 3260.725  17005.4  
hsa-miR-150 218.375  384.075  285.65  
hsa-miR-151 13117.675 25 14688.35 663 15538.825 761 
hsa-miR-152 18987.375 31 755.65  1465.425  
hsa-miR-153 382.2  401.1  11318.6 11 
hsa-miR-154 7100.625 1 -22.775  271.775  
hsa-miR-154* 17975.95 1 34.625  912.775  
hsa-miR-155 11192.9 3 2848.2  3134.25  
hsa-miR-15a 22522.9 26 19524.3  26758.25 24 
hsa-miR-15b 28595.55 141 31041.25  31095.65  
hsa-miR-16 33470.275 113 30938.7 30 39673.525 175 
hsa-miR-17-3p 2466.55 127 12596.35  8465.4  
hsa-miR-17-5p 5750.675  19068.95 66 18983.425 41 
hsa-miR-181a 18670.35 3 10045.725 5 25458.4 168 
hsa-miR-181b 14295.75 12 8847.075  16927.875 32 
hsa-miR-181c 2788.7  682.275  7002.5  
hsa-miR-181d 62.175  -2.175  90.1  
hsa-miR-182 42.325  22607.525 905 550.475  
hsa-miR-182* 1438.225  10733.8  1836.95  
hsa-miR-183 -33.925  22018.3 350 81.975  
hsa-miR-184 -66.9  -57.375  -64.05  
hsa-miR-185 3777.975 15 2916.5 35 5273.175 54 
hsa-miR-186 6239.4 5 12251.4 7 9514.575 11 
hsa-miR-187 175.95  17810.025  601.425  
hsa-miR-188 2539.95  6546.75  3812.425  
hsa-miR-189 3242.925  955.825  4497.675  
hsa-miR-18a 16946.9 15 38555.775 5 21930.15  
hsa-miR-18a* 689.275  5288.3  2379.125  
hsa-miR-18b 286.925  14586.7  445.9  
hsa-miR-190 916.275  685.95  833.075  
hsa-miR-191 24217.1 637 28955.3 156 25474.45 114 
hsa-miR-191* 544.675  288.325 8 419.075  
hsa-miR-192 3925.925  3832.775  1714.625  
hsa-miR-193a 7616.95 107 5496.625 15 2711.675  
hsa-miR-193b 23021.425 4 24114.6  15935  
hsa-miR-194 5697.925 3 9248.95  5345.075  
hsa-miR-195 2889.275  5001.525  20078.525 17 
hsa-miR-196a 34.675  226.125  -13.025  
hsa-miR-196b 892.025  915.55  1152.925  
hsa-miR-197 16281.875 5 17750.975  18851.175  
hsa-miR-198 -5.6  -9.6  11.95  
hsa-miR-199a 27301.35 13 1310.925  252.15  
hsa-miR-199a* 26668.375  1990.05  2735.375  
hsa-miR-199b 19162.375 21 1529.8  616.55  
hsa-miR-19a 9019.325 1 26388.95  19549.3  
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hsa-miR-19b 19885.525 16 35596.35 10 27437.525 11 
hsa-miR-200a 210.05  2169.4  3593.625  
hsa-miR-200a* 231.05  258.775  405.825  
hsa-miR-200b 515.125  1369.95  4528.075  
hsa-miR-200c 1467.775  34012.075 9 4677.375  
hsa-miR-202 71.175 2 66.475  75.125  
hsa-miR-202* 79.95  201.25  208.2  
hsa-miR-203 -22.175  1284.325  -47.575  
hsa-miR-204 573.975 1 3831.975  11941.6  
hsa-miR-205 311.7  33060.45  339.95  
hsa-miR-206 107.1  73.575  101.85  
hsa-miR-208 7.95  -3.2  26.45  
hsa-miR-20a 32988.475 3 49359.65 8 48799.45 20 
hsa-miR-20b 523.5  30115.525 33 1272.175  
hsa-miR-21 60194.2 880 52609.8 445 60194.2 3162 
hsa-miR-210 2055.325  2778.075 10 12255.025 209 
hsa-miR-211 40.1  128.8  167.9  
hsa-miR-212 1149.675  157.95  1678.55  
hsa-miR-213 7328.275  1047.5  13512.025  
hsa-miR-214 32464.7 31 2370.6  751.2  
hsa-miR-215 166.275  154.875  254.6  
hsa-miR-216 124.825  71.25  17  
hsa-miR-217 119.3  -20.55  -30.625  
hsa-miR-218 2935.55 1 1643  2190.5  
hsa-miR-219 340.95  6430.125 20 3926.425  
hsa-miR-22 30307.65 429 12782  15207.325 7 
hsa-miR-220 123.15  58.05  115.975  
hsa-miR-221 39477.875 36 25553.5 22 26006.95 134 
hsa-miR-222 20364.1 50 9796.3 28 10672.95 42 
hsa-miR-223 571.95  483.8  1489.325  
hsa-miR-224 350.55  320.9  -61.975  
hsa-miR-23a 26093.75 1967 16084.35  24093.625 53 
hsa-miR-23b 32919.925 110 24750.55  33122.575 20 
hsa-miR-24 52338 118 30677.8 24 46004.6 297 
hsa-miR-25 14252.775 3 25050.35 104 22441.175 166 
hsa-miR-26a 46963.975 740 36383.825 38 47355.825 393 
hsa-miR-26b 26512.125 6 22229.9  30797.525 34 
hsa-miR-27a 39063.9 30 19838.35  31238.2 43 
hsa-miR-27b 22172.975 3 15095.35 7 23353.025 170 
hsa-miR-28 22810.25 32 22512.625 47 20893.95 58 
hsa-miR-296 2813.85  10342.325  398.75  
hsa-miR-299-3p 2886.425 3 67.525  193.275  
hsa-miR-299-5p 10111.975  7.85  389.6  
hsa-miR-29a 30970.425 179 9670.875 30 19366.95 559 
hsa-miR-29b 40844.925 33 18588.875  22539.675  
hsa-miR-29c 14901.775  2103.575  11835.65 15 
hsa-miR-301 9689.15 1 19389.2  17149.325  
hsa-miR-302a 516.225  47356.75 105 71.1  
hsa-miR-302a* 174.1  43426.75 2370 337.2  
hsa-miR-302b 861.925  60194.2 115 186.325  
hsa-miR-302b* 682.2  26043.15 5 2945.625  
hsa-miR-302c 86.025  49973.2 68 37.925  
hsa-miR-302c* 50.8  22406.575  39.325  
hsa-miR-302d 1048.025  55611 75 3440.575  
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hsa-miR-30a-3p 2351.925 20 843.675 109 1158.6 131 
hsa-miR-30a-5p 13044.35 27 12822.95 44 10988.725 116 
hsa-miR-30b 19321.275 1 20225.8  24234.9 7 
hsa-miR-30c 27631 9 28416.625 16 28497.9 19 
hsa-miR-30d 9292.15 24 12824.9 30 15605.2 207 
hsa-miR-30e-3p 10628.55 8 17613.975  17140.15 13 
hsa-miR-30e-5p 9731.1 5 17184.525 151 14990.1 222 
hsa-miR-31 20408.1 89 16818.925 83 1173.65  
hsa-miR-32 3300.975 2 12269.15  5048.675  
hsa-miR-320 25302.25 7 29382.825 413 27345.575 448 
hsa-miR-323 9541.05 1 60.275  684.775  
hsa-miR-324-3p 12181.5  13475.55  16779.8  
hsa-miR-324-5p 9696.075 3 5266.025  13482.975 6 
hsa-miR-325 25.4  -2.775  38.55  
hsa-miR-326 6605.125  21285.875  812.25  
hsa-miR-328 756.45  161.3  2420.7  
hsa-miR-329 11857.775 8 70.975  411.025  
hsa-miR-33 7106.975 4 19471.95  15485.825  
hsa-miR-330 2047.275 1 3370.075  2179.225  
hsa-miR-331 16975.875 1 23872.825  19617.1  
hsa-miR-335 18889.4 8 18710.875 176 11532.9 101 
hsa-miR-337 179.65 109 -15.975  3.8  
hsa-miR-338 296.6  1548.05  17866.125  
hsa-miR-339 6894.2 3 3073.65  10733.475  
hsa-miR-33b 247.4 1 288.375  521.6  
hsa-miR-340 1372.575  6937.2 474 9242.475 682 
hsa-miR-342 3485.25 3 4479.175  8904.05 5 
hsa-miR-345 1886.7 6 1538.875  3570.6  
hsa-miR-346 176.85  928.2  2973.6  
hsa-miR-34a 16959.65  15913.9  13570.475  
hsa-miR-34b 3896.65 1 1366.8  282.875  
hsa-miR-34c 3228.725  1083.95  223.475  
hsa-miR-361 14055 10 17211.45  18222.45  
hsa-miR-362 450.45  788  917.475  
hsa-miR-363 521.125  16336.05 12 781.2  
hsa-miR-363* 13077  18848.975  16739.6  
hsa-miR-365 7208.9 3 5530.125  4439.425  
hsa-miR-367 77.55  47921.875 45 57.025  
hsa-miR-368 24448.4  81.65  4593.05  
hsa-miR-369-3p 21105.325 30 1243.1  1093.875  
hsa-miR-369-5p 2471.425  506.3  857.975  
hsa-miR-370 22553.675 1 204.9  1912.775  
hsa-miR-371 121.15  3794.575  354.1  
hsa-miR-372 648.325  911.475  938.775  
hsa-miR-373 -53.2  2577.925  -52.7  
hsa-miR-373* -2.65  111.075  -13.6  
hsa-miR-374 23789.4 3 28475.925 24 25977.675 35 
hsa-miR-375 96.375  221.025 5 46.1  
hsa-miR-376a 19895.85 251 57.925  637.65  
hsa-miR-376a* 11020.05  208.125  753.775  
hsa-miR-376b 20926.075 167 495.95  1995  
hsa-miR-377 5939.425 10 409.275  1287.75  
hsa-miR-378 1099 16 2606.475 488 3985.475 280 
hsa-miR-379 19072.55 6 -53.05  934.95 21 
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hsa-miR-380-3p 1028.85  226.9  89.025  
hsa-miR-380-5p 253.8  57.95  93.45  
hsa-miR-381 12827.325 1 404.3  1351.9  
hsa-miR-382 2813.075 36 -1.425  43.925  
hsa-miR-383 705.125  49.275  123.875  
hsa-miR-384 143.325  185.6  255.55  
hsa-miR-409-3p 14105.075 6 -23.025  276.45  
hsa-miR-409-5p 1091.7 1 -52.725  -38.6  
hsa-miR-410 14699.975 3 -45.75  159.65  
hsa-miR-411 16076.05 1 -33.3  1104.6  
hsa-miR-412 705.95  559.725  674.85  
hsa-miR-421 2118.45 1 11750.5 9 3183.7 7 
hsa-miR-422a -62.05  -49.65  -20.125  
hsa-miR-422b 2491.5  16246.15  13267.3  
hsa-miR-423 13788.55 1 18061.85 717 18156.175 2418 
hsa-miR-424 43872.45 72 25094.625 8 19925.95 6 
hsa-miR-425 1917.55 3 2631.85  2692.875  
hsa-miR-425-5p 3626.7 8 8401.55  7606.025  
hsa-miR-429 38275.125  39304.25  36678.45  
hsa-miR-431 17403.9  553.575  209.625  
hsa-miR-432 10139.125 12 161.35  549.85  
hsa-miR-432* 763.65  -38.3  -4.7  
hsa-miR-433 804.425 5 1.5  -26.525  
hsa-miR-448 -27.275  1252.4  -17.95  
hsa-miR-449 1155.4  317.25  1767.4  
hsa-miR-449b 1103.125  817.375  1820.875  
hsa-miR-450 16771.025  4589.475  9592.575 12 
hsa-miR-451 749.35  1073.225  818.1  
hsa-miR-452 437.725  397.325  213.625  
hsa-miR-452* 4944.475  5538.35  8810.05  
hsa-miR-453 162.85  148.55  401.575  
hsa-mir-454-3p 3620.15  5371.6  8606.375  
hsa-miR-454-5p 602.9  361.15  1114.05  
hsa-miR-455 4875.875 13 5202.175  8277.65  
hsa-miR-483 4402.1 2 1794.65  326.925  
hsa-miR-484 17698.55 6 21201.425  18129.975  
hsa-miR-485-3p 11234.325  228.3  1207.35  
hsa-miR-485-5p 1247.225 4 372.975  845.55  
hsa-miR-486 1737.8  2186.225  4441.6  
hsa-miR-487a 7322.725 1 18.375  266.675  
hsa-miR-487b 13064.825 3 72.525  409.575  
hsa-miR-488 46.325  36.5  49.15  
hsa-miR-489 -62.725  -1.5  -62.3  
hsa-miR-490 7514.175 5 77.025  3.5  
hsa-miR-491 4500.55 32 9934.075  6294.2  
hsa-miR-492 -15.625  -26.3  -15.075  
hsa-miR-493-3p 5843.175 119 -38.85  -22.225  
hsa-miR-493-5p 11067.975  193.875  423.5  
hsa-miR-494 20471.825 7 94.2  1013.725  
hsa-miR-495 7811.75 238 218.5  796.475  
hsa-miR-496 6027.325 3 -17.675  88.175  
hsa-miR-497 656.975  748.2  10340.6  
hsa-miR-498 10.1  541.875  39.625  
hsa-miR-499 2492.025  5212.95  6462.5  
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hsa-miR-500 1862.8  1909.6  4006.2  
hsa-miR-501 268.675 1 339.325  346.225  
hsa-miR-502 635.65  127.375  1148.15  
hsa-miR-503 26015.05 10 13689.925 48 5408.025  
hsa-miR-504 597.025  4582.625  4556.275  
hsa-miR-505 539.475  355.075  497.7  
hsa-miR-506 59.975  60.85  216.125  
hsa-miR-507 1291.125  1382.45  2238.65  
hsa-miR-508 228.175  48.75  2.85  
hsa-miR-509 37.925  293  16.175  
hsa-miR-510 -32.075  -9.425  -0.25  
hsa-miR-511 32.475  25.925  83.3  
hsa-miR-512-3p 3080.225  10647.425  5433.55  
hsa-miR-512-5p 1857.85  4487.9  3406.55  
hsa-miR-513 -56.95  -60.4  -60.925  
hsa-miR-514 -57.8  187.775  -57.275  
hsa-miR-515-3p 176.55  868  161.625  
hsa-miR-515-5p -23.25  4164.85  -23  
hsa-miR-516-3p 808.275  882.4  1664.075  
hsa-miR-516-5p -38.275  641.95  -43.475  
hsa-miR-517* 45.6  400.5  16.45  
hsa-miR-517a 2456.225  11035.3  6101.925  
hsa-miR-517b 163.3  9588.025  416.05  
hsa-miR-517c 728.75  2351.5  1366.025  
hsa-miR-518a 4465.175  13000.9  8817.825  
hsa-miR-518b 224.725  8811.575  674.275  
hsa-miR-518c -35.9  7924.5  -4.125  
hsa-miR-518c* 457.2  542.175  562.525  
hsa-miR-518d 872.25  1023.825  1969.725  
hsa-miR-518e 255.675  779.6  261.25  
hsa-miR-518f -36.175  11032.525  -32.075  
hsa-miR-518f* -1.15  2913.75  -4.15  
hsa-miR-519a 224.35  3563.35  295.925  
hsa-miR-519b 21344.65  27377.225  23355.85  
hsa-miR-519c 202.625  11481.4  292.35  
hsa-miR-519d -20.5  14451.1  59.7  
hsa-miR-519e 66.05  2253.3  198.575  
hsa-miR-519e* -5.4  6021.8  20.05  
hsa-miR-520a 90.525  276.275  74.55  
hsa-miR-520a* 74.575  3145.65  70.575  
hsa-miR-520b 118.325  7806.55  180.575  
hsa-miR-520c -46.65  2151.85  38.225  
hsa-miR-520d 19.4  282.375  18  
hsa-miR-520d* 63.45  340.375  167.175  
hsa-miR-520e -58.05  1812.2  -55  
hsa-miR-520f 55.1  13454.3  96.75  
hsa-miR-520g -34.6  1853.85  -13.525  
hsa-miR-520h -3.675  12537.6  -23.025  
hsa-miR-521 -43.325  1222.425  -16.875  
hsa-miR-522 69.325  1303.225  186.175  
hsa-miR-523 48.85  1483.15  66.4  
hsa-miR-524 -27.275  106.8  -22.55  
hsa-miR-524* -6.7  567.675  0.9  
hsa-miR-525 1169.5  1911.95  2019  
 228 
hsa-miR-525* 230.3  929.6  674.65  
hsa-miR-526a -41.525  195.7  -30.025  
hsa-miR-526b 11.225  115.5  85.025  
hsa-miR-526b* -52.975  3554.6  -53.475  
hsa-miR-526c 368.325  1412.2  475.825  
hsa-miR-527 61.95  389.2  43.825  
hsa-miR-532 2976.425 1 5673.25 42 9225.425 68 
hsa-miR-539 3379.1 3 582.6  424.85  
hsa-miR-542-3p 11001.15 4 1594.525  5562.475 16 
hsa-miR-542-5p 9033.475  1142.175  3056.4  
hsa-miR-544 2130.65  297.6  341.15  
hsa-miR-545 1111.625  1551.9  1616.15  
hsa-miR-548a 1627.65  2138.625  3204.825  
hsa-miR-548b 102.075  210.7  181.225  
hsa-miR-548c 288.625 1 280.775  478.65  
hsa-miR-548d 308.025  141.95  109.275  
hsa-miR-549 365.575  66.3  30.675  
hsa-miR-550 1308.95  1868.775  10567.9  
hsa-miR-551a 1655.4  9997.875  3400.725  
hsa-miR-551b 4820.975  2932.85  11195.575  
hsa-miR-552 -32.8  -27  -14.775  
hsa-miR-553 18.625  22.3  31.15  
hsa-miR-554 130.7  121.275  161.2  
hsa-miR-555 17.975  42.575  76.05  
hsa-miR-556 -34.975  106.5  118.125  
hsa-miR-557 -18.7  -33.575  -18.925  
hsa-miR-558 -17.1  -24.25  -6.35  
hsa-miR-559 159.625  79.15  101.2  
hsa-miR-560 676.65  699.425  1112.65  
hsa-miR-561 146.2  105.475  -14.7  
hsa-miR-562 -45.4  -53.825  -50.9  
hsa-miR-563 652.375  665.3  1005.7  
hsa-miR-564 802.9  874.7  2316.225  
hsa-miR-565 24441.7  17295.025  24140.375  
hsa-miR-566 127.075  274.55  268.3  
hsa-miR-567 80.275  40.175  129  
hsa-miR-568 553.75  550.925  923.575  
hsa-miR-569 45181.275  42533.775  44643.675  
hsa-miR-570 787.975  350.525  767.65  
hsa-miR-571 265.325  243.575  347.525  
hsa-miR-572 94.5  50.825  170.225  
hsa-miR-573 147.475  207.85  190.05  
hsa-miR-574 23159.525 1 7038.375  12947.1  
hsa-miR-575 96.325  5.1  48.05  
hsa-miR-576 2761.75  1863.975  4435.75  
hsa-miR-577 72.075  466.825  4.4  
hsa-miR-578 269.575  123.925  278.675  
hsa-miR-579 291.2  151.45  129.525  
hsa-miR-580 305.575  281.7  497.125  
hsa-miR-581 380.325  137.5  225.775  
hsa-miR-582 401.075  7007.55  67.475  
hsa-miR-583 1354.35  1378.475  2601.75  
hsa-miR-584 3531.1  638.5  1460.175  
hsa-miR-585 784.525  342.95  1345.15  
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hsa-miR-586 92.9  162.675  209.875  
hsa-miR-587 180.325  93.325  152.525  
hsa-miR-588 61.3  94.5  153.75  
hsa-miR-589 124.95  102.675  150.75  
hsa-miR-590 803.725  766.7  1458.4  
hsa-miR-591 54860.7  48746.1  52334.05  
hsa-miR-592 256.575  758.475  432.15  
hsa-miR-593 73.05  73.375  192.4  
hsa-miR-594 3604.8  902.3  5675.05  
hsa-miR-595 -33.975  -18.375  -32.7  
hsa-miR-596 345.075  270.175  282.8  
hsa-miR-597 215.5  341.225  314.7  
hsa-miR-598 1012.2  2538.375  2036.075  
hsa-miR-599 -25.45  61.675  -10.55  
hsa-miR-600 4.925  12.5  53.2  
hsa-miR-601 -19.625  -28.9  -37.85  
hsa-miR-602 56.275  99.95  117.175  
hsa-miR-603 217.225  318.175  274.725  
hsa-miR-604 -51.95  -48.625  27.625  
hsa-miR-605 -1.025  -25.55  -12.1  
hsa-miR-606 -71.85  -70.1  -71.275  
hsa-miR-607 148.875  18.175  82.625  
hsa-miR-608 7.625  -12.875  52  
hsa-miR-609 191.375  101.5  187.525  
hsa-miR-610 2185.7  991.925  3759.75  
hsa-miR-611 127.8  5016.325  -17.95  
hsa-miR-612 245.125  107.45  109.75  
hsa-miR-613 103.95  52.525  111  
hsa-miR-614 405.225  322.9  556.125  
hsa-miR-615 4422.05  8839.975  9021.75  
hsa-miR-616 196.825  78.975  122.175  
hsa-miR-617 108.85  191  144.5  
hsa-miR-618 1360.425  316.075  3161.675  
hsa-miR-619 11.575  -2.5  25.825  
hsa-miR-620 5.05  -19.175  10.575  
hsa-miR-621 -46.5  -47.95  -43.775  
hsa-miR-622 78.75  151.25  1983.675  
hsa-miR-623 3.2  -21.05  33.2  
hsa-miR-624 1932.6  1522.5  2813.15  
hsa-miR-625 4226.075 8 3972.325  4884.8  
hsa-miR-626 83.625  63.575  113.275  
hsa-miR-627 1229.95  671.425  1380.975  
hsa-miR-628 315.975  351.875  494.775  
hsa-miR-629 175.75 2 493.225  44.775  
hsa-miR-630 -31.875  -37  -36.85  
hsa-miR-631 56.15  63.975  186.7  
hsa-miR-632 322.575  671.1  2631.925  
hsa-miR-633 -27.4  -40.425  -31.9  
hsa-miR-634 77.3  100.55  178.075  
hsa-miR-635 -50.175  -55.625  -45.65  
hsa-miR-636 -40.9 1 -33.575  -37.525  
hsa-miR-637 -37.85  -51.075  -35.6  
hsa-miR-638 -46.6  13.175  -31.05  
hsa-miR-639 -0.95  -19.775  24.2  
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hsa-miR-640 -11.975  -21.6  4.775  
hsa-miR-641 937.75  1477.575  1195.75  
hsa-miR-642 118.775  30  58.35  
hsa-miR-643 313.575  359.6  449.175  
hsa-miR-644 80.9  -29.55  6.35  
hsa-miR-645 170.425  216.1  408.05  
hsa-miR-646 422.175  432.8  656.85  
hsa-miR-647 210.925  171.7  491.425  
hsa-miR-648 16.175  7.125  24.875  
hsa-miR-649 71.075  99.9  28.275  
hsa-miR-650 -34.05  -26.875  -27.125  
hsa-miR-651 478.925  2567.95  479.05  
hsa-miR-652 467 2 573.625  1492.85  
hsa-miR-653 -15.575  125.5  -13.575  
hsa-miR-654 4757.25 4 -9.675  87.375  
hsa-miR-655 9349.15 4 -41.35  124.9  
hsa-miR-656 3409 1 -34.15  -18.95  
hsa-miR-657 160.825  173.475  224.675  
hsa-miR-658 -21.825  8.425  -9.625  
hsa-miR-659 277.675  175.9  294.1  
hsa-miR-660 613.325  597.125  1204.85  
hsa-miR-661 92.65  43.125  78.75  
hsa-miR-662 -44.525  -39.975  -13.325  
hsa-miR-663 652.35  962.75  1095.025  
hsa-miR-668 620.5  59.525  100.85  
hsa-miR-671 1362.175  379.075  1207.2  
hsa-miR-675 880.8  1050.25  1468.15  
hsa-miR-7 8405.95 3 7776.975  17022.225 150 
hsa-miR-765 346.175  50.575  106.225  
hsa-miR-766 1281.575  5538.55  3384  
hsa-miR-767-3p 122.95  115.5  130.4  
hsa-miR-767-5p 157  719.975  268.6  
hsa-miR-768-3p 9309.225  9649.9  13357.475  
hsa-miR-768-5p 1628  927.7  3333.525  
hsa-miR-769-3p 2206.75  1348.425  4398.05  
hsa-miR-769-5p 2820.4  3979.7 11 8290.675 29 
hsa-miR-770-5p 582.825  -46.4  -30.1  
hsa-miR-801 65.9  283.675  107.9  
hsa-miR-802 61.525  91.525  96.3  
hsa-miR-9 73.575  6553.85  47993.65 870 
hsa-miR-9* 173.125  2987.75  50413.925 1299 
hsa-miR-92 13711.6 6 29756.625 18 24666.05 34 
hsa-miR-92b 2155.025 1 11014.775 25 20774.075 885 
hsa-miR-93 26791.2 6 40047.25 89 34049.55 72 
hsa-miR-95 -2.3  2426.1  6676.75  
hsa-miR-96 126  489.25 9 62.9  
hsa-miR-98 15483.85 26 85.775  16055.975 18 
hsa-miR-99a 3200  191.975  38789.975 44 
hsa-miR-99b 15648.85 1 12313.2 47 14491.425 124 
 
 
